Patent Publication Number: US-2023151429-A1

Title: Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     The present application is a continuation of U.S. Pat. Application No. 16/327,260, filed Feb. 21, 2019, which is the U.S. National Phase of PCT Application No. PCT/US2017/048486, filed Aug. 24, 2017, which claims benefit of priority under 35 U.S.C. §119(e) of U.S. Serial No. 62/379,178, filed Aug. 24, 2016, the entire contents of which is incorporated herein by reference in its entirety. 
    
    
     INCORPORATION OF SEQUENCE LISTING 
     The material in the accompanying sequence listing is hereby incorporated by reference into this application. The accompanying sequence listing file, name GENDX_014C1_Sequence_Listing.xml, was created on Aug. 15, 2002, and is 1.69 MB. 
     FIELD OF THE INVENTION 
     The present invention pertains to the field of personalized medicine and methods for treating prostate cancer. In particular, the invention relates to the use of genomic signatures to identify individuals in need of treatment for prostate cancer who will be responsive to post-operative radiation therapy. 
     BACKGROUND OF THE INVENTION 
     Cancer is the uncontrolled growth of abnormal cells anywhere in a body. The abnormal cells are termed cancer cells, malignant cells, or tumor cells. Many cancers and the abnormal cells that compose the cancer tissue are further identified by the name of the tissue that the abnormal cells originated from (for example, prostate cancer). Cancer cells can proliferate uncontrollably and form a mass of cancer cells. Cancer cells can break away from this original mass of cells, travel through the blood and lymph systems, and lodge in other organs where they can again repeat the uncontrolled growth cycle. This process of cancer cells leaving an area and growing in another body area is often termed metastatic spread or metastatic disease. For example, if prostate cancer cells spread to a bone (or anywhere else), it can mean that the individual has metastatic prostate cancer. 
     Standard clinical parameters such as tumor size, grade, lymph node involvement and tumor-node-metastasis (TNM) staging (American Joint Committee on Cancer) may correlate with outcome and serve to stratify patients with respect to (neo)adjuvant chemotherapy, immunotherapy, antibody therapy and/or radiotherapy regimens. Incorporation of molecular markers in clinical practice may define tumor subtypes that are more likely to respond to targeted therapy. However, stage-matched tumors grouped by histological or molecular subtypes may respond differently to the same treatment regimen. Additional key genetic and epigenetic alterations may exist with important etiological contributions. A more detailed understanding of the molecular mechanisms and regulatory pathways at work in cancer cells and the tumor microenvironment (TME) could dramatically improve the design of novel anti-tumor drugs and inform the selection of optimal therapeutic strategies. The development and implementation of diagnostic, prognostic and therapeutic biomarkers to characterize the biology of each tumor may assist clinicians in making important decisions with regard to individual patient care and treatment. 
     This background information is provided for the purpose of making known information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention. 
     SUMMARY OF THE INVENTION 
     The present invention is based on the discovery of a genomic signature that is useful for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer. In particular, the invention relates to a genomic signature based on expression levels of DNA damage repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy. The methods of the present invention are useful for generating a Post-Operative Radiation Therapy Outcome Score (PORTOS) to predict response to radiation therapy in prostate cancer patients. 
     In one aspect, the invention includes a method of predicting response to post-operative radiation therapy for prostate cancer, the method comprising: a) providing a biological sample comprising prostate cancer cells from a subject; b) assaying a level of expression of a plurality of genes in the biological sample, wherein said plurality of genes comprises one or more genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2; c) calculating a post-operative radiation therapy outcome score (PORTOS) based on the levels of expression of the plurality of genes in the biological sample to determine whether or not the subject is likely to benefit from the post-operative radiation therapy. A PORTOS greater than 0 (i.e., high PORTOS) indicates that a subject will benefit from post-operative radiation therapy, whereas a PORTOS of less than or equal to 0 (i.e., low PORTOS) indicates that a subject will not benefit from post-operative radiation therapy. 
     In one embodiment, the plurality of genes comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In another embodiment, the plurality of genes comprises DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In another embodiment, the plurality of genes is selected from DRAM1 and KRT14; DRAM1, KRT14 and PTPN22; DRAM1, KRT14, PTPN22 and ZMAT3; DRAM1, KRT14, PTPN22, ZMAT3 and ARHGAP15; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15 and IL1B; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B and ANLN; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN and RPS27A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A and MUM1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1 and TOP2A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A and GNG11; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11 and CDKN3; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3 and HCLS1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1 and DTL; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL and IL7R; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R and UBA7; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7 and NEK1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1 and CDKN2AIP; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP and APEX2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2 and KIF23; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23 and SULF2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2 and PLK2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2 and EME1; and DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1 and BIN2. 
     In certain embodiments, the method is performed after the patient undergoes a radical prostatectomy. The method is preferably performed prior to treatment of the subject with radiation therapy to determine if the subject will benefit from radiation therapy or should be administered some other anti-cancer treatment (e.g., chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or a combination thereof). The method may also be performed while the subject is undergoing radiation therapy to help evaluate whether continued treatment is likely to be efficacious. 
     The biological sample obtained from a patient is typically a biopsy or tumor sample, but can be any sample from bodily fluids or tissue of the patient that contains cancerous cells. In certain embodiments, nucleic acids comprising sequences from genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2, or complements thereof, are further isolated from the biological sample, and/or purified, and/or amplified prior to analysis. 
     The prostate cancer can be any type of prostate cancer, including but not limited to, adenocarcinoma, small cell prostate cancer, non-small cell prostate cancer, neuroendocrine prostate cancer, or metastatic castration resistant prostate cancer. Additionally, the prostate cancer may be biochemically recurrent or metastatic prostate cancer. 
     The expression levels of biomarker nucleic acids can be determined by a variety of methods including, but not limited to, microarray analysis, polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), a Northern blot, and serial analysis of gene expression (SAGE). 
     In one aspect, the method further comprises prescribing and/or administering the post-operative radiation therapy to the subject if the PORTOS indicates that the subject will benefit from the radiation therapy, or prescribing and/or administering a cancer treatment other than the post-operative radiation therapy to the subject if the PORTOS indicates the subject will not benefit from the post-operative radiation therapy. 
     In one aspect, the invention includes a method of predicting response to post-operative radiation therapy for prostate cancer, the method comprising: a) providing a biological sample comprising prostate cancer cells from a subject; b) assaying a level of expression of a plurality of genes in the biological sample, wherein said plurality of genes comprises one or more genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2; c) calculating a post-operative radiation therapy outcome score (PORTOS) based on the levels of expression of the plurality of genes in the biological sample to determine whether or not the subject is likely to benefit from the post-operative radiation therapy. A PORTOS greater than 0 (i.e., high PORTOS) indicates that a subject will benefit from post-operative radiation therapy, whereas a PORTOS of less than or equal to 0 (i.e., low PORTOS) indicates that a subject will not benefit from post-operative radiation therapy. 
     In one aspect, the method further comprises prescribing and/or administering the post-operative radiation therapy to the subject if the PORTOS indicates that the subject will benefit from the radiation therapy, or prescribing and/or administering a cancer treatment other than the post-operative radiation therapy to the subject if the PORTOS indicates the subject will not benefit from the post-operative radiation therapy. 
     In one aspect, the method further comprises prescribing and/or administering the post-operative radiation therapy to the subject if the PORTOS indicates that the subject will benefit from the radiation therapy, or prescribing and/or administering a cancer treatment other than the post-operative radiation therapy to the subject if the PORTOS indicates the subject will not benefit from the post-operative radiation therapy. 
     In one embodiment, the plurality of genes comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In another embodiment, the plurality of genes comprises DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In another embodiment, the plurality of genes is selected from DRAM1 and KRT14; DRAM1, KRT14 and PTPN22; DRAM1, KRT14, PTPN22 and ZMAT3; DRAM1, KRT14, PTPN22, ZMAT3 and ARHGAP15; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15 and IL1B; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B and ANLN; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN and RPS27A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A and MUM1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1 and TOP2A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A and GNG11; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11 and CDKN3; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3 and HCLS1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1 and DTL; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL and IL7R; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R and UBA7; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7 and NEK1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1 and CDKN2AIP; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP and APEX2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2 and KIF23; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23 and SULF2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2 and PLK2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2 and EME1; and DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1 and BIN2. 
     In certain embodiments, the method is performed after the patient undergoes a radical prostatectomy. The method is preferably performed prior to treatment of the subject with radiation therapy to determine if the subject will benefit from radiation therapy or should be administered some other anti-cancer treatment (e.g., chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or a combination thereof). The method may also be performed while the subject is undergoing radiation therapy to help evaluate whether continued treatment is likely to be efficacious. 
     The biological sample obtained from a patient is typically a biopsy or tumor sample, but can be any sample from bodily fluids or tissue of the patient that contains cancerous cells. In certain embodiments, nucleic acids comprising sequences from genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2, or complements thereof, are further isolated from the biological sample, and/or purified, and/or amplified prior to analysis. 
     The prostate cancer can be any type of prostate cancer, including but not limited to, adenocarcinoma, small cell prostate cancer, non-small cell prostate cancer, neuroendocrine prostate cancer, or metastatic castration resistant prostate cancer. Additionally, the prostate cancer may be biochemically recurrent or metastatic prostate cancer. 
     The expression levels of biomarker nucleic acids can be determined by a variety of methods including, but not limited to, microarray analysis, polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), a Northern blot, and serial analysis of gene expression (SAGE). 
     In another aspect, the invention includes a method of treating a subject for prostate cancer, the method comprising: a) determining whether or not the subject is likely to benefit from post-operative radiation therapy according to a PORTOS as described herein; and b) administering post-operative radiation therapy to the subject if the PORTOS indicates that the subject will benefit from post-operative radiation therapy, or administering a cancer treatment other than post-operative radiation therapy to the subject if the PORTOS indicates that the subject will not benefit from post-operative radiation therapy. Subjects, especially those identified as not likely to benefit from radiation therapy may be administered other cancer treatments such as, but not limited to, chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any combination thereof. 
     In another aspect, the invention includes a method for determining a treatment for a subject who has prostate cancer, the method comprising: a) determining whether or not the subject is likely to benefit from post-operative radiation therapy according to a PORTOS as described herein; and b) prescribing radiation therapy to the subject if the PORTOS indicates that the subject will benefit from radiation therapy, or prescribing a cancer treatment other than radiation therapy to the subject if the PORTOS indicates the subject will not benefit from radiation therapy. 
     In another aspect, the invention includes a probe set for predicting response of a subject to post-operative radiation therapy for prostate cancer, the probe set comprising a plurality of probes for detecting a plurality of target nucleic acids, wherein the plurality of target nucleic acids comprises one or more gene sequences, or complements thereof, of genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. Probes may be detectably labeled to facilitate detection. In one embodiment, the probe set comprises a plurality of probes for detecting a plurality of target nucleic acids comprising gene sequences, or complements thereof, of the genes DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. 
     In another aspect, the invention includes a system for predicting response of a subject to post-operative radiation therapy for prostate cancer, the system comprising: a) a probe set described herein; and b) an algorithm for generating a post-operative radiation therapy outcome score (PORTOS) based on an expression level of the plurality of target nucleic acids hybridized to the probes of the probe set in a biological sample from the subject. 
     In another aspect, the invention includes a kit for predicting response of a subject to post-operative radiation therapy for prostate cancer, the kit comprising agents for measuring levels of expression of a plurality of genes, wherein the plurality of genes comprises one or more genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. The kit may include one or more agents (e.g., hybridization probes, PCR primers, or microarray) for measuring levels of expression of a plurality of genes, wherein said plurality of genes comprises one or more genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2, a container for holding a biological sample comprising prostate cancer cells isolated from a human subject for testing, and printed instructions for reacting the agents with the biological sample or a portion of the biological sample to determine whether or not the subject is likely to benefit from radiation therapy. The agents may be packaged in separate containers. The kit may further comprise one or more control reference samples or other reagents for measuring gene expression (e.g., reagents for performing PCR, RT-PCR, microarray analysis, a Northern blot, SAGE, or an immunoassay). In one embodiment, the kit comprises agents for measuring the levels of expression of the genes DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. For example, the kit may comprise a probe set, as described herein, for detecting a plurality of target nucleic acids, wherein the plurality of target nucleic acids comprises one or more gene sequences, or complements thereof, of genes selected from DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2, or any combination thereof. 
     In another embodiment, the kit further comprises a system for predicting response of a subject to post-operative radiation therapy for prostate cancer, wherein the system comprises: a) a probe set comprising a plurality of probes for detecting a plurality of target nucleic acids, wherein the plurality of target nucleic acids comprises one or more gene sequences, or complements thereof, of genes selected from DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2, or any combination thereof; and b) an algorithm for generating a post-operative radiation therapy outcome score (PORTOS) based on an expression level of the plurality of target nucleic acids hybridized to the plurality of probes in a biological sample from the subject. 
     In another aspect, the invention includes a computer implemented method for predicting response of a patient to post-operative radiation therapy for prostate cancer, the computer performing steps comprising: a) receiving inputted patient data comprising values for levels of expression of a plurality of genes, wherein said plurality of genes comprises one or more genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2 in a biological sample comprising prostate cancer cells from the patient; b) calculating a post-operative radiation therapy outcome score (PORTOS) based on the levels of expression of the plurality of genes to determine whether or not the patient is likely to benefit from the radiation therapy, wherein a PORTOS greater than 0 indicates that the patient will benefit from the radiation therapy and a PORTOS less than or equal to 0 indicates that the patient will not benefit from the radiation therapy; and c) displaying information regarding whether or not the patient is likely to benefit from the post-operative radiation therapy. In one embodiment, the plurality of genes comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In another embodiment, the plurality of genes comprises DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In another embodiment, the plurality of genes is selected from DRAM1 and KRT14; DRAM1, KRT14 and PTPN22; DRAM1, KRT14, PTPN22 and ZMAT3; DRAM1, KRT14, PTPN22, ZMAT3 and ARHGAP15; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15 and IL1B; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B and ANLN; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN and RPS27A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A and MUM1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1 and TOP2A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A and GNG11; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11 and CDKN3; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3 and HCLS1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1 and DTL; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL and IL7R; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R and UBA7; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7 and NEK1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1 and CDKN2AIP; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP and APEX2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2 and KIF23; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23 and SULF2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2 and PLK2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2 and EME1; and DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1 and BIN2. 
     The significance of the expression levels of one or more biomarker genes may be evaluated using, for example, a T-test, P-value, KS (Kolmogorov Smirnov) P-value, accuracy, accuracy P-value, positive predictive value (PPV), negative predictive value (NPV), sensitivity, specificity, AUC, AUC P-value (Auc.pvalue), Wilcoxon Test P-value, Median Fold Difference (MFD), Kaplan Meier (KM) curves, survival AUC (survAUC), Kaplan Meier P-value (KM P-value), Univariable Analysis Odds Ratio P-value (uvaORPval), multivariable analysis Odds Ratio P-value (mvaORPval), Univariable Analysis Hazard Ratio P-value (uvaHRPval) and Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The significance of the expression level of the one or more targets may be based on two or more metrics selected from the group comprising AUC, AUC P-value (Auc.pvalue), Wilcoxon Test P-value, Median Fold Difference (MFD), Kaplan Meier (KM) curves, survival AUC (survAUC), Univariable Analysis Odds Ratio P-value (uvaORPval), multivariable analysis Odds Ratio P-value (mvaORPval), Kaplan Meier P-value (KM P-value), Univariable Analysis Hazard Ratio P-value (uvaHRPval) or Multivariable Analysis Hazard Ratio P-value (mvaHRPval). 
     These and other embodiments of the subject invention will readily occur to those of skill in the art in view of the disclosure herein. 
     INCORPORATION BY REFERENCE 
     All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entireties to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIGS.  1 A- 1 D  show interaction and bar plots of 10-year metastasis rates in a training and validation cohorts when comparing low and high PORTOS. In the line plots: Gray = treated with RT, black = not treated with RT. In the bar plots: Gray = low PORTOS, Black = high PORTOS, error bars = standard error. 
         FIGS.  2 A- 2 D  show cumulative incidence curves in the training and validation cohorts separating low and high PORTOS scores. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The practice of the present invention will employ, unless otherwise indicated, conventional methods of medicine, biochemistry, molecular biology and recombinant DNA techniques, within the skill of the art. Such techniques are explained fully in the literature. See, e.g.,  Radiotherapy in Prostate Cancer: Innovative Techniques and Current Controversies  (Medical Radiology, H. Geinitz, M. Roach III, and N. van As eds., Springer, 2015);  Prostate Cancer: Science and Clinical Practice  (J.H. Mydlo and C.J. Godec eds., Academic Press, 2 nd  edition, 2015);  Prostate Cancer: Biochemistry, Molecular Biology and Genetics  (Protein Reviews 16, D.J. Tindall ed., Springer, 2013); A.L. Lehninger,  Biochemistry  (Worth Publishers, Inc., current addition); Sambrook, et al.,  Molecular Cloning: A Laboratory Manual  (3 rd  Edition, 2001); and  Methods In Enzymology  (S. Colowick and N. Kaplan eds., Academic Press, Inc.). 
     I. Definitions 
     In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below. 
     It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a nucleic acid” includes a mixture of two or more such nucleic acids, and the like. 
     The term “survival” as used herein means the time from the start of cancer treatment (e.g., radiation therapy) to the time of death. 
     The terms “tumor,” “cancer” and “neoplasia” are used interchangeably and refer to a cell or population of cells whose growth, proliferation or survival is greater than growth, proliferation or survival of a normal counterpart cell, e.g. a cell proliferative, hyperproliferative or differentiative disorder. Typically, the growth is uncontrolled. The term “malignancy” refers to invasion of nearby tissue. The term “metastasis” or a secondary, recurring or recurrent tumor, cancer or neoplasia refers to spread or dissemination of a tumor, cancer or neoplasia to other sites, locations or regions within the subject, in which the sites, locations or regions are distinct from the primary tumor or cancer. Neoplasia, tumors and cancers include benign, malignant, metastatic and non-metastatic types, and include any stage (I, II, III, IV or V) or grade (G1, G2, G3, etc.) of neoplasia, tumor, or cancer, or a neoplasia, tumor, cancer or metastasis that is progressing, worsening, stabilized or in remission. In particular, the terms “tumor,” “cancer” and “neoplasia” include carcinomas, such as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, and small cell carcinoma. 
     The term “derived from” is used herein to identify the original source of a molecule but is not meant to limit the method by which the molecule is made which can be, for example, by chemical synthesis or recombinant means. 
     “Recombinant” as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation is not associated with all or a portion of the polynucleotide with which it is associated in nature. The term “recombinant” as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. In general, the gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions. 
     “Substantially purified” generally refers to isolation of a substance (compound, polynucleotide, oligonucleotide, protein, or polypeptide) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample, a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample. Techniques for purifying polynucleotides oligonucleotides and polypeptides of interest are well-known in the art and include, for example, ion-exchange chromatography, affinity chromatography and sedimentation according to density. 
     By “isolated” is meant, when referring to a polypeptide, that the indicated molecule is separate and discrete from the whole organism with which the molecule is found in nature or is present in the substantial absence of other biological macro molecules of the same type. The term “isolated” with respect to a polynucleotide or oligonucleotide is a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences in association therewith; or a molecule disassociated from the chromosome. 
     The terms “polynucleotide,” “oligonucleotide,” “nucleic acid” and “nucleic acid molecule” are used herein to include a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes triple-, double- and single-stranded DNA, as well as triple-, double- and single-stranded RNA. It also includes modifications, such as by methylation and/or by capping, and unmodified forms of the polynucleotide. More particularly, the terms “polynucleotide,” “oligonucleotide,” “nucleic acid” and “nucleic acid molecule” include polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), any other type of polynucleotide which is an N- or C-glycoside of a purine or pyrimidine base, and other polymers containing nonnucleotidic backbones, for example, polyamide (e.g., peptide nucleic acids (PNAs)) and polymorpholino (commercially available from the Anti-Virals, Inc., Corvallis, Oregon, as Neugene) polymers, and other synthetic sequence-specific nucleic acid polymers providing that the polymers contain nucleobases in a configuration which allows for base pairing and base stacking, such as is found in DNA and RNA. There is no intended distinction in length between the terms “polynucleotide,” “oligonucleotide,” “nucleic acid” and “nucleic acid molecule,” and these terms will be used interchangeably. Thus, these terms include, for example, 3′-deoxy-2′,5′-DNA, oligodeoxyribonucleotide N3′ P5′ phosphoramidates, 2′-O-alkyl-substituted RNA, double- and single-stranded DNA, as well as double- and single-stranded RNA, DNA:RNA hybrids, and hybrids between PNAs and DNA or RNA, and also include known types of modifications, for example, labels which are known in the art, methylation, “caps,” substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), with negatively charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), and with positively charged linkages (e.g., aminoalklyphosphoramidates, aminoalkylphosphotriesters), those containing pendant moieties, such as, for example, proteins (including nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide or oligonucleotide. The term also includes locked nucleic acids (e.g., comprising a ribonucleotide that has a methylene bridge between the 2′-oxygen atom and the 4′-carbon atom). See, for example, Kurreck et al. (2002) Nucleic Acids Res. 30: 1911-1918; Elayadi et al. (2001) Curr. Opinion Invest. Drugs 2: 558-561; Orum et al. (2001) Curr. Opinion Mol. Ther. 3: 239-243; Koshkin et al. (1998) Tetrahedron 54: 3607-3630; Obika et al. (1998) Tetrahedron Lett. 39: 5401-5404. 
     As used herein, the term “probe” or “oligonucleotide probe” refers to a polynucleotide, as defined above, that contains a nucleic acid sequence complementary to a nucleic acid sequence present in the target nucleic acid analyte (e.g., biomarker). The polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs. Probes may be labeled in order to detect the target sequence. Such a label may be present at the 5′ end, at the 3′ end, at both the 5′ and 3′ ends, and/or internally. 
     The term “primer” or “oligonucleotide primer” as used herein, refers to an oligonucleotide that hybridizes to the template strand of a nucleic acid and initiates synthesis of a nucleic acid strand complementary to the template strand when placed under conditions in which synthesis of a primer extension product is induced, i.e., in the presence of nucleotides and a polymerization inducing agent such as a DNA or RNA polymerase and at suitable temperature, pH, metal concentration, and salt concentration. The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer can first be treated to separate its strands before being used to prepare extension products. This denaturation step is typically effected by heat, but may alternatively be carried out using alkali, followed by neutralization. Thus, a “primer” is complementary to a template, and complexes by hydrogen bonding or hybridization with the template to give a primer/template complex for initiation of synthesis by a polymerase, which is extended by the addition of covalently bonded bases linked at its 3′ end complementary to the template in the process of DNA or RNA synthesis. Typically, nucleic acids are amplified using at least one set of oligonucleotide primers comprising at least one forward primer and at least one reverse primer capable of hybridizing to regions of a nucleic acid flanking the portion of the nucleic acid to be amplified. 
     The term “amplicon” refers to the amplified nucleic acid product of a PCR reaction or other nucleic acid amplification process (e.g., ligase chain reaction (LGR), nucleic acid sequence based amplification (NASBA), transcription-mediated amplification (TMA), Q-beta amplification, strand displacement amplification, or target mediated amplification). Amplicons may comprise RNA or DNA depending on the technique used for amplification. 
     The terms “hybridize” and “hybridization” refer to the formation of complexes between nucleotide sequences which are sufficiently complementary to form complexes via Watson-Crick base pairing. 
     It will be appreciated that the hybridizing sequences need not have perfect complementarity to provide stable hybrids. In many situations, stable hybrids will form where fewer than about 10% of the bases are mismatches, ignoring loops of four or more nucleotides. Accordingly, as used herein the term “complementary” refers to an oligonucleotide that forms a stable duplex with its “complement” under assay conditions, generally where there is about 90% or greater homology. 
     The terms “selectively detects” or “selectively detecting” refer to the detection of nucleic acids using oligonucleotides, e.g., primers or probes that are capable of detecting a particular nucleic acid, for example, by amplifying and/or binding to at least a portion of the biomarker nucleic acid, but do not amplify and/or bind to sequences from other nucleic acids under appropriate hybridization conditions. 
     As used herein, the terms “label” and “detectable label” refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorescers, chemiluminescers, chromophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, semiconductor nanoparticles, dyes, metal ions, metal sols, ligands (e.g., biotin, streptavidin or haptens) and the like. The term “fluorescer” refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used in the practice of the invention include, but are not limited to, a SYBR dye such as SYBR green and SYBR gold, a CAL Fluor dye such as CAL Fluor Gold 540, CAL Fluor Orange 560, CAL Fluor Red 590, CAL Fluor Red 610, and CAL Fluor Red 635, a Quasar dye such as Quasar 570, Quasar 670, and Quasar 705, an Alexa Fluor such as Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 594, Alexa Fluor 647, and Alexa Fluor 784, a cyanine dye such as Cy3, Cy3.5, Cy5, Cy5.5, and Cy7, fluorescein, 2′, 4′, 5′, 7′-tetrachloro-4-7-dichlorofluorescein (TET), carboxyfluorescein (FAM), 6-carboxy-4′5′-dichloro-2′,7′-dimethoxyfluorescein (JOE), hexachlorofluorescein (HEX), rhodamine, carboxy-X-rhodamine (ROX), tetramethyl rhodamine (TAMRA), FITC, dansyl, umbelliferone, dimethyl acridinium ester (DMAE), Texas red, luminol, quantum dots, NADPH, horseradish peroxidase (HRP), α-galactosidase, and β-galactosidase. 
     The terms “subject,” “individual,” and “patient,” are used interchangeably herein and refer to any mammalian subject, particularly humans. Other subjects may include cattle, dogs, cats, guinea pigs, rabbits, rats, mice, horses, and so on. In some cases, the methods of the invention find use in experimental animals, in veterinary application, and in the development of animal models, including, but not limited to, rodents including mice, rats, and hamsters; and primates. 
     II. Modes of Carrying Out the Invention 
     Before describing the present invention in detail, it is to be understood that this invention is not limited to particular formulations or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting. 
     Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein. 
     The present invention is based on the discovery of a genomic signature that is useful for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer. In particular, the invention relates to a genomic signature based on expression levels of DNA damage repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy (see Examples). 
     In order to further an understanding of the invention, a more detailed discussion is provided below regarding the genomic signature and methods of screening and treating subjects for prostate cancer. 
     A Genomic Signature for Predicting Response to Radiation Therapy 
     A genomic signature based on gene expression of DNA damage repair genes can be utilized to identify prostate cancer patients that may potentially benefit from radiation therapy. Exemplary DNA damage repair genes that display expression patterns that predict response to radiation therapy include DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. 
     In one aspect the invention includes a method of predicting the response of a subject to post-operative radiation therapy for prostate cancer. The method generally comprises: a) providing a biological sample comprising prostate cancer cells from a subject; b) assaying a level of expression of a plurality of genes in the biological sample, wherein the plurality of genes comprises one or more genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2; and c) predicting whether or not the subject is likely to benefit from post-operative radiation therapy based on the level of expression of the plurality of genes. 
     In certain embodiments, the plurality of genes comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 genes or more genes selected from the group consisting of DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In one embodiment, the plurality of genes comprises DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1, and BIN2. In another embodiment, the plurality of genes is selected from DRAM1 and KRT14; DRAM1, KRT14 and PTPN22; DRAM1, KRT14, PTPN22 and ZMAT3; DRAM1, KRT14, PTPN22, ZMAT3 and ARHGAP15; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15 and IL1B; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B and ANLN; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN and RPS27A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A and MUM1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1 and TOP2A; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A and GNG11; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11 and CDKN3; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3 and HCLS1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1 and DTL; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL and IL7R; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R and UBA7; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7 and NEK1; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1 and CDKN2AIP; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP and APEX2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2 and KIF23; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23 and SULF2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2 and PLK2; DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2 and EME1; and DRAM1, KRT14, PTPN22, ZMAT3, ARHGAP15, IL1B, ANLN, RPS27A, MUM1, TOP2A, GNG11, CDKN3, HCLS1, DTL, IL7R, UBA7, NEK1, CDKN2AIP, APEX2, KIF23, SULF2, PLK2, EME1 and BIN2. 
     In another embodiment, a post-operative radiation therapy outcome score (PORTOS) is calculated based on the levels of expression of the plurality of genes in the biological sample to determine whether or not the subject is likely to benefit from post-operative radiation therapy (see Examples). A PORTOS greater than 0 (i.e., high PORTOS) indicates that a subject will benefit from post-operative radiation therapy, whereas a PORTOS of less than or equal to 0 (i.e., low PORTOS) indicates that a subject will not benefit from post-operative radiation therapy. 
     In a further embodiment, the method is performed after the patient undergoes a radical prostatectomy. The method is preferably performed prior to treatment of the subject with radiation therapy to determine if the subject will benefit from radiation therapy or should be administered some other anti-cancer treatment. The method may also be performed while the subject is undergoing radiation therapy to help evaluate whether continued treatment is likely to be efficacious. Subjects, especially those identified as not likely to benefit from radiation therapy may be administered anti-cancer treatments other than radiation therapy such as, but not limited to, surgery, chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any combination thereof. 
     Targets 
     In some instances, assaying the expression level of a plurality of genes comprises detecting and/or quantifying a plurality of target analytes. In some embodiments, assaying the expression level of a plurality of genes comprises sequencing a plurality of target nucleic acids. In some embodiments, assaying the expression level of a plurality of biomarker genes comprises amplifying a plurality of target nucleic acids. In some embodiments, assaying the expression level of a plurality of biomarker genes comprises conducting a multiplexed reaction on a plurality of target analytes. 
     The methods disclosed herein often comprise assaying the expression level of a plurality of targets. The plurality of targets may comprise coding targets and/or non-coding targets of a protein-coding gene or a non-protein-coding gene. A protein-coding gene structure may comprise an exon and an intron. The exon may further comprise a coding sequence (CDS) and an untranslated region (UTR). The protein-coding gene may be transcribed to produce a pre-mRNA and the pre-mRNA may be processed to produce a mature mRNA. The mature mRNA may be translated to produce a protein. 
     A non-protein-coding gene structure may comprise an exon and intron. Usually, the exon region of a non-protein-coding gene primarily contains a UTR. The non-protein-coding gene may be transcribed to produce a pre-mRNA and the pre-mRNA may be processed to produce a non-coding RNA (ncRNA). 
     A coding target may comprise a coding sequence of an exon. A non-coding target may comprise a UTR sequence of an exon, intron sequence, intergenic sequence, promoter sequence, non-coding transcript, CDS antisense, intronic antisense, UTR antisense, or non-coding transcript antisense. A non-coding transcript may comprise a non-coding RNA (ncRNA). 
     In some instances, the plurality of targets comprises one or more targets selected from Table 1 or Table 2. In some instances, the plurality of targets comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, or at least about 24 targets selected from Table 2. 
     In some instances, the plurality of targets comprises a coding target, non-coding target, or any combination thereof. In some instances, the coding target comprises an exonic sequence. In other instances, the non-coding target comprises a non-exonic or exonic sequence. Alternatively, a non-coding target comprises a UTR sequence, an intronic sequence, antisense, or a non-coding RNA transcript. In some instances, a non-coding target comprises sequences which partially overlap with a UTR sequence or an intronic sequence. A non-coding target also includes non-exonic and/or exonic transcripts. Exonic sequences may comprise regions on a protein-coding gene, such as an exon, UTR, or a portion thereof. Non-exonic sequences may comprise regions on a protein-coding, non-protein-coding gene, or a portion thereof. For example, non-exonic sequences may comprise intronic regions, promoter regions, intergenic regions, a non-coding transcript, an exon anti-sense region, an intronic anti-sense region, UTR anti-sense region, non-coding transcript anti-sense region, or a portion thereof. In other instances, the plurality of targets comprises a non-coding RNA transcript. 
     The plurality of targets may comprise one or more targets selected from a classifier disclosed herein. The classifier may be generated from one or more models or algorithms. The one or more models or algorithms may be a Cox proportional hazards model, Naive Bayes (NB), recursive Partitioning (Rpart), random forest (RF), support vector machine (SVM), k-nearest neighbor (KNN), high dimensional discriminate analysis (HDDA), or a combination thereof. The classifier may have an AUC of equal to or greater than 0.60. The classifier may have an AUC of equal to or greater than 0.61. The classifier may have an AUC of equal to or greater than 0.62. The classifier may have an AUC of equal to or greater than 0.63. The classifier may have an AUC of equal to or greater than 0.64. The classifier may have an AUC of equal to or greater than 0.65. The classifier may have an AUC of equal to or greater than 0.66. The classifier may have an AUC of equal to or greater than 0.67. The classifier may have an AUC of equal to or greater than 0.68. The classifier may have an AUC of equal to or greater than 0.69. The classifier may have an AUC of equal to or greater than 0.70. The classifier may have an AUC of equal to or greater than 0.75. The classifier may have an AUC of equal to or greater than 0.77. The classifier may have an AUC of equal to or greater than 0.78. The classifier may have an AUC of equal to or greater than 0.79. The classifier may have an AUC of equal to or greater than 0.80. The AUC may be clinically significant based on its 95% confidence interval (CI). The accuracy of the classifier may be at least about 70%. The accuracy of the classifier may be at least about 73%. The accuracy of the classifier may be at least about 75%. The accuracy of the classifier may be at least about 77%. The accuracy of the classifier may be at least about 80%. The accuracy of the classifier may be at least about 83%. The accuracy of the classifier may be at least about 84%. The accuracy of the classifier may be at least about 86%. The accuracy of the classifier may be at least about 88%. The accuracy of the classifier may be at least about 90%. The p-value of the classifier may be less than or equal to 0.05. The p-value of the classifier may be less than or equal to 0.04. The p-value of the classifier may be less than or equal to 0.03. The p-value of the classifier may be less than or equal to 0.02. The p-value of the classifier may be less than or equal to 0.01. The p-value of the classifier may be less than or equal to 0.008. The p-value of the classifier may be less than or equal to 0.006. The p-value of the classifier may be less than or equal to 0.004. The p-value of the classifier may be less than or equal to 0.002. The p-value of the classifier may be less than or equal to 0.001. The p-value of the classifier may be less than or equal to 0.0001. 
     The plurality of targets may comprise one or more targets selected from a Cox proportional hazards model. The plurality of targets may comprise two or more targets selected from a Cox proportional hazards model. The plurality of targets may comprise three or more targets selected from a Cox proportional hazards model. The plurality of targets may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more targets selected from a Cox proportional hazards model. The Cox proportional hazards model may be a ridge-penalized Cox model. Predictions from a Cox model can be described in terms of a binary score (i.e., PORTOS) as discussed in the Examples.  
     
       
         
          TABLE 1
           
               
               
               
               
             
               
                 PORTOS Target Sequences 
               
               
                 SEQ ID NO. 
                 Affy Probeset ID 
                 Gene 
                 Sequence 
               
             
            
               
                 1 
                 2378938 
                 DTL 
                 AGATGCTGAAAAGAGAGTCGACTCC 
               
               
                 2 
                 2378938 
                 DTL 
                 CGGTTAGTCTCTCGCACTGCAGTCA 
               
               
                 3 
                 2378938 
                 DTL 
                 TCGACTCCGAAAAGGAGGCTGGGAC 
               
               
                 4 
                 2378938 
                 DTL 
                 CCTGCAGCGAGCCTTCGGTTAGTCT 
               
               
                 5 
                 2378943 
                 DTL 
                 GGAGGAAAACCTACATGGAAGAGAA 
               
               
                 6 
                 2378943 
                 DTL 
                 AGTCACGTCACCATTACTACTTGTG 
               
               
                 7 
                 2378943 
                 DTL 
                 CCTCTTTGTCCTCAGGGTCAAGGAG 
               
               
                 8 
                 2378943 
                 DTL 
                 ACTTGTGTGAAGAATACCTCTTTGT 
               
               
                 9 
                 2378944 
                 DTL 
                 AACAAGCTAACATATTGTGTCTTAG 
               
               
                 10 
                 2378944 
                 DTL 
                 ACCTTGTACATGATCGTCAACGGTT 
               
               
                 11 
                 2378944 
                 DTL 
                 GAGGGTTATACCTTGTACATGATCG 
               
               
                 12 
                 2378944 
                 DTL 
                 CGTCAACGGTTACTTCTTCCGAAAC 
               
               
                 13 
                 2378945 
                 DTL 
                 GTGACCTTACGGCAGAAACTGGACC 
               
               
                 14 
                 2378945 
                 DTL 
                 TACCTACCGAGTGACCTTACGGCAG 
               
               
                 15 
                 2378945 
                 DTL 
                 ACCTTACGGCAGAAACTGGACCGGA 
               
               
                 16 
                 2378945 
                 DTL 
                 ACCGAGTGACCTTACGGCAGAAACT 
               
               
                 17 
                 2378946 
                 DTL 
                 TCGGAGTTCAGTCAACGGAAAAGAT 
               
               
                 18 
                 2378946 
                 DTL 
                 TACGTTTCCAGTAGTTACGTCGGAG 
               
               
                 19 
                 2378946 
                 DTL 
                 CCTGCATTTTCGACCACTCGACTAA 
               
               
                 20 
                 2378946 
                 DTL 
                 ACCTTGTACGTTTCCAGTAGTTACG 
               
               
                 21 
                 2378952 
                 DTL 
                 CCGTTGTAATACCAGACCCTATGGT 
               
               
                 22 
                 2378952 
                 DTL 
                 ACCGTTGTAATACCAGACCCTATGG 
               
               
                 23 
                 2378952 
                 DTL 
                 TACCGTTGTAATACCAGACCCTATG 
               
               
                 24 
                 2378952 
                 DTL 
                 CGTTGTAATACCAGACCCTATGGTC 
               
               
                 25 
                 2378953 
                 DTL 
                 TTATGGAGTCTGTTCGTTTGGGGAA 
               
               
                 26 
                 2378953 
                 DTL 
                 GTTCACTTAGTTTAGTCACCTCGAG 
               
               
                 27 
                 2378953 
                 DTL 
                 ATATCCGTTCACTTAGTTTAGTCAC 
               
               
                 28 
                 2378953 
                 DTL 
                 GTTTAGTCACCTCGAGTGTTATGGA 
               
               
                 29 
                 2378954 
                 DTL 
                 CACCAGGAGAAAGTTCTGCTCTTAT 
               
               
                 30 
                 2378954 
                 DTL 
                 CTTATGGAATCAGAGTCGTCCTCGA 
               
               
                 31 
                 2378954 
                 DTL 
                 GGAGAAAGTTCTGCTCTTATGGAAT 
               
               
                 32 
                 2378954 
                 DTL 
                 AAGGTCGTTTCACAATGACACCAGG 
               
               
                 33 
                 2378956 
                 DTL 
                 AGATGAAATAAACGATTAACGTGTC 
               
               
                 34 
                 2378956 
                 DTL 
                 AACGTGTCTGCTATTGTAGATGTAC 
               
               
                 35 
                 2378956 
                 DTL 
                 CTATAAGTTCAGACTAAAACCTAAG 
               
               
                 36 
                 2378956 
                 DTL 
                 GTAGATGTACAAATTATACTGACCC 
               
               
                 37 
                 2378957 
                 DTL 
                 ATACATTTTAGGTCGGAATCAGGTC 
               
               
                 38 
                 2378957 
                 DTL 
                 TCAAAAATCAGTCACCGAGTTCACT 
               
               
                 39 
                 2378957 
                 DTL 
                 TTAGGTCGGAATCAGGTCTACTGGT 
               
               
                 40 
                 2378957 
                 DTL 
                 ACCGATAAAAGTTACCTGTGGTCTT 
               
               
                 41 
                 2378959 
                 DTL 
                 CGACCACAGGTAGACTGAAGTGTTT 
               
               
                 42 
                 2378959 
                 DTL 
                 CCAGTAAGAGTTCTCCAGTGCAGAC 
               
               
                 43 
                 2378959 
                 DTL 
                 GTGGGACCGTTGGAGGATGACACGA 
               
               
                 44 
                 2378959 
                 DTL 
                 AGGTGTGGGACCGTTGGAGGATGAC 
               
               
                 45 
                 2378960 
                 DTL 
                 TATTAATAGGTCAGTGTTCCGGAAT 
               
               
                 46 
                 2378960 
                 DTL 
                 CTCAGTCGAAACAACCTTTAGACCT 
               
               
                 47 
                 2378960 
                 DTL 
                 AGATATAGGACAAATAATCTGTTTT 
               
               
                 48 
                 2378960 
                 DTL 
                 TGTTCCGGAATTCTGTGTGGACAAA 
               
               
                 49 
                 2378961 
                 DTL 
                 GACCGCGAACTTATCTCCGAATCTC 
               
               
                 50 
                 2378961 
                 DTL 
                 TTAGACCGCGAACTTATCTCCGAAT 
               
               
                 51 
                 2378961 
                 DTL 
                 GCGAACTTATCTCCGAATCTCCTCT 
               
               
                 52 
                 2378961 
                 DTL 
                 TTTTTAGACCGCGAACTTATCTCCG 
               
               
                 53 
                 2378963 
                 DTL 
                 AGTCTTTCGACACCTTGCGATGGAG 
               
               
                 54 
                 2378963 
                 DTL 
                 ACACGACGGAACGACCATTGGTCCT 
               
               
                 55 
                 2378963 
                 DTL 
                 GGTGGACGAAGCCTCTGGTTCTAGT 
               
               
                 56 
                 2378963 
                 DTL 
                 CAGAGGATAGTCAGGCATACGAAGT 
               
               
                 57 
                 2378968 
                 DTL 
                 GTATGAAGGTATCTTTCAGGGTCCT 
               
               
                 58 
                 2378968 
                 DTL 
                 GACGTGTATGAAGGTATCTTTCAGG 
               
               
                 59 
                 2378968 
                 DTL 
                 AAGACACCAGGACTTGTGAGTTGTC 
               
               
                 60 
                 2378968 
                 DTL 
                 AGGACTTGTGAGTTGTCTTAATATC 
               
               
                 61 
                 2378969 
                 DTL 
                 ACCCACGGTTTCCAGTTGACATTAC 
               
               
                 62 
                 2378969 
                 DTL 
                 GGGACTCCTGACACATCTGAAATAC 
               
               
                 63 
                 2378969 
                 DTL 
                 AAGTCCACGTCAGTAGTCAAGAAAT 
               
               
                 64 
                 2378969 
                 DTL 
                 GACCCATATTGTACAGAGTGAACCT 
               
               
                 65 
                 2378970 
                 DTL 
                 AGATGTTTTTTCTTGATATCATCAG 
               
               
                 66 
                 2378970 
                 DTL 
                 ACTCGAAAAACGTAATGGATCTTCG 
               
               
                 67 
                 2378970 
                 DTL 
                 CGTAATGGATCTTCGTCAGATGTTT 
               
               
                 68 
                 2378970 
                 DTL 
                 TCGAAAAACGTAATGGATCTTCGTC 
               
               
                 69 
                 2378972 
                 DTL 
                 ACGTCAGACGTTTCCAGAAGTGTTT 
               
               
                 70 
                 2428797 
                 PTPN22 
                 AAAACGGATTTACCTCATATGGAAC 
               
               
                 71 
                 2428797 
                 PTPN22 
                 CATGTTACATAGGTTGTCTGTGAGT 
               
               
                 72 
                 2428797 
                 PTPN22 
                 TAAGGGACTGTCAATAAAAACGGAT 
               
               
                 73 
                 2428797 
                 PTPN22 
                 CCCAACGTTATGTTTGACGAGAACT 
               
               
                 74 
                 2428798 
                 PTPN22 
                 ATTCACGGTCAAAACGTAAAAGTAT 
               
               
                 75 
                 2428798 
                 PTPN22 
                 CGTTTTACGGTTATTCACGGTCAAA 
               
               
                 76 
                 2428798 
                 PTPN22 
                 TACTTCTATACGATTACACAATTAT 
               
               
                 77 
                 2428798 
                 PTPN22 
                 ATTCACGAGATATACGTATTATAGT 
               
               
                 78 
                 2428799 
                 PTPN22 
                 TCCTTAGGTGGTGGTTGAACCTTAT 
               
               
                 79 
                 2428799 
                 PTPN22 
                 GTTCCTTAGGTGGTGGTTGAACCTT 
               
               
                 80 
                 2428799 
                 PTPN22 
                 CTTAGGTGGTGGTTGAACCTTATAA 
               
               
                 81 
                 2428799 
                 PTPN22 
                 GGTTCCTTAGGTGGTGGTTGAACCT 
               
               
                 82 
                 2428800 
                 PTPN22 
                 AAGAACGGGTGGTTTGTTCGGACGT 
               
               
                 83 
                 2428800 
                 PTPN22 
                 ACAAGTCAGTTTATTGAGGTCGAGT 
               
               
                 84 
                 2428800 
                 PTPN22 
                 AGTTTATTGAGGTCGAGTAAAGACT 
               
               
                 85 
                 2428800 
                 PTPN22 
                 GAACGGGTGGTTTGTTCGGACGTCT 
               
               
                 86 
                 2428801 
                 PTPN22 
                 AGACTCAGACAGAAATCAGAAAGGG 
               
               
                 87 
                 2428801 
                 PTPN22 
                 CACTAGACTAGTTGTCAGTAGACTC 
               
               
                 88 
                 2428801 
                 PTPN22 
                 GAATTGTTAATATACACTAGACTAG 
               
               
                 89 
                 2428801 
                 PTPN22 
                 CATTCGTGGATGTAAAACAATTGTA 
               
               
                 90 
                 2428806 
                 PTPN22 
                 ACTTCTGAGGACCTTTTTCAAAGTG 
               
               
                 91 
                 2428806 
                 PTPN22 
                 CTTCTGAGGACCTTTTTCAAAGTGT 
               
               
                 92 
                 2428806 
                 PTPN22 
                 TCTGAGGACCTTTTTCAAAGTGTTC 
               
               
                 93 
                 2428806 
                 PTPN22 
                 GACTTCTGAGGACCTTTTTCAAAGT 
               
               
                 94 
                 2428809 
                 PTPN22 
                 ATAAAGACCGAAAGGGTCTGATCTT 
               
               
                 95 
                 2428809 
                 PTPN22 
                 CAATTCAAATCTCATTAAGTGAAGT 
               
               
                 96 
                 2428809 
                 PTPN22 
                 AGTGAAGTCCTTCAATGAACCAAGG 
               
               
                 97 
                 2428809 
                 PTPN22 
                 CCAAGGGTATTATCGAAGGTCATAA 
               
               
                 98 
                 2428810 
                 PTPN22 
                 ACATTTTGAGGCTTCAGGATTTAGT 
               
               
                 99 
                 2428811 
                 PTPN22 
                 CTTCCATTTTTAACCTTGTAGTGAC 
               
               
                 100 
                 2428811 
                 PTPN22 
                 ACTACTGAGACACTATGAATCTGGT 
               
               
                 101 
                 2428811 
                 PTPN22 
                 ACCCCACCTTGTAGACTTGGTTTCT 
               
               
                 102 
                 2428811 
                 PTPN22 
                 GAGACACTATGAATCTGGTTCGTTC 
               
               
                 103 
                 2428814 
                 PTPN22 
                 GGTGAAGGACATACCTGTGGACTTA 
               
               
                 104 
                 2428814 
                 PTPN22 
                 GGACTTAGTAAATAACACCAACTCC 
               
               
                 105 
                 2428814 
                 PTPN22 
                 GACATACCTGTGGACTTAGTAAATA 
               
               
                 106 
                 2428814 
                 PTPN22 
                 AAGGACATACCTGTGGACTTAGTAA 
               
               
                 107 
                 2428815 
                 PTPN22 
                 GGTACTGAGATCACGAGAACCACAT 
               
               
                 108 
                 2428815 
                 PTPN22 
                 TCTCGATCAAAACGTGGGACGATTT 
               
               
                 109 
                 2428815 
                 PTPN22 
                 AGTAGTACCGGAGGTTCACCATGGT 
               
               
                 110 
                 2428815 
                 PTPN22 
                 GGTTATCAACCCCTCGGAGAAGTCT 
               
               
                 111 
                 2428817 
                 PTPN22 
                 ATCTTGATAAATTCTCTGTCTACCT 
               
               
                 112 
                 2428817 
                 PTPN22 
                 TCTCTGTCTACCTACAATAGTCTCT 
               
               
                 113 
                 2428817 
                 PTPN22 
                 CCAGATGTTACGACATAATCTTGAT 
               
               
                 114 
                 2428817 
                 PTPN22 
                 ACTTGACCAGATGTTACGACATAAT 
               
               
                 115 
                 2428818 
                 PTPN22 
                 GTCTCCGGAAGTAATCAAGTTTGCG 
               
               
                 116 
                 2428818 
                 PTPN22 
                 CAAAAGTCAAACTAGGCCCTTTACG 
               
               
                 117 
                 2428818 
                 PTPN22 
                 CTCCGGAAGTAATCAAGTTTGCGTC 
               
               
                 118 
                 2428818 
                 PTPN22 
                 GCCCTTTACGCCTGTGTCTCCGGAA 
               
               
                 119 
                 2428819 
                 PTPN22 
                 ACGATAACTAATATGTACCTACAAC 
               
               
                 120 
                 2428819 
                 PTPN22 
                 AACTAATATGTACCTACAACGATTT 
               
               
                 121 
                 2428819 
                 PTPN22 
                 ACACGATAACTAATATGTACCTACA 
               
               
                 122 
                 2428819 
                 PTPN22 
                 GATAACTAATATGTACCTACAACGA 
               
               
                 123 
                 2428821 
                 PTPN22 
                 AGTAGACCCTACATGCAACAATGGT 
               
               
                 124 
                 2428821 
                 PTPN22 
                 CTACTGTCACAAGGGTATACGTAAG 
               
               
                 125 
                 2428821 
                 PTPN22 
                 ATATCTGGGATAAGAACTCGAGTAG 
               
               
                 126 
                 2428821 
                 PTPN22 
                 CTACATGGAAGTAGATATCTGGGAT 
               
               
                 127 
                 2428823 
                 PTPN22 
                 GACTAATATATTAGTCCTGAGATTT 
               
               
                 128 
                 2428823 
                 PTPN22 
                 CTAATATATTAGTCCTGAGATTTTC 
               
               
                 129 
                 2428823 
                 PTPN22 
                 ATATATTAGTCCTGAGATTTTCAAT 
               
               
                 130 
                 2428823 
                 PTPN22 
                 ATATTAGTCCTGAGATTTTCAATTC 
               
               
                 131 
                 2428826 
                 PTPN22 
                 ACAATACCGTACGTACCTCATACTT 
               
               
                 132 
                 2428826 
                 PTPN22 
                 ATACCGTACGTACCTCATACTTTAC 
               
               
                 133 
                 2428826 
                 PTPN22 
                 TACGTACCTCATACTTTACCCTTTC 
               
               
                 134 
                 2428826 
                 PTPN22 
                 AGTAACAATACCGTACGTACCTCAT 
               
               
                 135 
                 2428828 
                 PTPN22 
                 AGGGACTATTGGAGACTACTCCTAA 
               
               
                 136 
                 2428828 
                 PTPN22 
                 TATCGGCCCATCTTGATAGGGACTA 
               
               
                 137 
                 2428828 
                 PTPN22 
                 CTAATATCGGCCCATCTTGATAGGG 
               
               
                 138 
                 2428828 
                 PTPN22 
                 CTTGATAGGGACTATTGGAGACTAC 
               
               
                 139 
                 2428829 
                 PTPN22 
                 GATAGGATGTTGACACCGACTCTTC 
               
               
                 140 
                 2428829 
                 PTPN22 
                 CCGTCTGTTTTGGATAGGATGTTGA 
               
               
                 141 
                 2428829 
                 PTPN22 
                 GTTAGATGGTTCATGTTCCGTCTGT 
               
               
                 142 
                 2428829 
                 PTPN22 
                 TTTCCGTTAGATGGTTCATGTTCCG 
               
               
                 143 
                 2428831 
                 PTPN22 
                 TACCTGGTTTCTCTTTAAGACGTCT 
               
               
                 144 
                 2428831 
                 PTPN22 
                 TCTCCTCAAACGGTTACTTAAAGAC 
               
               
                 145 
                 2428831 
                 PTPN22 
                 TTAATGATTTCTCCTCAAACGGTTA 
               
               
                 146 
                 2428831 
                 PTPN22 
                 CTACTCCGGGTTTCGTTCTTTTAAT 
               
               
                 147 
                 2482925 
                 RPS27A 
                 CGCAGACCATCTAACGACTAAGAGA 
               
               
                 148 
                 2482925 
                 RPS27A 
                 CGGGTTCCTCGCAGACCATCTAACG 
               
               
                 149 
                 2482925 
                 RPS27A 
                 CCTCGCAGACCATCTAACGACTAAG 
               
               
                 150 
                 2482925 
                 RPS27A 
                 CGTCCCTCCGCGATGTCCTCTCTTT 
               
               
                 151 
                 2482926 
                 RPS27A 
                 ATCGGTGCAACTAACATGCCCTTTT 
               
               
                 152 
                 2482926 
                 RPS27A 
                 AAGAGAATCGGTGCAACTAACATGC 
               
               
                 153 
                 2482926 
                 RPS27A 
                 GAGAATCGGTGCAACTAACATGCCC 
               
               
                 154 
                 2482926 
                 RPS27A 
                 GTGCAACTAACATGCCCTTTTCGGA 
               
               
                 155 
                 2482927 
                 RPS27A 
                 AAAGCTTTCGTAAGGCTTCCGATTT 
               
               
                 156 
                 2482928 
                 RPS27A 
                 AGCGACCCTGCCGTCAGTCCGTAAA 
               
               
                 157 
                 2482928 
                 RPS27A 
                 TGCTTCAAGTGCAGGATCAGACCGT 
               
               
                 158 
                 2482928 
                 RPS27A 
                 AGACCGTGGCCCAACCTAACAGCGA 
               
               
                 159 
                 2482928 
                 RPS27A 
                 CCTCTCCTCTTTGCTTCAAGTGCAG 
               
               
                 160 
                 2482929 
                 RPS27A 
                 AGAACACTAGGGACTGGATTGGACA 
               
               
                 161 
                 2482929 
                 RPS27A 
                 CGACGAGAGCCCAATCGTGGGATAC 
               
               
                 162 
                 2482929 
                 RPS27A 
                 AGACGTGAAGCCGACGAGAGCCCAA 
               
               
                 163 
                 2482929 
                 RPS27A 
                 CGTGGGATACCACGGAAGAGAACAC 
               
               
                 164 
                 2482931 
                 RPS27A 
                 AAACGACTCGTTGCTGGATCTCCAC 
               
               
                 165 
                 2482931 
                 RPS27A 
                 TGGACAGAGGAGAGCTCCCCAAGGT 
               
               
                 166 
                 2482931 
                 RPS27A 
                 TCGGTTCCAGGCTTATTCCAGGACT 
               
               
                 167 
                 2482931 
                 RPS27A 
                 CAGAATCTGGTACTAAGGCTTAAAC 
               
               
                 168 
                 2482934 
                 RPS27A 
                 TCACTCACCGCGTCAGTGACGTTGG 
               
               
                 169 
                 2482934 
                 RPS27A 
                 GTAAGCTTATCGTCATCTAAAAATC 
               
               
                 170 
                 2482934 
                 RPS27A 
                 CCTTTTACCGTAAGCTTATCGTCAT 
               
               
                 171 
                 2482934 
                 RPS27A 
                 CTCACTCACCGCGTCAGTGACGTTG 
               
               
                 172 
                 2482935 
                 RPS27A 
                 TACAGGGATATTTGACAGTCAATTC 
               
               
                 173 
                 2482935 
                 RPS27A 
                 CATAGGGTACCACATTACATTACGT 
               
               
                 174 
                 2482935 
                 RPS27A 
                 ACTCTTCGTGACGATATCAAGAGGG 
               
               
                 175 
                 2482935 
                 RPS27A 
                 GAGGGTAATACTTAAAACGTTCAAC 
               
               
                 176 
                 2482936 
                 RPS27A 
                 ACTTTCGAACGAAGTAAGAAGGTAA 
               
               
                 177 
                 2482936 
                 RPS27A 
                 ACCTTAGTACTTTCGAACGAAGTAA 
               
               
                 178 
                 2482936 
                 RPS27A 
                 CGAACGAAGTAAGAAGGTAATTGTC 
               
               
                 179 
                 2482936 
                 RPS27A 
                 TAGTACTTTCGAACGAAGTAAGAAG 
               
               
                 180 
                 2482937 
                 RPS27A 
                 TCTTCTTCAGAATGTGGTGAGGGTT 
               
               
                 181 
                 2482937 
                 RPS27A 
                 CGTGTTCTCTTTCTTCCAATTCGAC 
               
               
                 182 
                 2482937 
                 RPS27A 
                 ACAACTCTGAAGCACCACCACGATT 
               
               
                 183 
                 2482937 
                 RPS27A 
                 CAATTCGACCGACAGGACTTTATAA 
               
               
                 184 
                 2482940 
                 RPS27A 
                 CAAATACCGTTCAGTGAAACTGTCT 
               
               
                 185 
                 2482940 
                 RPS27A 
                 ACCGTTTTAATCAGCGGAAGCAGCT 
               
               
                 186 
                 2482940 
                 RPS27A 
                 GCGGAAGCAGCTCTCACGGGAAGAC 
               
               
                 187 
                 2482940 
                 RPS27A 
                 ACAGACTGAATGACAAAGTTGTTTG 
               
               
                 188 
                 2482941 
                 RPS27A 
                 CGATAGCGACACACTTACAACGGAG 
               
               
                 189 
                 2482941 
                 RPS27A 
                 GTCCACGGTTGGTGAACATTTCCAG 
               
               
                 190 
                 2482941 
                 RPS27A 
                 GGTCACCAAGACATATGGACGGTCC 
               
               
                 191 
                 2482941 
                 RPS27A 
                 AACGGAGACCCCTAATACACTGGGT 
               
               
                 192 
                 2482944 
                 RPS27A 
                 AGTCGGGACAGCGACCAAGCCAAGT 
               
               
                 193 
                 2482944 
                 RPS27A 
                 CCATTAACAGTTTGATTTACTCAAG 
               
               
                 194 
                 2482944 
                 RPS27A 
                 TTTACTCAAGACGACATCAAGGAAT 
               
               
                 195 
                 2482944 
                 RPS27A 
                 GGAATTACACATTGGTTGTACGAAA 
               
               
                 196 
                 2482946 
                 RPS27A 
                 TGAACGCACTTAAACCTGTGAATAA 
               
               
                 197 
                 2482946 
                 RPS27A 
                 ATGGATCTAACCTTAGGAACTCCAC 
               
               
                 198 
                 2482946 
                 RPS27A 
                 CGTGTCATGGATCTAACCTTAGGAA 
               
               
                 199 
                 2482946 
                 RPS27A 
                 CTCCACATAAAGTGAACGCACTTAA 
               
               
                 200 
                 2508612 
                 ARHGAP15 
                 CAAAGTTATTGTCCAGTAACGGCTC 
               
               
                 201 
                 2508612 
                 ARHGAP15 
                 TGTCCGGATGAGAATGCTGTACACT 
               
               
                 202 
                 2508612 
                 ARHGAP15 
                 TAATTGTCAATCCTCAACTACCGTC 
               
               
                 203 
                 2508612 
                 ARHGAP15 
                 AATTCGTCGTAGGTTGTGTCCGGAT 
               
               
                 204 
                 2508620 
                 ARHGAP15 
                 TCCTTAGTAAGTGTCGTATAGAACT 
               
               
                 205 
                 2508620 
                 ARHGAP15 
                 TTAGTAAGTGTCGTATAGAACTTTC 
               
               
                 206 
                 2508620 
                 ARHGAP15 
                 TTCCTTAGTAAGTGTCGTATAGAAC 
               
               
                 207 
                 2508620 
                 ARHGAP15 
                 CCTTAGTAAGTGTCGTATAGAACTT 
               
               
                 208 
                 2508622 
                 ARHGAP15 
                 ACCAACTTTTTCTTCCAATAGACGT 
               
               
                 209 
                 2508627 
                 ARHGAP15 
                 ACTTAATTCGTTACTGTGTACTCCG 
               
               
                 210 
                 2508627 
                 ARHGAP15 
                 CTTAATTCGTTACTGTGTACTCCGA 
               
               
                 211 
                 2508627 
                 ARHGAP15 
                 AACTTAATTCGTTACTGTGTACTCC 
               
               
                 212 
                 2508627 
                 ARHGAP15 
                 AAACTTAATTCGTTACTGTGTACTC 
               
               
                 213 
                 2508628 
                 ARHGAP15 
                 TTCTTAGGTTCGTTGTCCGAGACAG 
               
               
                 214 
                 2508628 
                 ARHGAP15 
                 TTTCTTAGGTTCGTTGTCCGAGACA 
               
               
                 215 
                 2508628 
                 ARHGAP15 
                 AACAAGAAAGATCAGCTTCTTAACT 
               
               
                 216 
                 2508628 
                 ARHGAP15 
                 GAAAGATCAGCTTCTTAACTTAAAA 
               
               
                 217 
                 2508633 
                 ARHGAP15 
                 CACGTAAGAACATGCACTCCACAAA 
               
               
                 218 
                 2508633 
                 ARHGAP15 
                 CGACCACGTAAGAACATGCACTCCA 
               
               
                 219 
                 2508633 
                 ARHGAP15 
                 CCACGTAAGAACATGCACTCCACAA 
               
               
                 220 
                 2508633 
                 ARHGAP15 
                 GACCACGTAAGAACATGCACTCCAC 
               
               
                 221 
                 2508634 
                 ARHGAP15 
                 TTTGACCCGTGTTTGGTCTTTCACA 
               
               
                 222 
                 2508634 
                 ARHGAP15 
                 TTTTGACCCGTGTTTGGTCTTTCAC 
               
               
                 223 
                 2508634 
                 ARHGAP15 
                 TCCTTTTTAGCTCGTCTTTCTTACA 
               
               
                 224 
                 2508674 
                 ARHGAP15 
                 GTATCAAAGAAATGGACAGATAAAG 
               
               
                 225 
                 2508674 
                 ARHGAP15 
                 AACCTCATTAAGTCGAGATCGGGAT 
               
               
                 226 
                 2508674 
                 ARHGAP15 
                 ATCTCTCGCCAAGTTTTACGAGGGT 
               
               
                 227 
                 2508674 
                 ARHGAP15 
                 CGGGATGAGACTGAATTAGCAAGAT 
               
               
                 228 
                 2508675 
                 ARHGAP15 
                 AGTAGTATAACCTAACCAAGGTGCG 
               
               
                 229 
                 2508675 
                 ARHGAP15 
                 GGTGCGATAGTTTTTACGTTAACTG 
               
               
                 230 
                 2508675 
                 ARHGAP15 
                 CTCAAGGAAGATGTCAGTCTATAAC 
               
               
                 231 
                 2508675 
                 ARHGAP15 
                 GTGTTGTCATAGTCCTTTACTCAAG 
               
               
                 232 
                 2508676 
                 ARHGAP15 
                 AGGAGATCGTGACTTAACGATTCAG 
               
               
                 233 
                 2508676 
                 ARHGAP15 
                 AAGTTTTAGGTTTCTAGGAGATCGT 
               
               
                 234 
                 2508676 
                 ARHGAP15 
                 ACGATTCAGTGATGCTGTCACTATA 
               
               
                 235 
                 2508676 
                 ARHGAP15 
                 GGTAGTTCTTTGGACCTTAATAAGT 
               
               
                 236 
                 2508677 
                 ARHGAP15 
                 GAACGAGTAAAATTCAAACAGATTT 
               
               
                 237 
                 2508677 
                 ARHGAP15 
                 ACGAGTAAAATTCAAACAGATTTAC 
               
               
                 238 
                 2508677 
                 ARHGAP15 
                 TGAACGAGTAAAATTCAAACAGATT 
               
               
                 239 
                 2508677 
                 ARHGAP15 
                 CGAGTAAAATTCAAACAGATTTACG 
               
               
                 240 
                 2508678 
                 ARHGAP15 
                 CTAAACACGTGACCTCCCGTCAGAC 
               
               
                 241 
                 2508678 
                 ARHGAP15 
                 AGTATGAGTACCTTCTAAGCATCGG 
               
               
                 242 
                 2508678 
                 ARHGAP15 
                 ATCGGTAAAGGACCGGTCCCTAAAC 
               
               
                 243 
                 2508678 
                 ARHGAP15 
                 GTAGTAACAACCATTACGGAAAACT 
               
               
                 244 
                 2508691 
                 ARHGAP15 
                 CTATGTTCGCTGTTTTTAGCTCAAT 
               
               
                 245 
                 2508691 
                 ARHGAP15 
                 ACAAGTCTGACGTAGTGTCACGAAG 
               
               
                 246 
                 2508691 
                 ARHGAP15 
                 GCTGTTTTTAGCTCAATTTTCGTCT 
               
               
                 247 
                 2508691 
                 ARHGAP15 
                 GTGTCACGAAGGCTATGTTCGCTGT 
               
               
                 248 
                 2508699 
                 ARHGAP15 
                 AAACATTTCGTTACGTAACTTCGAC 
               
               
                 249 
                 2508699 
                 ARHGAP15 
                 ACGTGTTTCACACACTTGCACTTTT 
               
               
                 250 
                 2508699 
                 ARHGAP15 
                 AGGTGTCAAGGCACCAAACATTTCG 
               
               
                 251 
                 2508699 
                 ARHGAP15 
                 GTGTTTCACACACTTGCACTTTTAA 
               
               
                 252 
                 2508700 
                 ARHGAP15 
                 GGAGATGTGTTGGTTATGAGTTCAA 
               
               
                 253 
                 2508700 
                 ARHGAP15 
                 ACGGTGGACTAAACAGACTCTTCGG 
               
               
                 254 
                 2508700 
                 ARHGAP15 
                 GAGTTCAATCGTCACGGTGGACTAA 
               
               
                 255 
                 2508700 
                 ARHGAP15 
                 ACACGTCGTCAAGGGGGGTAATGAC 
               
               
                 256 
                 2508706 
                 ARHGAP15 
                 CAGATCTACAACTACCTTATATAGC 
               
               
                 257 
                 2508706 
                 ARHGAP15 
                 AGCTCAATCACCGTTAGACCGTTGT 
               
               
                 258 
                 2508706 
                 ARHGAP15 
                 ATCACCGTTAGACCGTTGTTATGTC 
               
               
                 259 
                 2508706 
                 ARHGAP15 
                 CCTTATATAGCTCAATCACCGTTAG 
               
               
                 260 
                 2508711 
                 ARHGAP15 
                 GGTCGGGAAGATAGTCTTGACCTAC 
               
               
                 261 
                 2508711 
                 ARHGAP15 
                 TCTTGACCTACCTCTGGACACCTGT 
               
               
                 262 
                 2508711 
                 ARHGAP15 
                 CGGGAAGATAGTCTTGACCTACCTC 
               
               
                 263 
                 2508711 
                 ARHGAP15 
                 AGACCTTATGGTCGGGAAGATAGTC 
               
               
                 264 
                 2508712 
                 ARHGAP15 
                 GACGTCTAAAAAGTGTCACCAGTAA 
               
               
                 265 
                 2508712 
                 ARHGAP15 
                 TGGAGGTCTCGTTCGGTTATTAAAC 
               
               
                 266 
                 2508712 
                 ARHGAP15 
                 TCACCAGTAAACTGGAGGTCTCGTT 
               
               
                 267 
                 2508712 
                 ARHGAP15 
                 CGACGTCTAAAAAGTGTCACCAGTA 
               
               
                 268 
                 2508716 
                 ARHGAP15 
                 TCACCTAACCTCTGGTAGTGGAAAG 
               
               
                 269 
                 2508716 
                 ARHGAP15 
                 TTCACCTAACCTCTGGTAGTGGAAA 
               
               
                 270 
                 2508716 
                 ARHGAP15 
                 ACCTAACCTCTGGTAGTGGAAAGAG 
               
               
                 271 
                 2508716 
                 ARHGAP15 
                 CACCTAACCTCTGGTAGTGGAAAGA 
               
               
                 272 
                 2508717 
                 ARHGAP15 
                 GGTTTCCTGGACACTAGAGTGGACG 
               
               
                 273 
                 2508717 
                 ARHGAP15 
                 TTAACCTGGTGATGTCCGAGACTGG 
               
               
                 274 
                 2508717 
                 ARHGAP15 
                 ACTAGGGTTGGTTTGTATCACTTCC 
               
               
                 275 
                 2508717 
                 ARHGAP15 
                 CCGAGACTGGTGTACATACTCTTCG 
               
               
                 276 
                 2508718 
                 ARHGAP15 
                 TCGAAGTCTCCAGGCTTAAACCGGT 
               
               
                 277 
                 2508718 
                 ARHGAP15 
                 CTGAAGCCGGCAATTCTAAACGAAG 
               
               
                 278 
                 2508718 
                 ARHGAP15 
                 GACCCTCTGAGCACGAGACATTCGT 
               
               
                 279 
                 2508718 
                 ARHGAP15 
                 TAGTACGACTGTATCTCCGTGGAAC 
               
               
                 280 
                 2508719 
                 ARHGAP15 
                 TTGTAAGAGTTTTCCCGTGTCCGGG 
               
               
                 281 
                 2508719 
                 ARHGAP15 
                 GACCAGCAGATAACACAGTCTTTCG 
               
               
                 282 
                 2508719 
                 ARHGAP15 
                 GACAGTTCATCAGTGTGCCTTTAAT 
               
               
                 283 
                 2508719 
                 ARHGAP15 
                 GATTGATTAACTTGATGACCAGCAG 
               
               
                 284 
                 2508725 
                 ARHGAP15 
                 CCTGTAGGTGCAACAGTGGCCTCGT 
               
               
                 285 
                 2508725 
                 ARHGAP15 
                 TCGACTTAAACCTGCTGTCGGTCAC 
               
               
                 286 
                 2508725 
                 ARHGAP15 
                 ACTCGGCGAGAAGGGAATGTCAAAG 
               
               
                 287 
                 2508725 
                 ARHGAP15 
                 GTGGCCTCGTGACTTCTACAAAAAG 
               
               
                 288 
                 2508741 
                 ARHGAP15 
                 GAGGCGGTTTAGCACTGTGGTACTT 
               
               
                 289 
                 2508741 
                 ARHGAP15 
                 AGAACATGTTTTTGAGGGAGGCGGT 
               
               
                 290 
                 2508741 
                 ARHGAP15 
                 TAACTTCGACATTTTAGAGAACATG 
               
               
                 291 
                 2508741 
                 ARHGAP15 
                 GCGGTTTAGCACTGTGGTACTTTCA 
               
               
                 292 
                 2508742 
                 ARHGAP15 
                 ACGCATGTAGAGCATAAAAGGGAAC 
               
               
                 293 
                 2508742 
                 ARHGAP15 
                 CATGGTGCACGACCCCGGTGTTTAT 
               
               
                 294 
                 2508742 
                 ARHGAP15 
                 GGGAACATCGACTTGATCCAGAAAG 
               
               
                 295 
                 2508742 
                 ARHGAP15 
                 ACGAACAGTCTTGGTAGCGGACCTG 
               
               
                 296 
                 2508746 
                 ARHGAP15 
                 GTCTTTTCGTGAGGTAAAAACGTCT 
               
               
                 297 
                 2508746 
                 ARHGAP15 
                 GAATTACGCCGTGTCAACCTGATCT 
               
               
                 298 
                 2508746 
                 ARHGAP15 
                 AAGGTGAACTGGATGCATGAGATGT 
               
               
                 299 
                 2508746 
                 ARHGAP15 
                 CCCTTACATTACTTCACGGTTTTTA 
               
               
                 300 
                 2508762 
                 ARHGAP15 
                 CTTTGTACCGCTAGGTGTACCAGAT 
               
               
                 301 
                 2508762 
                 ARHGAP15 
                 CGAACCCCTAACATAAACCTGGATG 
               
               
                 302 
                 2508762 
                 ARHGAP15 
                 ACCAGATGGTCTTGGTCTATCGACT 
               
               
                 303 
                 2508762 
                 ARHGAP15 
                 AACCTGGATGGGAAGACGCTCGACT 
               
               
                 304 
                 2508763 
                 ARHGAP15 
                 ATTCTAGAAGCCGAGTCTCCTTCTG 
               
               
                 305 
                 2508763 
                 ARHGAP15 
                 CATTCTAGAAGCCGAGTCTCCTTCT 
               
               
                 306 
                 2508763 
                 ARHGAP15 
                 TCTAGAAGCCGAGTCTCCTTCTGAC 
               
               
                 307 
                 2508763 
                 ARHGAP15 
                 CTAGAAGCCGAGTCTCCTTCTGACT 
               
               
                 308 
                 2508764 
                 ARHGAP15 
                 CGATGACTTATGCAAGTGTAGACAG 
               
               
                 309 
                 2508764 
                 ARHGAP15 
                 ATGTAAAGACATTTGTATAAAGACT 
               
               
                 310 
                 2508764 
                 ARHGAP15 
                 GAAAGTTCGCTGTCTACGGAGTAAA 
               
               
                 311 
                 2508764 
                 ARHGAP15 
                 AACACAAATTCAAGGTTTGTAAACT 
               
               
                 312 
                 2571511 
                 IL1B 
                 GGTGTAAGACTACTCGTTGGCGAAG 
               
               
                 313 
                 2571511 
                 IL1B 
                 CCTGAGTTAGGGATCCCGACCGTCT 
               
               
                 314 
                 2571511 
                 IL1B 
                 CGGGAAAACAACTCGGTCCGGAGAG 
               
               
                 315 
                 2571511 
                 IL1B 
                 TTCTCCTAGAGGACAGGTAGTCGGT 
               
               
                 316 
                 2571512 
                 IL1B 
                 GGTTTCCGCCGGTCCTATATTGACT 
               
               
                 317 
                 2571512 
                 IL1B 
                 TTGACTGAAGTGGTACGTTAAACAC 
               
               
                 318 
                 2571512 
                 IL1B 
                 TTGTACGGGCAGAAGGACCCTCCCT 
               
               
                 319 
                 2571512 
                 IL1B 
                 GACCTTAAACTCAGACGGGTCAAGG 
               
               
                 320 
                 2571513 
                 IL1B 
                 GCGGGGGTAGGGATCCTTTTCGACC 
               
               
                 321 
                 2571513 
                 IL1B 
                 TTACGATACCTTACTTCGGGAAGAG 
               
               
                 322 
                 2571513 
                 IL1B 
                 ACTTACGATACCTTACTTCGGGAAG 
               
               
                 323 
                 2571513 
                 IL1B 
                 AACTGTTAAAACGTAATTACATTTA 
               
               
                 324 
                 2571514 
                 IL1B 
                 AGGACGCACAACTTTCTACTATTCG 
               
               
                 325 
                 2571514 
                 IL1B 
                 CCACAAGAGGTACAGGAAACATGTT 
               
               
                 326 
                 2571514 
                 IL1B 
                 TAGACATGGACAGGACGCACAACTT 
               
               
                 327 
                 2571514 
                 IL1B 
                 ACTATTCGGGTGAGATGTCGACCTC 
               
               
                 328 
                 2571517 
                 IL1B 
                 CGTGCTACGTGGACATGCTAGTGAC 
               
               
                 329 
                 2571517 
                 IL1B 
                 ATTGCTCCGAATACACGTGCTACGT 
               
               
                 330 
                 2571517 
                 IL1B 
                 AGACCAGGTATACTTGACTTTCGAG 
               
               
                 331 
                 2571517 
                 IL1B 
                 AGTGACTTGACGTGCGAGGCCCTGA 
               
               
                 332 
                 2571518 
                 IL1B 
                 GGAGGGACACCCGATCACAATACTG 
               
               
                 333 
                 2571518 
                 IL1B 
                 CGACCTTGGGTACAGATTATCACAG 
               
               
                 334 
                 2571518 
                 IL1B 
                 GTCCCCGGAAAGTGAATGTAACAGT 
               
               
                 335 
                 2571518 
                 IL1B 
                 ATTCATCGAGACAACGAGCCGGTGT 
               
               
                 336 
                 2571519 
                 IL1B 
                 GTCCGGCGCAGTCAACAACACCGGT 
               
               
                 337 
                 2571519 
                 IL1B 
                 CCTACCGCCGTAGGTCGATGCTTAG 
               
               
                 338 
                 2571519 
                 IL1B 
                 CGCAGTCAACAACACCGGTACCTGT 
               
               
                 339 
                 2571519 
                 IL1B 
                 ATGCTTAGAGGCTGGTGGTGATGTC 
               
               
                 340 
                 2571520 
                 IL1B 
                 CCTACTGAACAAGAAACTTCGACTA 
               
               
                 341 
                 2571520 
                 IL1B 
                 CGTTACTCCTACTGAACAAGAAACT 
               
               
                 342 
                 2571520 
                 IL1B 
                 TACTCCTACTGAACAAGAAACTTCG 
               
               
                 343 
                 2571520 
                 IL1B 
                 CTCCTACTGAACAAGAAACTTCGAC 
               
               
                 344 
                 2571522 
                 IL1B 
                 TCATGGACTCGAGCGGTCACTTTAC 
               
               
                 345 
                 2571522 
                 IL1B 
                 GCGGTCACTTTACTACCGAATAATG 
               
               
                 346 
                 2571522 
                 IL1B 
                 TGGACTCGAGCGGTCACTTTACTAC 
               
               
                 347 
                 2571522 
                 IL1B 
                 TCGAGCGGTCACTTTACTACCGAAT 
               
               
                 348 
                 2571523 
                 IL1B 
                 CAGTACCCCTTCAGTGAGTAAAAGA 
               
               
                 349 
                 2571523 
                 IL1B 
                 CGGCAGTACCCCTTCAGTGAGTAAA 
               
               
                 350 
                 2571523 
                 IL1B 
                 ACTTGCATCGGCAGTACCCCTTCAG 
               
               
                 351 
                 2571523 
                 IL1B 
                 CTTTAGTGTGTACTTGCATCGGCAG 
               
               
                 352 
                 2571524 
                 IL1B 
                 TATAAGACCCTTACCTATGACGAAT 
               
               
                 353 
                 2571524 
                 IL1B 
                 GAATACTGAGCCCTTTATAAGACCC 
               
               
                 354 
                 2571524 
                 IL1B 
                 TTCCAATCACAGTTTCGGAGACGAG 
               
               
                 355 
                 2571524 
                 IL1B 
                 GTTGATCCACGATTCCCTCAGAGAG 
               
               
                 356 
                 2571525 
                 IL1B 
                 CGGTATTTTTGTCGCTCCCTCTTTG 
               
               
                 357 
                 2571525 
                 IL1B 
                 TGGAGAAGCTCCGTGTTCCGTGTTG 
               
               
                 358 
                 2571525 
                 IL1B 
                 TCTATGGTTTGGAGAAGCTCCGTGT 
               
               
                 359 
                 2571525 
                 IL1B 
                 GGTTTGGAGAAGCTCCGTGTTCCGT 
               
               
                 360 
                 2674763 
                 UBA7 
                 ATCGAGTTACCTCGGGGCCTAGGGT 
               
               
                 361 
                 2674763 
                 UBA7 
                 TACCTCGGGGCCTAGGGTTCGGGAC 
               
               
                 362 
                 2674763 
                 UBA7 
                 ACAGTGGATCGAGTTACCTCGGGGC 
               
               
                 363 
                 2674763 
                 UBA7 
                 GTGGGACAGTGGATCGAGTTACCTC 
               
               
                 364 
                 2674764 
                 UBA7 
                 CACTGCTGCTCCTGTGACGGAAGGG 
               
               
                 365 
                 2674764 
                 UBA7 
                 CCGTCGCCCACAACCACGATCTCGA 
               
               
                 366 
                 2674764 
                 UBA7 
                 CGTCGCCCACAACCACGATCTCGAC 
               
               
                 367 
                 2674766 
                 UBA7 
                 GCCTACCAGTGGACTTTTCGTCCGG 
               
               
                 368 
                 2674766 
                 UBA7 
                 TACGCCGGCCTACCAGTGGACTTTT 
               
               
                 369 
                 2674766 
                 UBA7 
                 GTCGGGACGAGATACGCCGGCCTAC 
               
               
                 370 
                 2674766 
                 UBA7 
                 TGGACTTTTCGTCCGGGTCGTGGAC 
               
               
                 371 
                 2674767 
                 UBA7 
                 CACACGGGACAACGATGGGGTTGGG 
               
               
                 372 
                 2674767 
                 UBA7 
                 GACCACAGACTGGAAAGAGGAGATC 
               
               
                 373 
                 2674767 
                 UBA7 
                 ACGGGACAACGATGGGGTTGGGGGT 
               
               
                 374 
                 2674767 
                 UBA7 
                 TCGACCACAGACTGGAAAGAGGAGA 
               
               
                 375 
                 2674768 
                 UBA7 
                 CTGGCAGACTTCCATGGTCGACCCG 
               
               
                 376 
                 2674768 
                 UBA7 
                 GTGGACTTCACCTGGAGAACCCTGG 
               
               
                 377 
                 2674768 
                 UBA7 
                 CCTCAGCGACGACCGAGTAGAAGTC 
               
               
                 378 
                 2674768 
                 UBA7 
                 TCACCTGGAGAACCCTGGCAGACTT 
               
               
                 379 
                 2674772 
                 UBA7 
                 GCCGTCGATCGGACTCTACAGTCTT 
               
               
                 380 
                 2674772 
                 UBA7 
                 CTAAGGTGGCCAGTTGGCACGGGTC 
               
               
                 381 
                 2674772 
                 UBA7 
                 CTGAAACACCATCGCCGTCGATCGG 
               
               
                 382 
                 2674772 
                 UBA7 
                 GACTCTACAGTCTTGATGCCCTAAG 
               
               
                 383 
                 2674773 
                 UBA7 
                 TGTTTCGGGACCTTCAGACCTCACA 
               
               
                 384 
                 2674773 
                 UBA7 
                 GGGACTTCGGAGACTACAAACTCTT 
               
               
                 385 
                 2674773 
                 UBA7 
                 GTCGTCTTCCTTGACTTGTTTCGGG 
               
               
                 386 
                 2674773 
                 UBA7 
                 CCTCACACCCGGGAGGGGACTTCGG 
               
               
                 387 
                 2674775 
                 UBA7 
                 AGGAGATGCATGACCGTCGACGGTT 
               
               
                 388 
                 2674775 
                 UBA7 
                 TAGATCTCGACCGAAGCCGAAGACG 
               
               
                 389 
                 2674775 
                 UBA7 
                 GTCCTGACCTGACGTGAGTCCCTCG 
               
               
                 390 
                 2674775 
                 UBA7 
                 CGGTTGGACATACGGGTCTACGTAC 
               
               
                 391 
                 2674776 
                 UBA7 
                 GGGAGTCTCGTCTCCATCCGTAAAG 
               
               
                 392 
                 2674776 
                 UBA7 
                 GGTCTCTCTCGGTACGAACACGTAT 
               
               
                 393 
                 2674776 
                 UBA7 
                 ACCCTAAGACATCCCTCGAGGTTCT 
               
               
                 394 
                 2674776 
                 UBA7 
                 CGTTTCCGTCCGTGAGTTTGTCTAG 
               
               
                 395 
                 2674777 
                 UBA7 
                 CACGAACTCCTACCTTGAGGGAAGA 
               
               
                 396 
                 2674777 
                 UBA7 
                 CAGTCCAGGGTTTGTCACAGGGGTC 
               
               
                 397 
                 2674777 
                 UBA7 
                 GGGAAGACCAGTCCAGGGTTTGTCA 
               
               
                 398 
                 2674777 
                 UBA7 
                 CGAACTCCTACCTTGAGGGAAGACC 
               
               
                 399 
                 2674778 
                 UBA7 
                 TCGGGTCGTCGAAGATGAATGGATG 
               
               
                 400 
                 2674778 
                 UBA7 
                 CGGGTCGTCGAAGATGAATGGATGG 
               
               
                 401 
                 2674778 
                 UBA7 
                 GTCGTCGAAGATGAATGGATGGATC 
               
               
                 402 
                 2674778 
                 UBA7 
                 CACACCGATCCCCAACCCTGCGACC 
               
               
                 403 
                 2674779 
                 UBA7 
                 CGACTCCGTGAAGGGTGGATTATTT 
               
               
                 404 
                 2674779 
                 UBA7 
                 TTTGAGACGAAAGTAATACCGTAGT 
               
               
                 405 
                 2674779 
                 UBA7 
                 TACCGTAGTTTGTCGACGACTCCGT 
               
               
                 406 
                 2674779 
                 UBA7 
                 ACGACTCCGTGAAGGGTGGATTATT 
               
               
                 407 
                 2674780 
                 UBA7 
                 CACACCGCACCCGAGAACCGGTGAC 
               
               
                 408 
                 2674780 
                 UBA7 
                 ACACCGCACCCGAGAACCGGTGACC 
               
               
                 409 
                 2674781 
                 UBA7 
                 AGGACTCTCACGCAGGTGTCTTGAC 
               
               
                 410 
                 2674781 
                 UBA7 
                 CTCTCACGCAGGTGTCTTGACCGTT 
               
               
                 411 
                 2674781 
                 UBA7 
                 GACTCTCACGCAGGTGTCTTGACCG 
               
               
                 412 
                 2674781 
                 UBA7 
                 CCCAGGACTCTCACGCAGGTGTCTT 
               
               
                 413 
                 2674782 
                 UBA7 
                 CGGTGTCTGTGAGTGGAATGACTTC 
               
               
                 414 
                 2674782 
                 UBA7 
                 CCTACTCGGTGTCTGTGAGTGGAAT 
               
               
                 415 
                 2674782 
                 UBA7 
                 TGTACCTACTCGGTGTCTGTGAGTG 
               
               
                 416 
                 2674782 
                 UBA7 
                 ACTCGGTGTCTGTGAGTGGAATGAC 
               
               
                 417 
                 2674784 
                 UBA7 
                 AAACTTCTTGAGAAGGCTGACAGAC 
               
               
                 418 
                 2674784 
                 UBA7 
                 GAAGGCTGACAGACGTCTCTGGTAG 
               
               
                 419 
                 2674784 
                 UBA7 
                 ACTTCTTGAGAAGGCTGACAGACGT 
               
               
                 420 
                 2674784 
                 UBA7 
                 CTTGAGAAGGCTGACAGACGTCTCT 
               
               
                 421 
                 2674785 
                 UBA7 
                 CCGCGATACACCGACGAGCAACGTG 
               
               
                 422 
                 2674785 
                 UBA7 
                 AACGTGGGTGATAGACTTCGGTGAC 
               
               
                 423 
                 2674785 
                 UBA7 
                 GGATGGGACAGACATGGCACGCCAT 
               
               
                 424 
                 2674785 
                 UBA7 
                 ATGGCACGCCATGAAGGGATCGTGT 
               
               
                 425 
                 2674786 
                 UBA7 
                 GAACTGAAGCCTCCAGTCAGGGAAC 
               
               
                 426 
                 2674786 
                 UBA7 
                 ACTCACGAACTGAAGCCTCCAGTCA 
               
               
                 427 
                 2674786 
                 UBA7 
                 AAGCCTCCAGTCAGGGAACGGGTGT 
               
               
                 428 
                 2674786 
                 UBA7 
                 ACTGAAGCCTCCAGTCAGGGAACGG 
               
               
                 429 
                 2674787 
                 UBA7 
                 GAGGGCACACCTACCACACCGACGA 
               
               
                 430 
                 2674787 
                 UBA7 
                 TCTGAATGTCCACTAGGGCGAGTGG 
               
               
                 431 
                 2674787 
                 UBA7 
                 GGTGTCTCGTGTAGATACCCCTATT 
               
               
                 432 
                 2674787 
                 UBA7 
                 CACTAGGGCGAGTGGATGGGTGACC 
               
               
                 433 
                 2674789 
                 UBA7 
                 CACTCACGACTGGGGAGAGGTGTGA 
               
               
                 434 
                 2674789 
                 UBA7 
                 ACTCACGACTGGGGAGAGGTGTGAG 
               
               
                 435 
                 2674790 
                 UBA7 
                 TCGCGAGGTTAGAGTCGGCAGTCAA 
               
               
                 436 
                 2674790 
                 UBA7 
                 ACGAGTTTCAGAAACGGGATCACCC 
               
               
                 437 
                 2674790 
                 UBA7 
                 TACCTGGTGTATCTCGCGAGGTTAG 
               
               
                 438 
                 2674790 
                 UBA7 
                 CTGACAACAACTGTACCTGGTGTAT 
               
               
                 439 
                 2674791 
                 UBA7 
                 TCCGTCGGCGATACTACCCGTTTAA 
               
               
                 440 
                 2674791 
                 UBA7 
                 AGTCCTCTTTGACTCTGCGGTCGTG 
               
               
                 441 
                 2674791 
                 UBA7 
                 ACTACCCGTTTAACGTCACAAACCC 
               
               
                 442 
                 2674791 
                 UBA7 
                 TTGACTCTGCGGTCGTGATGGAGGA 
               
               
                 443 
                 2674792 
                 UBA7 
                 CGGGAGCTAACAGAAGGCCTTCTAC 
               
               
                 444 
                 2674792 
                 UBA7 
                 ATGAAACTACGGGAGCTAACAGAAG 
               
               
                 445 
                 2674792 
                 UBA7 
                 AACAGAAGGCCTTCTACCCCTCGAG 
               
               
                 446 
                 2674792 
                 UBA7 
                 CAGAAGGCCTTCTACCCCTCGAGGA 
               
               
                 447 
                 2674793 
                 UBA7 
                 TGGGTCGCGATCTCTCGTCGGGACC 
               
               
                 448 
                 2674793 
                 UBA7 
                 GACCCACTTCGGAGGTCGGTCCTAG 
               
               
                 449 
                 2674793 
                 UBA7 
                 CACAGTCTCCCGTGGGTCGCGATCT 
               
               
                 450 
                 2674793 
                 UBA7 
                 GGACCTCGGAAGTGGTTGGACCCAC 
               
               
                 451 
                 2674794 
                 UBA7 
                 GAACTCGGGATACCACCGGTACGAC 
               
               
                 452 
                 2674794 
                 UBA7 
                 TCAGCGGGATTCGTCACGTCCACAG 
               
               
                 453 
                 2674794 
                 UBA7 
                 GACCTTGGTGACTTCGCCTGTCTCC 
               
               
                 454 
                 2674794 
                 UBA7 
                 TACTCCGGGATCACGCCTGTCAGCG 
               
               
                 455 
                 2674795 
                 UBA7 
                 ATACGGGTGTCTCAGGATGGTTGTC 
               
               
                 456 
                 2674795 
                 UBA7 
                 GTCCGACCCCGATGATACGGGTGTC 
               
               
                 457 
                 2674795 
                 UBA7 
                 ACCCCGATGATACGGGTGTCTCAGG 
               
               
                 458 
                 2674795 
                 UBA7 
                 CGACCCCGATGATACGGGTGTCTCA 
               
               
                 459 
                 2674796 
                 UBA7 
                 ACGTAGTCCGGAAGACACGTGACGT 
               
               
                 460 
                 2674796 
                 UBA7 
                 TAGTCCGGAAGACACGTGACGTGTT 
               
               
                 461 
                 2674796 
                 UBA7 
                 GTAGTCCGGAAGACACGTGACGTGT 
               
               
                 462 
                 2674796 
                 UBA7 
                 CGTGGAGGTACCGGCCGGTGGGGTC 
               
               
                 463 
                 2674797 
                 UBA7 
                 AAAGAGAGCCATGAACGCACCACCC 
               
               
                 464 
                 2674797 
                 UBA7 
                 TGTTGAAAGAGAGCCATGAACGCAC 
               
               
                 465 
                 2674797 
                 UBA7 
                 CATGAACGCACCACCCCGATAGTGA 
               
               
                 466 
                 2674797 
                 UBA7 
                 CTCTGTGTTGTTGAAAGAGAGCCAT 
               
               
                 467 
                 2674798 
                 UBA7 
                 CCAACTCGAGTTGCTGACACTAGGG 
               
               
                 468 
                 2674798 
                 UBA7 
                 GAACCACTGAAAGAGCCCTTAACTC 
               
               
                 469 
                 2674798 
                 UBA7 
                 CCCGGTTATGGGTGATGAAGGCACT 
               
               
                 470 
                 2674798 
                 UBA7 
                 TTAACTCCCTTACCAACTCGAGTTG 
               
               
                 471 
                 2674799 
                 UBA7 
                 AAGACACTGAAACCACTCCTGAAGT 
               
               
                 472 
                 2674799 
                 UBA7 
                 ACAAGACACTGAAACCACTCCTGAA 
               
               
                 473 
                 2674799 
                 UBA7 
                 CAAGACACTGAAACCACTCCTGAAG 
               
               
                 474 
                 2674801 
                 UBA7 
                 TCCACCCGTGGAACACAGTATTCGT 
               
               
                 475 
                 2674801 
                 UBA7 
                 GACTTCCACCCGTGGAACACAGTAT 
               
               
                 476 
                 2674801 
                 UBA7 
                 CCGTGGAACACAGTATTCGTACCTC 
               
               
                 477 
                 2674801 
                 UBA7 
                 TCAAACGAAAGACCGCCGACTGTGG 
               
               
                 478 
                 2674802 
                 UBA7 
                 ACGTGTGCCCACTGTAGTGACTCCT 
               
               
                 479 
                 2674802 
                 UBA7 
                 GAGTTGTCTCGACAGGTCCAGCAGC 
               
               
                 480 
                 2674802 
                 UBA7 
                 GAGAGTTCTCGAGAACCGAGTCGAG 
               
               
                 481 
                 2674802 
                 UBA7 
                 ACTCCTGGACGACAACCTGAAGGTC 
               
               
                 482 
                 2674804 
                 UBA7 
                 ACCCGTCGGAGTGAGACGTACTAGG 
               
               
                 483 
                 2674804 
                 UBA7 
                 CGTCGGAGTGAGACGTACTAGGGGT 
               
               
                 484 
                 2674804 
                 UBA7 
                 CCCGTCGGAGTGAGACGTACTAGGG 
               
               
                 485 
                 2674804 
                 UBA7 
                 GGGTGGACGACCAGGCTGGACCGAC 
               
               
                 486 
                 2674805 
                 UBA7 
                 TACCTACGGGACCTGCGAAGCTTCG 
               
               
                 487 
                 2674805 
                 UBA7 
                 TGCGAAGCTTCGATGACCTACTCCT 
               
               
                 488 
                 2674805 
                 UBA7 
                 ACCTGCGAAGCTTCGATGACCTACT 
               
               
                 489 
                 2674805 
                 UBA7 
                 ACGGGACCTGCGAAGCTTCGATGAC 
               
               
                 490 
                 2674806 
                 UBA7 
                 ATGACAGTGGCGGTGGATGTGTTTC 
               
               
                 491 
                 2674806 
                 UBA7 
                 CGGTGGATGTGTTTCTGGGATAGAG 
               
               
                 492 
                 2674806 
                 UBA7 
                 ACAGTGGCGGTGGATGTGTTTCTGG 
               
               
                 493 
                 2674806 
                 UBA7 
                 GTGGCGGTGGATGTGTTTCTGGGAT 
               
               
                 494 
                 2674807 
                 UBA7 
                 GACACTGGTCGTCGCAGGGAATAAG 
               
               
                 495 
                 2674807 
                 UBA7 
                 CCAAGGACAAACGTGACCGATGTCG 
               
               
                 496 
                 2674807 
                 UBA7 
                 TAAGCGAACCGGAACCAAGGACAAA 
               
               
                 497 
                 2674807 
                 UBA7 
                 GTCGTCGCAGGGAATAAGCGAACCG 
               
               
                 498 
                 2691669 
                 HCLS1 
                 CAGGAGAGATAGGACCTACTCGAGT 
               
               
                 499 
                 2691669 
                 HCLS1 
                 GGGCCCTTTCATGCAGATCTAACAC 
               
               
                 500 
                 2691669 
                 HCLS1 
                 GAAAGACAAGTCAGGATTTTAAGCT 
               
               
                 501 
                 2691669 
                 HCLS1 
                 ACCAAACGGAGTAACACGATAAACG 
               
               
                 502 
                 2691670 
                 HCLS1 
                 CCCCGTCTCTGTCGTACCCCTTCCT 
               
               
                 503 
                 2691670 
                 HCLS1 
                 CAAGACCTGTCTGAAGGGAGAGGAC 
               
               
                 504 
                 2691670 
                 HCLS1 
                 AGTAATTCCCGAACCCCGTCTCTGT 
               
               
                 505 
                 2691670 
                 HCLS1 
                 GGGAGAGGACGAAGTAATTCCCGAA 
               
               
                 506 
                 2691671 
                 HCLS1 
                 GGGATAAGGACGACGTTTACAGATT 
               
               
                 507 
                 2691671 
                 HCLS1 
                 GACAGATGACGTTGACACTAAAGGG 
               
               
                 508 
                 2691671 
                 HCLS1 
                 GGAGGGATAAGGACGACGTTTACAG 
               
               
                 509 
                 2691671 
                 HCLS1 
                 AGGGATAAGGACGACGTTTACAGAT 
               
               
                 510 
                 2691672 
                 HCLS1 
                 CTGCATTAGTGACTGTAACTCTACC 
               
               
                 511 
                 2691672 
                 HCLS1 
                 AGGAAACTAGGCCTGCTGCATTAGT 
               
               
                 512 
                 2691672 
                 HCLS1 
                 CTTCACTACTCGAAAGGAAACTAGG 
               
               
                 513 
                 2691672 
                 HCLS1 
                 GGCCTGCTGCATTAGTGACTGTAAC 
               
               
                 514 
                 2691674 
                 HCLS1 
                 TCGACACCGACATATACTAATGGTT 
               
               
                 515 
                 2691674 
                 HCLS1 
                 AGTCGACACCGACATATACTAATGG 
               
               
                 516 
                 2691674 
                 HCLS1 
                 GTCGACACCGACATATACTAATGGT 
               
               
                 517 
                 2691674 
                 HCLS1 
                 GACACCGACATATACTAATGGTTCC 
               
               
                 518 
                 2691675 
                 HCLS1 
                 CCTCCACGAGCTCGGACTTCTAAGA 
               
               
                 519 
                 2691675 
                 HCLS1 
                 CCACGAGCTCGGACTTCTAAGAAGA 
               
               
                 520 
                 2691675 
                 HCLS1 
                 CTGATACTCCTCCACGAGCTCGGAC 
               
               
                 521 
                 2691675 
                 HCLS1 
                 CCCTGATACTCCTCCACGAGCTCGG 
               
               
                 522 
                 2691676 
                 HCLS1 
                 CAACTCCTCTACCTGTCCGTACTCG 
               
               
                 523 
                 2691676 
                 HCLS1 
                 TCCTCTACCTGTCCGTACTCGTCCT 
               
               
                 524 
                 2691676 
                 HCLS1 
                 TGCAACTCCTCTACCTGTCCGTACT 
               
               
                 525 
                 2691676 
                 HCLS1 
                 ACTCCTCTACCTGTCCGTACTCGTC 
               
               
                 526 
                 2691677 
                 HCLS1 
                 CTCGGGCTCGGACTCTTACTGATAC 
               
               
                 527 
                 2691677 
                 HCLS1 
                 CGGGCTCGGACTCTTACTGATACTC 
               
               
                 528 
                 2691677 
                 HCLS1 
                 CATGCTTCGTCTCGGACTCGGACTC 
               
               
                 529 
                 2691677 
                 HCLS1 
                 TGCTTCGTCTCGGACTCGGACTCGG 
               
               
                 530 
                 2691678 
                 HCLS1 
                 TCGAGACGGGGGATCCTGAGACCTT 
               
               
                 531 
                 2691679 
                 HCLS1 
                 GGAGGTAGTAGTCTCAGACTCGGAC 
               
               
                 532 
                 2691679 
                 HCLS1 
                 TGGGTCACGGGAACGACGGGTAATC 
               
               
                 533 
                 2691679 
                 HCLS1 
                 ACGGGTAATCCGTCTGAGAGGGCCT 
               
               
                 534 
                 2691679 
                 HCLS1 
                 ACCGGAGGTCAACCCTGAGGAGGTA 
               
               
                 535 
                 2691680 
                 HCLS1 
                 TGACGGGTTCTTTTAGAGGAGTCTC 
               
               
                 536 
                 2691680 
                 HCLS1 
                 GGTCACTATCGATACCTTCTCGGTC 
               
               
                 537 
                 2691680 
                 HCLS1 
                 TCACTATCGATACCTTCTCGGTCGT 
               
               
                 538 
                 2691680 
                 HCLS1 
                 CTCGGTCGTCATGGCCGGGGTGACG 
               
               
                 539 
                 2691684 
                 HCLS1 
                 AAACCACCGGTCATACCTTAGGTCT 
               
               
                 540 
                 2691684 
                 HCLS1 
                 AACCACCGGTCATACCTTAGGTCTT 
               
               
                 541 
                 2691684 
                 HCLS1 
                 CCGAAACCACCGGTCATACCTTAGG 
               
               
                 542 
                 2691684 
                 HCLS1 
                 CGAAACCACCGGTCATACCTTAGGT 
               
               
                 543 
                 2691686 
                 HCLS1 
                 ACCTCTTCCTATTTACCCTGTTTCG 
               
               
                 544 
                 2691686 
                 HCLS1 
                 CTCTCTGCCTCTTTGTGCTCAGGGT 
               
               
                 545 
                 2691686 
                 HCLS1 
                 TTCGTCGAGACCCTATACTGATGTT 
               
               
                 546 
                 2691686 
                 HCLS1 
                 GATGTTCCCTCTCTGCCTCTTTGTG 
               
               
                 547 
                 2691692 
                 HCLS1 
                 GTCGTCAGCCGAAACTAATATTTCC 
               
               
                 548 
                 2691692 
                 HCLS1 
                 TCGTCAGCCGAAACTAATATTTCCT 
               
               
                 549 
                 2691692 
                 HCLS1 
                 GTCAGCCGAAACTAATATTTCCTCT 
               
               
                 550 
                 2691692 
                 HCLS1 
                 AGTCGTCAGCCGAAACTAATATTTC 
               
               
                 551 
                 2691693 
                 HCLS1 
                 ACGAGACATCATAGGACACAGGTAT 
               
               
                 552 
                 2691693 
                 HCLS1 
                 TGGGTCAGTCACACAGTACATTTAG 
               
               
                 553 
                 2691693 
                 HCLS1 
                 CGGACGGAAACGAATTAGTGGCTAA 
               
               
                 554 
                 2691693 
                 HCLS1 
                 CGAGGTTTTGAGACGCCATTACAAC 
               
               
                 555 
                 2691694 
                 HCLS1 
                 AATTAATCCACCTGTACGTAGGAAT 
               
               
                 556 
                 2691694 
                 HCLS1 
                 AACAATTAATCCACCTGTACGTAGG 
               
               
                 557 
                 2691694 
                 HCLS1 
                 ACAATTAATCCACCTGTACGTAGGA 
               
               
                 558 
                 2691694 
                 HCLS1 
                 TTAATCCACCTGTACGTAGGAATTT 
               
               
                 559 
                 2691695 
                 HCLS1 
                 TGTCGAGGAAGTGTCAATCGACTCT 
               
               
                 560 
                 2691695 
                 HCLS1 
                 GTCGAGGAAGTGTCAATCGACTCTA 
               
               
                 561 
                 2691695 
                 HCLS1 
                 CTCCTGTCGAGGAAGTGTCAATCGA 
               
               
                 562 
                 2691695 
                 HCLS1 
                 CCTGTCGAGGAAGTGTCAATCGACT 
               
               
                 563 
                 2691696 
                 HCLS1 
                 CTTAGTAGATTCGAGAAGAAAACCG 
               
               
                 564 
                 2691696 
                 HCLS1 
                 ATGAGTACGGCAAATCCTTTTGTCT 
               
               
                 565 
                 2691696 
                 HCLS1 
                 AATCGTAGTTAGATACTTCAGGTCT 
               
               
                 566 
                 2691696 
                 HCLS1 
                 TATTAAGGAGTTCGGTGACCAAAAA 
               
               
                 567 
                 2691697 
                 HCLS1 
                 CGACACTCCTGGACTGTGGCAGTGT 
               
               
                 568 
                 2691697 
                 HCLS1 
                 GGAACCACGGTTACAACCTTCGGTG 
               
               
                 569 
                 2691697 
                 HCLS1 
                 TACCTCCGTGTACGAAGAAACAACT 
               
               
                 570 
                 2691697 
                 HCLS1 
                 CCTTCGGTGTACGACTCGACTTTCT 
               
               
                 571 
                 2691698 
                 HCLS1 
                 CTGGTGAGAGAGAGGGTTGGTGGGT 
               
               
                 572 
                 2691698 
                 HCLS1 
                 CATTCACTGGTGAGAGAGAGGGTTG 
               
               
                 573 
                 2691698 
                 HCLS1 
                 CACTGGTGAGAGAGAGGGTTGGTGG 
               
               
                 574 
                 2691698 
                 HCLS1 
                 TTCACTGGTGAGAGAGAGGGTTGGT 
               
               
                 575 
                 2691699 
                 HCLS1 
                 GTACTCATACAACGGCTCCACCTCT 
               
               
                 576 
                 2691699 
                 HCLS1 
                 CGAAACCCCCGTTCATGCCTCAACT 
               
               
                 577 
                 2691699 
                 HCLS1 
                 CGTGAGAAGAGTCTGCCTACGACGG 
               
               
                 578 
                 2691699 
                 HCLS1 
                 ATGCCTCAACTCTCCCTGTCCCGTC 
               
               
                 579 
                 2691700 
                 HCLS1 
                 GATACCTCCAGCCAAACCTCATCTT 
               
               
                 580 
                 2691700 
                 HCLS1 
                 CTCAGTCCCGGGTTTCGTAGGGTAC 
               
               
                 581 
                 2691700 
                 HCLS1 
                 CTCATCTTTCTCTGGCTTACCTGTT 
               
               
                 582 
                 2691700 
                 HCLS1 
                 ACTCCTTGTTTCATAGTCTCCTCGT 
               
               
                 583 
                 2691701 
                 HCLS1 
                 TACTCGGAACCAGTACACCAAAGAA 
               
               
                 584 
                 2691701 
                 HCLS1 
                 CGGAACCAGTACACCAAAGAAGGTC 
               
               
                 585 
                 2691701 
                 HCLS1 
                 CTCGGAACCAGTACACCAAAGAAGG 
               
               
                 586 
                 2691701 
                 HCLS1 
                 TCGGAACCAGTACACCAAAGAAGGT 
               
               
                 587 
                 2691708 
                 HCLS1 
                 GTTGACCTACTGTTATGGTGTAACA 
               
               
                 588 
                 2691708 
                 HCLS1 
                 CACCTACTGGTGTAACGTGTTCGTT 
               
               
                 589 
                 2691708 
                 HCLS1 
                 AAAATTTTTCACAGTCACCTACTGG 
               
               
                 590 
                 2691708 
                 HCLS1 
                 TCGTTGTATGACACTTTCGGACCGT 
               
               
                 591 
                 2691709 
                 HCLS1 
                 CACCCAGATAACCTAATTGACGGAG 
               
               
                 592 
                 2691709 
                 HCLS1 
                 ATGGACACACAGTAACGTATAAAGG 
               
               
                 593 
                 2691709 
                 HCLS1 
                 GGAAATCATTCCGTACTCTCTAAGT 
               
               
                 594 
                 2691709 
                 HCLS1 
                 AGATCTCAGACAAGGACACACATGG 
               
               
                 595 
                 2691710 
                 HCLS1 
                 TCGGGTTTCTTTTGAGCCTCTGAAC 
               
               
                 596 
                 2691710 
                 HCLS1 
                 TCTCGGGTTTCTTTTGAGCCTCTGA 
               
               
                 597 
                 2691711 
                 HCLS1 
                 TAGCTCCCCAGACCTGCGTGTCTTG 
               
               
                 598 
                 2691711 
                 HCLS1 
                 TCGGTTCTGGTAGCTCCCCAGACCT 
               
               
                 599 
                 2691711 
                 HCLS1 
                 CTGGTAGCTCCCCAGACCTGCGTGT 
               
               
                 600 
                 2691711 
                 HCLS1 
                 GTTCTGGTAGCTCCCCAGACCTGCG 
               
               
                 601 
                 2691714 
                 HCLS1 
                 CTGTCCGGTACCGTCCGATGTGACT 
               
               
                 602 
                 2691714 
                 HCLS1 
                 CCCCGTACGTGCTATGGACCATAGT 
               
               
                 603 
                 2691714 
                 HCLS1 
                 GTAGACCCGGTGAGACACTAGAAAC 
               
               
                 604 
                 2691714 
                 HCLS1 
                 TGTCGGGAGTATGACCCTGATTAAC 
               
               
                 605 
                 2691715 
                 HCLS1 
                 GGTACTACACAGACAAAGGCACCTC 
               
               
                 606 
                 2691715 
                 HCLS1 
                 GGGTCCCACTACTAACCCTGTGTCT 
               
               
                 607 
                 2691715 
                 HCLS1 
                 AGACATCACCCGGTACTACACAGAC 
               
               
                 608 
                 2691715 
                 HCLS1 
                 AACCCTGTGTCTAGGACTGAAACAC 
               
               
                 609 
                 2691717 
                 HCLS1 
                 TCGGCCCGCGAATCTTGTCTCCGAA 
               
               
                 610 
                 2691717 
                 HCLS1 
                 CGAATCTTGTCTCCGAACGTGTCCA 
               
               
                 611 
                 2691717 
                 HCLS1 
                 CGTCGTCGAGTCAAAGAGTGAGGCT 
               
               
                 612 
                 2691717 
                 HCLS1 
                 GTCAAAGAGTGAGGCTTCACCGTCG 
               
               
                 613 
                 2706793 
                 ZMAT3 
                 CCCCGACGTCTTACTGTTTGCACAG 
               
               
                 614 
                 2706793 
                 ZMAT3 
                 TGCGTAAAACACAAGGTCAAATTAT 
               
               
                 615 
                 2706793 
                 ZMAT3 
                 GACGAAAACAACTACCGAGTAAAAC 
               
               
                 616 
                 2706793 
                 ZMAT3 
                 AGCCTCACGGTCAGTGACGAAACCT 
               
               
                 617 
                 2706794 
                 ZMAT3 
                 ATCTTTGCGGGACGATCTGACTAAA 
               
               
                 618 
                 2706794 
                 ZMAT3 
                 GACCTCATACAGTCTAGGACGAAAT 
               
               
                 619 
                 2706794 
                 ZMAT3 
                 TTCGGGCTGCGTCAACGATTTTTAG 
               
               
                 620 
                 2706794 
                 ZMAT3 
                 ACAAGTGGACACCATAGGAACTGAC 
               
               
                 621 
                 2706795 
                 ZMAT3 
                 GATTTGACTCACACGGGACATTAGG 
               
               
                 622 
                 2706795 
                 ZMAT3 
                 GGGTCACGGGAATTACCTACAATAC 
               
               
                 623 
                 2706795 
                 ZMAT3 
                 GGGATGGTAACACTCGTCAATGACA 
               
               
                 624 
                 2706795 
                 ZMAT3 
                 ACGACCGGCGAACCAAGATACTAAT 
               
               
                 625 
                 2706796 
                 ZMAT3 
                 ACTATCTAGTGAAACCGTAGACTAT 
               
               
                 626 
                 2706796 
                 ZMAT3 
                 AACATTAAGCCGAAAGAACTTCTAT 
               
               
                 627 
                 2706796 
                 ZMAT3 
                 TCAAAGTGATAGAAGCAAAGGTCAT 
               
               
                 628 
                 2706796 
                 ZMAT3 
                 TAGACTAAGAATGCCAAATGAATGT 
               
               
                 629 
                 2706797 
                 ZMAT3 
                 GGGTGTCACCATGGTACTCTACAGT 
               
               
                 630 
                 2706797 
                 ZMAT3 
                 CGGACTGCCGAATCTTGAAACTGAT 
               
               
                 631 
                 2706797 
                 ZMAT3 
                 ACAGTTGAACGGGACGAAACACCAG 
               
               
                 632 
                 2706797 
                 ZMAT3 
                 CCAGTTACCACAACTCGGCGAGTAT 
               
               
                 633 
                 2706798 
                 ZMAT3 
                 CACAATGAGGTTCACCGGTCAAAAT 
               
               
                 634 
                 2706798 
                 ZMAT3 
                 AGACTTGTCGCCATGTCCTTACTCT 
               
               
                 635 
                 2706798 
                 ZMAT3 
                 CGTTCGTTGTATTCTCGTTCCACAG 
               
               
                 636 
                 2706798 
                 ZMAT3 
                 AATGACGAGTTACACATTACAACCT 
               
               
                 637 
                 2706799 
                 ZMAT3 
                 AGGAATGAAGTTAGGGGCGAGAGCC 
               
               
                 638 
                 2706799 
                 ZMAT3 
                 AATGAAGTTAGGGGCGAGAGCCGTC 
               
               
                 639 
                 2706799 
                 ZMAT3 
                 CAGGAATGAAGTTAGGGGCGAGAGC 
               
               
                 640 
                 2706799 
                 ZMAT3 
                 GGAATGAAGTTAGGGGCGAGAGCCG 
               
               
                 641 
                 2706801 
                 ZMAT3 
                 ACTACGGATTGTCCTCTTTATACAT 
               
               
                 642 
                 2706801 
                 ZMAT3 
                 CAAATTCTACTACGGATTGTCCTCT 
               
               
                 643 
                 2706801 
                 ZMAT3 
                 AGTCTCGACCCAGTTGCCGCCCGGT 
               
               
                 644 
                 2706801 
                 ZMAT3 
                 TTCTACTACGGATTGTCCTCTTTAT 
               
               
                 645 
                 2706802 
                 ZMAT3 
                 GTTCCCTTCTTAGTACGGTTCTCCG 
               
               
                 646 
                 2706802 
                 ZMAT3 
                 ACACCGAGTCCGAGTGATAGTTCCC 
               
               
                 647 
                 2706802 
                 ZMAT3 
                 CCGAGTGATAGTTCCCTTCTTAGTA 
               
               
                 648 
                 2706802 
                 ZMAT3 
                 TTCTTAGTACGGTTCTCCGACGCCG 
               
               
                 649 
                 2706803 
                 ZMAT3 
                 GGCTCACTAGGACCGGTGCCTCTTA 
               
               
                 650 
                 2706803 
                 ZMAT3 
                 TAGGACCGGTGCCTCTTACTAATGA 
               
               
                 651 
                 2706803 
                 ZMAT3 
                 GAAATTCGGTCCTCCGGCTCACTAG 
               
               
                 652 
                 2706803 
                 ZMAT3 
                 CTCCGGCTCACTAGGACCGGTGCCT 
               
               
                 653 
                 2706804 
                 ZMAT3 
                 CACCAGCTCGGACGTCGATGAGGTC 
               
               
                 654 
                 2706804 
                 ZMAT3 
                 TCGTTACACCAGCTCGGACGTCGAT 
               
               
                 655 
                 2706804 
                 ZMAT3 
                 GTTACACCAGCTCGGACGTCGATGA 
               
               
                 656 
                 2706804 
                 ZMAT3 
                 TACTCGTTACACCAGCTCGGACGTC 
               
               
                 657 
                 2706805 
                 ZMAT3 
                 CATTCTTTGAGGCTTTAATGATACG 
               
               
                 658 
                 2706805 
                 ZMAT3 
                 CTTTGAGGCTTTAATGATACGTCGT 
               
               
                 659 
                 2706805 
                 ZMAT3 
                 AGGCTTTAATGATACGTCGTTTATC 
               
               
                 660 
                 2706805 
                 ZMAT3 
                 TAGTACCATTCTTTGAGGCTTTAAT 
               
               
                 661 
                 2706806 
                 ZMAT3 
                 CATGACGTTTGAGACGTTACAGTGG 
               
               
                 662 
                 2706806 
                 ZMAT3 
                 GAGACGTTACAGTGGAACTTGAGAC 
               
               
                 663 
                 2706806 
                 ZMAT3 
                 TTACAGTGGAACTTGAGACGTGTCG 
               
               
                 664 
                 2706806 
                 ZMAT3 
                 CGTTTGAGACGTTACAGTGGAACTT 
               
               
                 665 
                 2706807 
                 ZMAT3 
                 GAAAACCCGTCCTCCGAAGGAACGG 
               
               
                 666 
                 2706807 
                 ZMAT3 
                 TACTAGGAGAACGTTGTGCGGCACG 
               
               
                 667 
                 2706807 
                 ZMAT3 
                 AAGGAACGGAGAACGTCCCCTTCTT 
               
               
                 668 
                 2706807 
                 ZMAT3 
                 CAGTCACCGGTGGTCCAGATGTCCT 
               
               
                 669 
                 2706808 
                 ZMAT3 
                 AGAGTAGTGGGTGACCTAATACGGG 
               
               
                 670 
                 2706808 
                 ZMAT3 
                 AGTAGTGGGTGACCTAATACGGGGT 
               
               
                 671 
                 2706808 
                 ZMAT3 
                 AAGAGTAGTGGGTGACCTAATACGG 
               
               
                 672 
                 2706808 
                 ZMAT3 
                 GTAGTGGGTGACCTAATACGGGGTC 
               
               
                 673 
                 2706814 
                 ZMAT3 
                 GCACTACCGTAGGTATGGCCCAACT 
               
               
                 674 
                 2706814 
                 ZMAT3 
                 TAGACACGCACGTCGACGGAACCGG 
               
               
                 675 
                 2706814 
                 ZMAT3 
                 CCCCTAAGGTAGGAAGCACTACCGT 
               
               
                 676 
                 2706814 
                 ZMAT3 
                 GTCCACCTAGTAGACACGCACGTCG 
               
               
                 677 
                 2706815 
                 ZMAT3 
                 GGAGGTGCACTGTCCCGAACGCGAC 
               
               
                 678 
                 2706815 
                 ZMAT3 
                 TCGCCAAGGAAAGGCTACGAGAAAG 
               
               
                 679 
                 2706815 
                 ZMAT3 
                 GCACTGTCCCGAACGCGACGAAGAT 
               
               
                 680 
                 2706815 
                 ZMAT3 
                 CCCTGATCGCCAAGGAAAGGCTACG 
               
               
                 681 
                 2706816 
                 ZMAT3 
                 GCCGCGCCTCTGACGGCCGCGCAGG 
               
               
                 682 
                 2706816 
                 ZMAT3 
                 GCGCCTCTGACGGCCGCGCAGGGCC 
               
               
                 683 
                 2706817 
                 ZMAT3 
                 CCAGCCCAACCTGACTGAAAACTGT 
               
               
                 684 
                 2706817 
                 ZMAT3 
                 CGCCGGCCGCCTCTTTCAACGAGGC 
               
               
                 685 
                 2706817 
                 ZMAT3 
                 ACTGAAAACTGTCAGTCGGAAGCCG 
               
               
                 686 
                 2706817 
                 ZMAT3 
                 AACTGTCAGTCGGAAGCCGACGCCT 
               
               
                 687 
                 2706819 
                 ZMAT3 
                 GTGTACGCGTCACCGCTGCGGCTCG 
               
               
                 688 
                 2706819 
                 ZMAT3 
                 GTTACAAACCTAGGGTTACTGACCT 
               
               
                 689 
                 2706819 
                 ZMAT3 
                 AATTGGCGGTTGGTCGTCCGATTCC 
               
               
                 690 
                 2706819 
                 ZMAT3 
                 CTACTTTCAACGTTTTCGAGACGGG 
               
               
                 691 
                 2733718 
                 BIN2 
                 TTCATAGATATCTGTGTCTGTGAAC 
               
               
                 692 
                 2753897 
                 CDKN2AIP 
                 AACAAACCAGAAATCCGGACGCCTC 
               
               
                 693 
                 2753897 
                 CDKN2AIP 
                 CGCCTCCCCGCAATAGACCTCCCGG 
               
               
                 694 
                 2753897 
                 CDKN2AIP 
                 GAGACCCGCGACAACAAACCAGAAA 
               
               
                 695 
                 2753897 
                 CDKN2AIP 
                 CGGCGCCCACGTCCGGCGTCACTGT 
               
               
                 696 
                 2753898 
                 CDKN2AIP 
                 ACACAAGCGCCGGACGTCCGGGTTG 
               
               
                 697 
                 2753899 
                 CDKN2AIP 
                 GCTGCCGCTCTGACTGTTTGTGACC 
               
               
                 698 
                 2753899 
                 CDKN2AIP 
                 GTGGCGGCCCTAAAAAACGAAGCGT 
               
               
                 699 
                 2753899 
                 CDKN2AIP 
                 AAAAGGTACCGGACCCGCTTGGTGC 
               
               
                 700 
                 2753899 
                 CDKN2AIP 
                 GCGACGGAGGCGATCGTGCCTACTT 
               
               
                 701 
                 2753903 
                 CDKN2AIP 
                 TTTTATGAATCATACCGACTTCCGT 
               
               
                 702 
                 2753903 
                 CDKN2AIP 
                 AGTTTCACTGTCTACGAGGTTGGAT 
               
               
                 703 
                 2753903 
                 CDKN2AIP 
                 TGTTGTTCTCTACTTGACCAACGGT 
               
               
                 704 
                 2753903 
                 CDKN2AIP 
                 CTGTCTACGAGGTTGGATATGTTGT 
               
               
                 705 
                 2753904 
                 CDKN2AIP 
                 TTTTCTCCCTATAGCTCATCGTTAC 
               
               
                 706 
                 2753904 
                 CDKN2AIP 
                 CTTTTCTCCCTATAGCTCATCGTTA 
               
               
                 707 
                 2753905 
                 CDKN2AIP 
                 CCATCTTCTCGGTAGGTTTTTTGCT 
               
               
                 708 
                 2753905 
                 CDKN2AIP 
                 CATCTTCTCGGTAGGTTTTTTGCTC 
               
               
                 709 
                 2753905 
                 CDKN2AIP 
                 ATCTTCTCGGTAGGTTTTTTGCTCA 
               
               
                 710 
                 2753905 
                 CDKN2AIP 
                 TCTTCTCGGTAGGTTTTTTGCTCAA 
               
               
                 711 
                 2753906 
                 CDKN2AIP 
                 ACCTCTAGCTAGACAAAGGTCGGTT 
               
               
                 712 
                 2753906 
                 CDKN2AIP 
                 GGAGACGGTTCTGTCTTGCACGTAG 
               
               
                 713 
                 2753906 
                 CDKN2AIP 
                 GACCGTAGAGGTCAGTCTTATCGAG 
               
               
                 714 
                 2753906 
                 CDKN2AIP 
                 AAGTTGCACATATCCCAGCCGGTAG 
               
               
                 715 
                 2753907 
                 CDKN2AIP 
                 GGTTTGGATCAAGTCTCTGTCGAAG 
               
               
                 716 
                 2753907 
                 CDKN2AIP 
                 CCGTGTAGGAATGACTGAGGGTTCT 
               
               
                 717 
                 2753907 
                 CDKN2AIP 
                 CGTCTTCGAGGTCTATTTGTGCCAA 
               
               
                 718 
                 2753907 
                 CDKN2AIP 
                 CGAGTCTCTAGCTCCACGGGAACAA 
               
               
                 719 
                 2753908 
                 CDKN2AIP 
                 TGAAGGAATCGTTCACACAGGGTCA 
               
               
                 720 
                 2753908 
                 CDKN2AIP 
                 GTCAACCGAAGATTCTCATCAAGAG 
               
               
                 721 
                 2753908 
                 CDKN2AIP 
                 GAGGGTCTGGTCACCTAGAGACCAA 
               
               
                 722 
                 2753908 
                 CDKN2AIP 
                 CAAGAGTCTGATCGTGGAGTGTCAA 
               
               
                 723 
                 2753909 
                 CDKN2AIP 
                 GGAACTACTTCTTAGCTCCGGACAT 
               
               
                 724 
                 2753909 
                 CDKN2AIP 
                 GTTCAGACACATAAACCCGTGACCG 
               
               
                 725 
                 2753909 
                 CDKN2AIP 
                 GTACCTCTCGAGGATTTACGTCGAT 
               
               
                 726 
                 2753909 
                 CDKN2AIP 
                 CCACCGAAATCAGGGTTACACTTAG 
               
               
                 727 
                 2753910 
                 CDKN2AIP 
                 CCATACGTAATCGTCGTATAATCAT 
               
               
                 728 
                 2753910 
                 CDKN2AIP 
                 ACACATCAAGCCATCTCAGGATTTT 
               
               
                 729 
                 2753910 
                 CDKN2AIP 
                 GATCAAGAGAAGTGTGTCATCGTCA 
               
               
                 730 
                 2753910 
                 CDKN2AIP 
                 CATAATTCAACAGATGGTACAAAAG 
               
               
                 731 
                 2753911 
                 CDKN2AIP 
                 AGTGGTACTGAAACTGGCGACTTCT 
               
               
                 732 
                 2753911 
                 CDKN2AIP 
                 GTGTCATAAACTTACAAACTTTCAG 
               
               
                 733 
                 2753911 
                 CDKN2AIP 
                 ACAACGGGCATTACAACTTGCACAG 
               
               
                 734 
                 2753911 
                 CDKN2AIP 
                 ACACTGATGATAATTGTCTAACTAA 
               
               
                 735 
                 2793222 
                 NEK1 
                 AGATTATAGGCTTTGATTTATGAAC 
               
               
                 736 
                 2793222 
                 NEK1 
                 ATAAAGATTATAGGCTTTGATTTAT 
               
               
                 737 
                 2793222 
                 NEK1 
                 TATAGGCTTTGATTTATGAACTAAA 
               
               
                 738 
                 2793222 
                 NEK1 
                 GATTATAGGCTTTGATTTATGAACT 
               
               
                 739 
                 2793223 
                 NEK1 
                 CCTGGTCTTGGTCCTTATGATATAG 
               
               
                 740 
                 2793223 
                 NEK1 
                 TCGTCCGACCAACCGTATTATACAT 
               
               
                 741 
                 2793223 
                 NEK1 
                 CCCGAGACAAATGTAGATATGTAAA 
               
               
                 742 
                 2793223 
                 NEK1 
                 CCACAGATGTCAGGTCTACAAGAAG 
               
               
                 743 
                 2793227 
                 NEK1 
                 AATCAGTACCGTCTACCTCGGATGG 
               
               
                 744 
                 2793227 
                 NEK1 
                 TACCGTCTACCTCGGATGGTTCTTC 
               
               
                 745 
                 2793227 
                 NEK1 
                 AAGAAGTAAATCAGTACCGTCTACC 
               
               
                 746 
                 2793227 
                 NEK1 
                 GTCGTAGAAATACGGTTCTAAGAAG 
               
               
                 747 
                 2793228 
                 NEK1 
                 CTTACGCTATCACAGAAATTGGTAA 
               
               
                 748 
                 2793228 
                 NEK1 
                 CTTTTTAAGAAACTCCAAATACTCT 
               
               
                 749 
                 2793228 
                 NEK1 
                 CACTTACACTTACGCTATCACAGAA 
               
               
                 750 
                 2793228 
                 NEK1 
                 AATTGGTAAATCTCCTTGACTCTGA 
               
               
                 751 
                 2793229 
                 NEK1 
                 ACGTCCGGAGCTACCTTGTCAATGA 
               
               
                 752 
                 2793229 
                 NEK1 
                 ATGAATCCCTTGTTGGACCACTTCT 
               
               
                 753 
                 2793229 
                 NEK1 
                 ACTTTCACGGGACTTGCTTCTTACC 
               
               
                 754 
                 2793229 
                 NEK1 
                 TGTGTCTAAATGTTCTCGACGTCCG 
               
               
                 755 
                 2793230 
                 NEK1 
                 CTCTACAAGCAGTTCTGTTAGAACT 
               
               
                 756 
                 2793231 
                 NEK1 
                 GACAAGTCTTGGGAATACCTACAAG 
               
               
                 757 
                 2793231 
                 NEK1 
                 TGGGAATACCTACAAGGGTGGCATC 
               
               
                 758 
                 2793231 
                 NEK1 
                 GAGAGTTTCGACAAGTCTTGGGAAT 
               
               
                 759 
                 2793231 
                 NEK1 
                 TCTTGGGAATACCTACAAGGGTGGC 
               
               
                 760 
                 2793236 
                 NEK1 
                 CCTTGGTTACTAAGAGTCGTGAGAT 
               
               
                 761 
                 2793236 
                 NEK1 
                 GTCAAGTCACAAGTGGTCTTCTTAG 
               
               
                 762 
                 2793236 
                 NEK1 
                 GGAACGACTAACCTGAAAGTTGACC 
               
               
                 763 
                 2793236 
                 NEK1 
                 ACGTAAAGCTAGAGTGAGCGTAAAT 
               
               
                 764 
                 2793238 
                 NEK1 
                 GTTCTCGGTTCACCTTGTTTGTTTC 
               
               
                 765 
                 2793238 
                 NEK1 
                 CTACTCTCGAACGGTACGTGATAAT 
               
               
                 766 
                 2793238 
                 NEK1 
                 CTCTCGAACGGTACGTGATAATGAC 
               
               
                 767 
                 2793238 
                 NEK1 
                 ACTCTCGAACGGTACGTGATAATGA 
               
               
                 768 
                 2793239 
                 NEK1 
                 CAACTAAGAGGACAACTCTGTTTTT 
               
               
                 769 
                 2793239 
                 NEK1 
                 ATTTGGGTAGTCGATAACAACTAAG 
               
               
                 770 
                 2793239 
                 NEK1 
                 ACAACTCTGTTTTTCAGGGCTCAAG 
               
               
                 771 
                 2793239 
                 NEK1 
                 GGGCTCAAGTCACTCCGTAGAGGTG 
               
               
                 772 
                 2793240 
                 NEK1 
                 GCTGTCTAAGACAAGATTTCTATGA 
               
               
                 773 
                 2793240 
                 NEK1 
                 TTAATCCAGGATTACCTAGAGGTTC 
               
               
                 774 
                 2793240 
                 NEK1 
                 CCCTTTTCAGGCTGTCTAAGACAAG 
               
               
                 775 
                 2793240 
                 NEK1 
                 CCTCTTCGACTTGATGTTGAAGTCT 
               
               
                 776 
                 2793241 
                 NEK1 
                 GGAGACCTACTCAATTGTGATCTAT 
               
               
                 777 
                 2793241 
                 NEK1 
                 ATCTATGTAGGAAGAGATGTTGACT 
               
               
                 778 
                 2793241 
                 NEK1 
                 ACTCAATTGTGATCTATGTAGGAAG 
               
               
                 779 
                 2793241 
                 NEK1 
                 CAGTTGAACACTAAGGAGACCTACT 
               
               
                 780 
                 2793242 
                 NEK1 
                 CTTTATGAAGCATCTAATTTACTTT 
               
               
                 781 
                 2793242 
                 NEK1 
                 TAGACTAGCGTTCTTCACCCTCCGT 
               
               
                 782 
                 2793242 
                 NEK1 
                 TCGCTCTTTATGAAGCATCTAATTT 
               
               
                 783 
                 2793242 
                 NEK1 
                 TTTAGTCAAAGTAGACTAGCGTTCT 
               
               
                 784 
                 2793243 
                 NEK1 
                 ACTATGGGCCCTTTGAAGTCTTCTC 
               
               
                 785 
                 2793243 
                 NEK1 
                 TGACTATGGGCCCTTTGAAGTCTTC 
               
               
                 786 
                 2793243 
                 NEK1 
                 GGGCCCTTTGAAGTCTTCTCTACGT 
               
               
                 787 
                 2793243 
                 NEK1 
                 CCTTTGAAGTCTTCTCTACGTTTTC 
               
               
                 788 
                 2793244 
                 NEK1 
                 TTCGTTGTCTACTCTAGACAATAAA 
               
               
                 789 
                 2793244 
                 NEK1 
                 TCGTTGTCTACTCTAGACAATAAAG 
               
               
                 790 
                 2793244 
                 NEK1 
                 GAGGTAGTTTCGTTGTCTACTCTAG 
               
               
                 791 
                 2793244 
                 NEK1 
                 GGTAGTTTCGTTGTCTACTCTAGAC 
               
               
                 792 
                 2793246 
                 NEK1 
                 CGACGACATGATTTTCTTGTTGATC 
               
               
                 793 
                 2793246 
                 NEK1 
                 GCACGACGACATGATTTTCTTGTTG 
               
               
                 794 
                 2793246 
                 NEK1 
                 ACGTGCACGACGACATGATTTTCTT 
               
               
                 795 
                 2793246 
                 NEK1 
                 TTACGTGCACGACGACATGATTTTC 
               
               
                 796 
                 2793247 
                 NEK1 
                 CTCCGCGTTTTTTTAGCTTAGTGAC 
               
               
                 797 
                 2793247 
                 NEK1 
                 ACTGTACTCCGCGTTTTTTTAGCTT 
               
               
                 798 
                 2793247 
                 NEK1 
                 CGCGTTTTTTTAGCTTAGTGACTTC 
               
               
                 799 
                 2793247 
                 NEK1 
                 GTACTCCGCGTTTTTTTAGCTTAGT 
               
               
                 800 
                 2793249 
                 NEK1 
                 CGTCGATACATACCTCCGTCCGGGT 
               
               
                 801 
                 2793249 
                 NEK1 
                 TGGACCGTCGATACATACCTCCGTC 
               
               
                 802 
                 2793249 
                 NEK1 
                 TACATACCTCCGTCCGGGTCGAGAA 
               
               
                 803 
                 2793249 
                 NEK1 
                 ACGTTTTGGACCGTCGATACATACC 
               
               
                 804 
                 2793255 
                 NEK1 
                 TACGGGTCGGTCTTACCTACATGAT 
               
               
                 805 
                 2793255 
                 NEK1 
                 CCACGGAGGCATATAGAAGTATCAA 
               
               
                 806 
                 2793255 
                 NEK1 
                 AATCTCGCTAAACCCCAAGTGTCGT 
               
               
                 807 
                 2793255 
                 NEK1 
                 GTGACCGAAAAGAGTGAATGATTAT 
               
               
                 808 
                 2793256 
                 NEK1 
                 TATCGAATCATGGATGTGAAACACC 
               
               
                 809 
                 2793256 
                 NEK1 
                 AAGACTCCACGTTTAAACCGGGAAC 
               
               
                 810 
                 2793256 
                 NEK1 
                 GAACCCATGTTATTAAAAGACTCCA 
               
               
                 811 
                 2793256 
                 NEK1 
                 AACCGGGAACTAATGAGACTTTCGT 
               
               
                 812 
                 2793258 
                 NEK1 
                 AATGGTACGGTAAAAACTGGTTTAC 
               
               
                 813 
                 2793258 
                 NEK1 
                 CCCTGATATCGAGGTAGTAGAAAAA 
               
               
                 814 
                 2793258 
                 NEK1 
                 GTAGAAAAAGAAGAGCTCCTGTCAT 
               
               
                 815 
                 2793258 
                 NEK1 
                 ATATACCAGCTCCAGAAGGTCTTTC 
               
               
                 816 
                 2793261 
                 NEK1 
                 ACCTTTCTTATTTATCCCGGTCCCT 
               
               
                 817 
                 2793261 
                 NEK1 
                 GTTCCTACCTCTTTACACGATTCAC 
               
               
                 818 
                 2793261 
                 NEK1 
                 TATTTATCCCGGTCCCTTGTTCCTA 
               
               
                 819 
                 2793261 
                 NEK1 
                 TACCTCTTTACACGATTCACGACCA 
               
               
                 820 
                 2793264 
                 NEK1 
                 GTCTCTTCTCTCACTTATGACCTCT 
               
               
                 821 
                 2793264 
                 NEK1 
                 CTCTTCTCTCACTTATGACCTCTTC 
               
               
                 822 
                 2793264 
                 NEK1 
                 TCTCTTCTCTCACTTATGACCTCTT 
               
               
                 823 
                 2793266 
                 NEK1 
                 ACTAGTACAATGTATGGTACACAAT 
               
               
                 824 
                 2793266 
                 NEK1 
                 TCGGAATGTCCTCAGTATTTTTCAG 
               
               
                 825 
                 2793266 
                 NEK1 
                 CCTTACAGGAGGAAGACACAAAATG 
               
               
                 826 
                 2793266 
                 NEK1 
                 AAACTCGTTGGATTCGTCTCGGTAA 
               
               
                 827 
                 2793267 
                 NEK1 
                 CCTTATGGAAATCGTATATTCTTTA 
               
               
                 828 
                 2793267 
                 NEK1 
                 CGGACGGCGATTTATACCTTATGGA 
               
               
                 829 
                 2793267 
                 NEK1 
                 ATACCTTATGGAAATCGTATATTCT 
               
               
                 830 
                 2793267 
                 NEK1 
                 TTTCGGACGGCGATTTATACCTTAT 
               
               
                 831 
                 2793268 
                 NEK1 
                 CGAAGTCCTGTTTTGAGCTAAAGAC 
               
               
                 832 
                 2793268 
                 NEK1 
                 GAGCTAAAGACAATACGGACGAGTC 
               
               
                 833 
                 2793268 
                 NEK1 
                 CCTGTTTTGAGCTAAAGACAATACG 
               
               
                 834 
                 2793268 
                 NEK1 
                 TGGTCGAAGTCCTGTTTTGAGCTAA 
               
               
                 835 
                 2793269 
                 NEK1 
                 AAGCTTCAAACCTAGTGTCGGATAT 
               
               
                 836 
                 2793269 
                 NEK1 
                 AAAAGCTTCAAACCTAGTGTCGGAT 
               
               
                 837 
                 2793269 
                 NEK1 
                 TGTAAAAGCTTCAAACCTAGTGTCG 
               
               
                 838 
                 2793269 
                 NEK1 
                 TTCAAACCTAGTGTCGGATATGGTC 
               
               
                 839 
                 2793277 
                 NEK1 
                 TTGGACCATGACTTCTATTATAGAC 
               
               
                 840 
                 2793277 
                 NEK1 
                 GACACAGAAACGTAATAAGGATACT 
               
               
                 841 
                 2793277 
                 NEK1 
                 AAGGATACTAGAGGCGTCAAACCAC 
               
               
                 842 
                 2793277 
                 NEK1 
                 GATCCCTATCTGGTAGTCAGTTGAG 
               
               
                 843 
                 2793278 
                 NEK1 
                 ACTCGACACATGTGAATTTGTACGA 
               
               
                 844 
                 2793278 
                 NEK1 
                 TACTCGACACATGTGAATTTGTACG 
               
               
                 845 
                 2793281 
                 NEK1 
                 AACCTTAACGATCTCAAGAATTATC 
               
               
                 846 
                 2793281 
                 NEK1 
                 CCTCTAAAACCTTAACGATCTCAAG 
               
               
                 847 
                 2793281 
                 NEK1 
                 GATTTCTACCTTGTCATGTTGAACC 
               
               
                 848 
                 2793281 
                 NEK1 
                 CTACCTTGTCATGTTGAACCTCTAA 
               
               
                 849 
                 2793282 
                 NEK1 
                 CCGGGACTTTGTACATGTACTATCT 
               
               
                 850 
                 2793282 
                 NEK1 
                 AGAAGTAGCTCTGTAATTTAGAGTC 
               
               
                 851 
                 2793282 
                 NEK1 
                 AAAACCTGACCAAACATGTCTATAC 
               
               
                 852 
                 2793282 
                 NEK1 
                 CTTTTTAAGAAGTAGCTCTGTAATT 
               
               
                 853 
                 2793284 
                 NEK1 
                 CCTCCCCTAGACAAATTCGCTTATT 
               
               
                 854 
                 2793284 
                 NEK1 
                 GTATCATTACCTAATGACACTCCCT 
               
               
                 855 
                 2793284 
                 NEK1 
                 GTCTTTCCGCAAAACAAAGTTCTCC 
               
               
                 856 
                 2793284 
                 NEK1 
                 TTTACCGAGAGAGATGTATCATTAC 
               
               
                 857 
                 2793287 
                 NEK1 
                 CTCTTCAACGTCATAACCGTTTGTA 
               
               
                 858 
                 2793287 
                 NEK1 
                 CTCTCTTCAACGTCATAACCGTTTG 
               
               
                 859 
                 2793287 
                 NEK1 
                 TCTCTTCAACGTCATAACCGTTTGT 
               
               
                 860 
                 2793287 
                 NEK1 
                 TCTTCAACGTCATAACCGTTTGTAC 
               
               
                 861 
                 2793288 
                 NEK1 
                 ACCTCTTCATACAATCTGATGTCTT 
               
               
                 862 
                 2793288 
                 NEK1 
                 AGATGTCTTCTACCGTCTGTCATAC 
               
               
                 863 
                 2793288 
                 NEK1 
                 CCGTCTGTCATACAATAGTTCCTTT 
               
               
                 864 
                 2793288 
                 NEK1 
                 TTCGGTAAGAACAATTTAGATGTCT 
               
               
                 865 
                 2793289 
                 NEK1 
                 GTATAGACATTTCTACGGAATCTTT 
               
               
                 866 
                 2793289 
                 NEK1 
                 GATCGTATAGACATTTCTACGGAAT 
               
               
                 867 
                 2793289 
                 NEK1 
                 ATTTACAGATCGTATAGACATTTCT 
               
               
                 868 
                 2793289 
                 NEK1 
                 ACAGATCGTATAGACATTTCTACGG 
               
               
                 869 
                 2793293 
                 NEK1 
                 GGATGATTGCAGGACACAGTGACTC 
               
               
                 870 
                 2793293 
                 NEK1 
                 CAGTAGTGGCAATAAGGATGATTGC 
               
               
                 871 
                 2793293 
                 NEK1 
                 CGGTGTGGATCTGACTACGAATAAT 
               
               
                 872 
                 2793293 
                 NEK1 
                 TTACGCCCTACCATGGAGACGAAAT 
               
               
                 873 
                 2793294 
                 NEK1 
                 GACGACGACCAATCTGTCAGAACCA 
               
               
                 874 
                 2793294 
                 NEK1 
                 CTCTCAGAGTCACGGGGGAAAGTCA 
               
               
                 875 
                 2793294 
                 NEK1 
                 ACGGGGGAAAGTCAGACCTGACACT 
               
               
                 876 
                 2793294 
                 NEK1 
                 ACGACCAATCTGTCAGAACCAAAGA 
               
               
                 877 
                 2793295 
                 NEK1 
                 AATCAGGCGTAAGCGAGGTCCCAAA 
               
               
                 878 
                 2793295 
                 NEK1 
                 CGTGCACCGTCAGTTCATCGAAGGG 
               
               
                 879 
                 2793295 
                 NEK1 
                 TCACAGCTGGACAGAATGCCCGCAG 
               
               
                 880 
                 2793295 
                 NEK1 
                 CACCGGTGATCGTTGCTGGAGACAC 
               
               
                 881 
                 2806469 
                 IL7R 
                 GGATCTAGATTCGAAGAGACAGAAG 
               
               
                 882 
                 2806469 
                 IL7R 
                 GTAAGTAAAGTATGTGTGACCGAGT 
               
               
                 883 
                 2806469 
                 IL7R 
                 AAGTAAAGTATGTGTGACCGAGTGT 
               
               
                 884 
                 2806469 
                 IL7R 
                 GGGATCTAGATTCGAAGAGACAGAA 
               
               
                 885 
                 2806470 
                 IL7R 
                 AATGAAGTTCAGCAAAGACCTCTTT 
               
               
                 886 
                 2806470 
                 IL7R 
                 ATGAAGTTCAGCAAAGACCTCTTTC 
               
               
                 887 
                 2806470 
                 IL7R 
                 GATCCATGTTGAAAACCGTACCAAA 
               
               
                 888 
                 2806470 
                 IL7R 
                 TGAAGTTCAGCAAAGACCTCTTTCA 
               
               
                 889 
                 2806471 
                 IL7R 
                 GAGTAAGAGTACGATATCGGTCAAC 
               
               
                 890 
                 2806471 
                 IL7R 
                 TGAGTAAGAGTACGATATCGGTCAA 
               
               
                 891 
                 2806472 
                 IL7R 
                 AAAACTCCTGGGTCTACAGTTGTAG 
               
               
                 892 
                 2806472 
                 IL7R 
                 CTGGGTCTACAGTTGTAGTGGTTAG 
               
               
                 893 
                 2806472 
                 IL7R 
                 CTACAGTTGTAGTGGTTAGACCTTA 
               
               
                 894 
                 2806472 
                 IL7R 
                 TTGTAGTGGTTAGACCTTAAACTTT 
               
               
                 895 
                 2806474 
                 IL7R 
                 ACCTCTTTTCTCAGATTGGACGTTT 
               
               
                 896 
                 2806474 
                 IL7R 
                 CGTTATATACACACTTCCAACCTCT 
               
               
                 897 
                 2806474 
                 IL7R 
                 GACGTTTTTTTATCTGGATTGGTGA 
               
               
                 898 
                 2806474 
                 IL7R 
                 CTCTATATAAAGTAGCTCTGTTTCT 
               
               
                 899 
                 2806477 
                 IL7R 
                 ATTTTCAAAATTACGTGCTACATCG 
               
               
                 900 
                 2806477 
                 IL7R 
                 AACTGGACTCACAGCAGATAGCCCT 
               
               
                 901 
                 2806477 
                 IL7R 
                 TCACAGCAGATAGCCCTTCCTCGGT 
               
               
                 902 
                 2806477 
                 IL7R 
                 ATCGAATGGCGGTCCTTTTCCTACT 
               
               
                 903 
                 2806479 
                 IL7R 
                 TTAAATAGGTCGTGTTTCGACTGTG 
               
               
                 904 
                 2806479 
                 IL7R 
                 GTACACTTAAATAGGTCGTGTTTCG 
               
               
                 905 
                 2806479 
                 IL7R 
                 ACACTTAAATAGGTCGTGTTTCGAC 
               
               
                 906 
                 2806479 
                 IL7R 
                 ACTTAAATAGGTCGTGTTTCGACTG 
               
               
                 907 
                 2806480 
                 IL7R 
                 CATACTCTAATTTCAAGCTAGGTAG 
               
               
                 908 
                 2806480 
                 IL7R 
                 TCTTTCGAGGTTGGCCGTCGTTACA 
               
               
                 909 
                 2806480 
                 IL7R 
                 GAGGTTGGCCGTCGTTACATACTCT 
               
               
                 910 
                 2806480 
                 IL7R 
                 GCTAGGTAGGGACTAGTGATAAAAT 
               
               
                 911 
                 2806485 
                 IL7R 
                 GGGTCAGAGGGGCTAGTATTCTTCT 
               
               
                 912 
                 2806485 
                 IL7R 
                 ATTCGGATAGCATACCGGGTCAGAG 
               
               
                 913 
                 2806485 
                 IL7R 
                 CAGAGGGGCTAGTATTCTTCTGAGA 
               
               
                 914 
                 2806485 
                 IL7R 
                 CTAATTCGGATAGCATACCGGGTCA 
               
               
                 915 
                 2806486 
                 IL7R 
                 AACCCTGATGTTTGTCGTGCGACGG 
               
               
                 916 
                 2806486 
                 IL7R 
                 TTGGGTCAACGAGTCCCAGTCGGGT 
               
               
                 917 
                 2806486 
                 IL7R 
                 CCTTAGGACTGTAACTTGGGTCAAC 
               
               
                 918 
                 2806486 
                 IL7R 
                 GGACCTGACGGTCTAAGTATCCCAC 
               
               
                 919 
                 2806487 
                 IL7R 
                 GCAGTGATCATTGTCCCACACGGAT 
               
               
                 920 
                 2806487 
                 IL7R 
                 GGGACCTGTACCCATGCAAACTGCT 
               
               
                 921 
                 2806487 
                 IL7R 
                 ATGGCACTCGCTGTTTCTACTAAAT 
               
               
                 922 
                 2806487 
                 IL7R 
                 ATACCCGACAAGTCTCCACGTGTGG 
               
               
                 923 
                 2858024 
                 PLK2 
                 ACTGGTAAAATTTGGCAACCGTTAT 
               
               
                 924 
                 2858024 
                 PLK2 
                 ACAACTGGTAAAATTTGGCAACCGT 
               
               
                 925 
                 2858025 
                 PLK2 
                 GTACACCACCATGCTTTTGTTAAGG 
               
               
                 926 
                 2858025 
                 PLK2 
                 TGTCCGATTCCGTATGTCAAGAACT 
               
               
                 927 
                 2858025 
                 PLK2 
                 GCATTGACACTTGATACCGGTATAT 
               
               
                 928 
                 2858025 
                 PLK2 
                 CTGAAAAGCTTACCTGGGATACCCT 
               
               
                 929 
                 2858026 
                 PLK2 
                 CGGGACTTGTACGAGAATGTTTCTA 
               
               
                 930 
                 2858026 
                 PLK2 
                 AGTTACTCCTATCCTATAGATGTTG 
               
               
                 931 
                 2858026 
                 PLK2 
                 TTTAGCTTACCTTATACGGGACTTG 
               
               
                 932 
                 2858026 
                 PLK2 
                 ACTTCTTATGGAAGAGTGGATGTAG 
               
               
                 933 
                 2858028 
                 PLK2 
                 ACGAGAAATTACTACCGTGGAAAGT 
               
               
                 934 
                 2858028 
                 PLK2 
                 CGATTTTAGACTATTCCGGGATTAC 
               
               
                 935 
                 2858028 
                 PLK2 
                 CACCTCTAGACGGATCACAATGACT 
               
               
                 936 
                 2858028 
                 PLK2 
                 CACAATGACTATAAGCTTCTGGAGC 
               
               
                 937 
                 2858029 
                 PLK2 
                 AAACATCCGTGATTGAGTGAGAGGA 
               
               
                 938 
                 2858029 
                 PLK2 
                 TTGAGTGAGAGGATTAGAGAAGGTC 
               
               
                 939 
                 2858029 
                 PLK2 
                 TTATTATTATCTCACGTACGATGTT 
               
               
                 940 
                 2858030 
                 PLK2 
                 TGTCAAGTGATAATGCGTCTCGAAC 
               
               
                 941 
                 2858030 
                 PLK2 
                 AGTTCACTGCCACGACTTTATGAAA 
               
               
                 942 
                 2858030 
                 PLK2 
                 AATGCGTCTCGAACCGGTTACGAGT 
               
               
                 943 
                 2858030 
                 PLK2 
                 AGGACTCGTTAAATAATCAGTTCAC 
               
               
                 944 
                 2858031 
                 PLK2 
                 AAAGTCACCCAGTGGTTTACCCAAC 
               
               
                 945 
                 2858031 
                 PLK2 
                 TGGCAGCCACAGGAAAAGTTGTTAC 
               
               
                 946 
                 2858031 
                 PLK2 
                 AACCCATGGTCGAGAGTCTGGTGTG 
               
               
                 947 
                 2858031 
                 PLK2 
                 AAGTTGTTACCACGAGTGTACTCGG 
               
               
                 948 
                 2858032 
                 PLK2 
                 GTACCCTTCACAACGTCTGTGTCAC 
               
               
                 949 
                 2858032 
                 PLK2 
                 CTGTGTCACCGTTCCCAAGAAGCCC 
               
               
                 950 
                 2858032 
                 PLK2 
                 TCATGGTACCCTTCACAACGTCTGT 
               
               
                 951 
                 2858032 
                 PLK2 
                 AACTTCTGTCATGGTACCCTTCACA 
               
               
                 952 
                 2858034 
                 PLK2 
                 GTCTAACCCCTACGATAAGCCTACT 
               
               
                 953 
                 2858034 
                 PLK2 
                 TCCAGACCTTGTGGGCGTCATCTTT 
               
               
                 954 
                 2858034 
                 PLK2 
                 CCTACGATAAGCCTACTATCAGTCT 
               
               
                 955 
                 2858034 
                 PLK2 
                 CCTTGTGGGCGTCATCTTTTGTTCG 
               
               
                 956 
                 2858035 
                 PLK2 
                 TGACGCAATAGAAAATAGACCGAAC 
               
               
                 957 
                 2858035 
                 PLK2 
                 ACGGAGTGAGAGTAGAATTAGACCT 
               
               
                 958 
                 2858035 
                 PLK2 
                 CGAAAAACTACTCGAAAGGGTCGTT 
               
               
                 959 
                 2858035 
                 PLK2 
                 CGTACGTTCACTCAAATGACGCAAT 
               
               
                 960 
                 2858036 
                 PLK2 
                 CTTTTTCTGAAGTTATTGAGTCGTT 
               
               
                 961 
                 2858036 
                 PLK2 
                 CTTCTGTAGATGTTCGAATCCGTAC 
               
               
                 962 
                 2858036 
                 PLK2 
                 TAGATGTTCGAATCCGTACTAAACT 
               
               
                 963 
                 2858036 
                 PLK2 
                 TCTGAAGTTATTGAGTCGTTGGGTC 
               
               
                 964 
                 2858037 
                 PLK2 
                 GTTTCGTTCTATATAACTGTGTGTA 
               
               
                 965 
                 2858037 
                 PLK2 
                 TTTCGTTCTATATAACTGTGTGTAT 
               
               
                 966 
                 2858038 
                 PLK2 
                 CGACAACAGTATGTCAAGGTCTAAA 
               
               
                 967 
                 2858038 
                 PLK2 
                 CAAGGTCTAAAGGTGAATAGTTCGG 
               
               
                 968 
                 2858038 
                 PLK2 
                 GAATAGTTCGGGTCGATTCTTAAAG 
               
               
                 969 
                 2858038 
                 PLK2 
                 GAGGCCTGTCTGACAGAAGATCGAC 
               
               
                 970 
                 2858040 
                 PLK2 
                 TCGTTCCATATGTTACGGCAGGAGT 
               
               
                 971 
                 2858040 
                 PLK2 
                 GGTCTCCTAGCAGGGTCAAACCTAC 
               
               
                 972 
                 2858040 
                 PLK2 
                 CCTACTGTAGTAAGCTGTACTGAAA 
               
               
                 973 
                 2858040 
                 PLK2 
                 CGAGGACGGTTCGTGAATTAACGAT 
               
               
                 974 
                 2858042 
                 PLK2 
                 TGCTATACACCATGGGGTTTAATAG 
               
               
                 975 
                 2858042 
                 PLK2 
                 ACACTTAGTCTGTAAACCCGGGACC 
               
               
                 976 
                 2858042 
                 PLK2 
                 AATAGAGAGAGGACTTCAGGAGTTG 
               
               
                 977 
                 2858042 
                 PLK2 
                 TTCAGGAGTTGTTTGTTCCTGTACC 
               
               
                 978 
                 2858044 
                 PLK2 
                 CCGTCGGTCCGATCTTGGGAACCTT 
               
               
                 979 
                 2858044 
                 PLK2 
                 CTTGAAAAAATAATTACTTCGGTAC 
               
               
                 980 
                 2858044 
                 PLK2 
                 CCTGAAGCCAGACCGTCGGTCCGAT 
               
               
                 981 
                 2858044 
                 PLK2 
                 TCCGATCTTGGGAACCTTGTGTCTT 
               
               
                 982 
                 2858045 
                 PLK2 
                 TGCGGTTTTCGACTCAAAACACAAT 
               
               
                 983 
                 2858045 
                 PLK2 
                 CATTCAGTAACTGCGGTTTTCGACT 
               
               
                 984 
                 2858046 
                 PLK2 
                 GGTCTTCAAGCTATGATGGAGTCCG 
               
               
                 985 
                 2858046 
                 PLK2 
                 ATGGAGTCCGTCTAACACAGACCTG 
               
               
                 986 
                 2858046 
                 PLK2 
                 TTCAAGCTATGATGGAGTCCGTCTA 
               
               
                 987 
                 2858046 
                 PLK2 
                 AACACAGACCTGACTTTATGGAAGT 
               
               
                 988 
                 2858047 
                 PLK2 
                 CATTCACAGTTGAGGATAAACTCTT 
               
               
                 989 
                 2858047 
                 PLK2 
                 TCTCATAAAATAGACCCTAAAATCG 
               
               
                 990 
                 2858047 
                 PLK2 
                 GGGCTTAATTGTACCATAAGTTTCT 
               
               
                 991 
                 2858047 
                 PLK2 
                 CTCTTGTAAACGAATGGGGCTTAAT 
               
               
                 992 
                 2858048 
                 PLK2 
                 ACGTCAAAATGGTGATGAAGCTCCT 
               
               
                 993 
                 2858048 
                 PLK2 
                 CTTTTGTAAATGTAAGAGAACCTTA 
               
               
                 994 
                 2858048 
                 PLK2 
                 AAGAAGTAGTATTCGTACATCACGT 
               
               
                 995 
                 2858048 
                 PLK2 
                 AGAGAACCTTATGACGTCATCTTCC 
               
               
                 996 
                 2858049 
                 PLK2 
                 ACTGAGAACTCATTTCATAAAAGAA 
               
               
                 997 
                 2858049 
                 PLK2 
                 CACGCATACTGAGAACTCATTTCAT 
               
               
                 998 
                 2858049 
                 PLK2 
                 TTTACAGAAGACGTACACATTAGTG 
               
               
                 999 
                 2858049 
                 PLK2 
                 GAAGACGTACACATTAGTGACCGAA 
               
               
                 1000 
                 2858050 
                 PLK2 
                 CGTCTCATCGATTTGGAGTAGTTTC 
               
               
                 1001 
                 2858050 
                 PLK2 
                 TGCGGCGTTTTTAATAAGGAGTGTC 
               
               
                 1002 
                 2858050 
                 PLK2 
                 TATTGTTTCAGATGCGGCGTTTTTA 
               
               
                 1003 
                 2858050 
                 PLK2 
                 AACGTTTTACAATGCTCTACTGTCT 
               
               
                 1004 
                 2858051 
                 PLK2 
                 ATAGACGAGGGTCCCTTAAAAGGAC 
               
               
                 1005 
                 2858051 
                 PLK2 
                 AAGTACTCCCTCGAAATTGCTTCAG 
               
               
                 1006 
                 2858051 
                 PLK2 
                 CGGCAGGTAAAAACACGGTAGGAGT 
               
               
                 1007 
                 2858051 
                 PLK2 
                 GAGTTAAGGCAGAGCCGAAACAAAG 
               
               
                 1008 
                 2858052 
                 PLK2 
                 GGTGCTGACCCTTCGCGATGACGGC 
               
               
                 1009 
                 2858052 
                 PLK2 
                 TGAGCTTCTTCTTCGCCGGCGGCGT 
               
               
                 1010 
                 2858052 
                 PLK2 
                 TGGTAAGCGTGAGCCCCGGCCTCTA 
               
               
                 1011 
                 2858052 
                 PLK2 
                 CCGGCCTCTAGAGCGCCTAATAGCA 
               
               
                 1012 
                 2858053 
                 PLK2 
                 AGTGAGCGTGTTCACCTGGCCCCAC 
               
               
                 1013 
                 2858053 
                 PLK2 
                 TCCGTTCCCACGCTCCTGGTGCCGG 
               
               
                 1014 
                 2858053 
                 PLK2 
                 TGGTGCCGGCCGAGCCTGCACACTG 
               
               
                 1015 
                 2858053 
                 PLK2 
                 GCTCGCGAGAGTGAGCGTGTTCACC 
               
               
                 1016 
                 2997377 
                 ANLN 
                 TTTAAACTTGCCGACGTCTCCGGCT 
               
               
                 1017 
                 2997377 
                 ANLN 
                 CTTTAAGTTTAAACTTGCCGACGTC 
               
               
                 1018 
                 2997377 
                 ANLN 
                 ACACCCTCTCAAGGGGGCGGAGTCT 
               
               
                 1019 
                 2997377 
                 ANLN 
                 GGCTCAGGCAGTGACCTTCGGCTCT 
               
               
                 1020 
                 2997378 
                 ANLN 
                 TAGCAGAGCATCAGGCTGCGGACCC 
               
               
                 1021 
                 2997378 
                 ANLN 
                 TGTGTGACTCGACTCTGAGTGAAAA 
               
               
                 1022 
                 2997378 
                 ANLN 
                 CTTGGTGGCAAAGGTAGCAGAGCAT 
               
               
                 1023 
                 2997378 
                 ANLN 
                 GGACTTAAACTTGGTGGCAAAGGTA 
               
               
                 1024 
                 2997379 
                 ANLN 
                 CCTCCTTCCGAAACTCAGACAGGAT 
               
               
                 1025 
                 2997379 
                 ANLN 
                 AGGATTTTCCGACAACGCTCTCCAG 
               
               
                 1026 
                 2997379 
                 ANLN 
                 TCCGACAACGCTCTCCAGAAAGTCG 
               
               
                 1027 
                 2997379 
                 ANLN 
                 ACTCAGACAGGATTTTCCGACAACG 
               
               
                 1028 
                 2997380 
                 ANLN 
                 AGGACCGCGTCGTTCTCACTCCGCG 
               
               
                 1029 
                 2997380 
                 ANLN 
                 GCCTTGCCCAGGACGACCTTCGTCG 
               
               
                 1030 
                 2997380 
                 ANLN 
                 CGGGCGTCCCCTCTACGATTACTTT 
               
               
                 1031 
                 2997380 
                 ANLN 
                 CACTAAACGCCTCAAGTGCGTCGGG 
               
               
                 1032 
                 2997381 
                 ANLN 
                 GCTTGGGCACGGTCCGCTCTCTTAG 
               
               
                 1033 
                 2997381 
                 ANLN 
                 TTGACGACCTCGCTTGGGCACGGTC 
               
               
                 1034 
                 2997381 
                 ANLN 
                 GACGACCTCGCTTGGGCACGGTCCG 
               
               
                 1035 
                 2997381 
                 ANLN 
                 CGGTCCGCTCTCTTAGAAGTCTCTT 
               
               
                 1036 
                 2997382 
                 ANLN 
                 GTCGTCGAGGTTCCAGATACTGAGT 
               
               
                 1037 
                 2997382 
                 ANLN 
                 CCAGATACTGAGTACGATTCGCTCG 
               
               
                 1038 
                 2997382 
                 ANLN 
                 GAGTACGATTCGCTCGATCTGTCGG 
               
               
                 1039 
                 2997382 
                 ANLN 
                 GATTCGCTCGATCTGTCGGTGAAAG 
               
               
                 1040 
                 2997384 
                 ANLN 
                 TCTTTAGAACATGTTTTGGTAGCGG 
               
               
                 1041 
                 2997384 
                 ANLN 
                 ACCTTTTATTTGTTGGTCAACTCAG 
               
               
                 1042 
                 2997384 
                 ANLN 
                 AACAAGAGGTTCAGGACACAGAGGA 
               
               
                 1043 
                 2997384 
                 ANLN 
                 AGCGGTAGTTTTTTTGCGACAAGAC 
               
               
                 1044 
                 2997385 
                 ANLN 
                 TTGAACGTCTCGTTGCCGCGGCAAC 
               
               
                 1045 
                 2997385 
                 ANLN 
                 CGGTGTTCGTCGTCTATGGTAGTCA 
               
               
                 1046 
                 2997385 
                 ANLN 
                 CACTAAGACAACGACAGGGCCGTAG 
               
               
                 1047 
                 2997385 
                 ANLN 
                 GCGGCAACCCTATTACTACTATACT 
               
               
                 1048 
                 2997387 
                 ANLN 
                 ACGACGTTGATAAACGAGGACCCTT 
               
               
                 1049 
                 2997387 
                 ANLN 
                 CGAAAGTTTACGGAGCCGTTGAGGT 
               
               
                 1050 
                 2997387 
                 ANLN 
                 TTACGGAGCCGTTGAGGTCAACCGT 
               
               
                 1051 
                 2997387 
                 ANLN 
                 GTCTTCCCCGGCAGACCGGTTAGAA 
               
               
                 1052 
                 2997388 
                 ANLN 
                 CGGGATAGGAGTTCACGACTACTAC 
               
               
                 1053 
                 2997388 
                 ANLN 
                 CTACCGCTACGGAGAAACTTATTTC 
               
               
                 1054 
                 2997388 
                 ANLN 
                 CGGACCATGGCGAACAAATAGGTTT 
               
               
                 1055 
                 2997388 
                 ANLN 
                 CACAATTCGTCCTTCGATGTAAGAC 
               
               
                 1056 
                 2997389 
                 ANLN 
                 AATAGGGTCTGTCAAGGTAGGTTCC 
               
               
                 1057 
                 2997389 
                 ANLN 
                 CCATAGCTTTGGTTAACACTTCAGT 
               
               
                 1058 
                 2997389 
                 ANLN 
                 TCAACACTCCCTGTTTTAGGACTCG 
               
               
                 1059 
                 2997389 
                 ANLN 
                 AGGTCACTTTAGATGATGTAGATAG 
               
               
                 1060 
                 2997391 
                 ANLN 
                 CGAAACCTCTCGCAACAGTTCTTGT 
               
               
                 1061 
                 2997391 
                 ANLN 
                 TCGGAAAGGACCTTGCGAAACCTCT 
               
               
                 1062 
                 2997391 
                 ANLN 
                 GTTTCTTTCAGGTCGAGCATCGTGT 
               
               
                 1063 
                 2997391 
                 ANLN 
                 GAGGTTTATGTTTCCGGTAGGTTCT 
               
               
                 1064 
                 2997393 
                 ANLN 
                 CCCGTTATATACCTCACGTCTTTTT 
               
               
                 1065 
                 2997393 
                 ANLN 
                 CGGCTAAACTGTTCCCGTTATATAC 
               
               
                 1066 
                 2997393 
                 ANLN 
                 TCTTGATCGTACAGAAGCACCGGCT 
               
               
                 1067 
                 2997393 
                 ANLN 
                 CACGTCTTTTTCCGCCTTTGAGTTT 
               
               
                 1068 
                 2997394 
                 ANLN 
                 TCCACTGGCTTTTGGTCTATGGTCG 
               
               
                 1069 
                 2997394 
                 ANLN 
                 AAAGTTTTTGAGTCAGTGAAGGTCA 
               
               
                 1070 
                 2997394 
                 ANLN 
                 TATGGTCGGTTTTTAAGATCATGTC 
               
               
                 1071 
                 2997394 
                 ANLN 
                 CAAAGTTTTTGAGTCAGTGAAGGTC 
               
               
                 1072 
                 2997395 
                 ANLN 
                 GTAGTCTGGGTTTCCAACTCGTCTT 
               
               
                 1073 
                 2997396 
                 ANLN 
                 AGAAGTCACTACAGGATCTCCTTCC 
               
               
                 1074 
                 2997396 
                 ANLN 
                 CGTGACTTATAGAGGAGTTACAGAA 
               
               
                 1075 
                 2997396 
                 ANLN 
                 CCTAGTTCGTAATCGTCTTTCGTCG 
               
               
                 1076 
                 2997396 
                 ANLN 
                 AACGTGGTAACCGTGTTTGTCAACC 
               
               
                 1077 
                 2997397 
                 ANLN 
                 GTGGATCTGACCTTAACTTTCTGTG 
               
               
                 1078 
                 2997397 
                 ANLN 
                 CTGACCTTAACTTTCTGTGGTCGTC 
               
               
                 1079 
                 2997397 
                 ANLN 
                 TCAAATCACAGGTGTGGATCTGACC 
               
               
                 1080 
                 2997397 
                 ANLN 
                 AGGTGTGGATCTGACCTTAACTTTC 
               
               
                 1081 
                 2997399 
                 ANLN 
                 CTTTGTCTTGCAGGTAGTTATTTCG 
               
               
                 1082 
                 2997399 
                 ANLN 
                 TTGCAGGTAGTTATTTCGTCCACTA 
               
               
                 1083 
                 2997399 
                 ANLN 
                 ACTAACAAGCCTTCCTTCTACAATG 
               
               
                 1084 
                 2997399 
                 ANLN 
                 AAGTTTCTTTGTCTTGCAGGTAGTT 
               
               
                 1085 
                 2997400 
                 ANLN 
                 TCGTCTTTCTGAAGAAGATTAACGT 
               
               
                 1086 
                 2997400 
                 ANLN 
                 TGTCTGTCACTAGATAGTTCGATCG 
               
               
                 1087 
                 2997400 
                 ANLN 
                 CTTGAGTTATTGCTTTATTTATACG 
               
               
                 1088 
                 2997400 
                 ANLN 
                 TCGATCGGTCCGAGAATTGACGACA 
               
               
                 1089 
                 2997402 
                 ANLN 
                 ACGGTAGGTTTCCTAGTCAATGAAA 
               
               
                 1090 
                 2997402 
                 ANLN 
                 AGGCGAACGGAGATTTTCGTCTAAA 
               
               
                 1091 
                 2997402 
                 ANLN 
                 AATGAAACAGTCTTTAGGCGAACGG 
               
               
                 1092 
                 2997402 
                 ANLN 
                 GTCTAAAACAGACGTCATGCCAAGT 
               
               
                 1093 
                 2997403 
                 ANLN 
                 GAGAATTGCCACTACGAGACTGTAA 
               
               
                 1094 
                 2997403 
                 ANLN 
                 TACCATCGGTGTGGTAATCGTTCAT 
               
               
                 1095 
                 2997403 
                 ANLN 
                 GACTGTAAGTGATGATGTAAATGAG 
               
               
                 1096 
                 2997403 
                 ANLN 
                 AGTTTGAGAGAATTGCCACTACGAG 
               
               
                 1097 
                 2997406 
                 ANLN 
                 TTTCTAGGGAGTCCGGAACTATTCT 
               
               
                 1098 
                 2997406 
                 ANLN 
                 TTCTTTCTAGGGAGTCCGGAACTAT 
               
               
                 1099 
                 2997406 
                 ANLN 
                 TCTAGGGAGTCCGGAACTATTCTTC 
               
               
                 1100 
                 2997406 
                 ANLN 
                 CTTTCTAGGGAGTCCGGAACTATTC 
               
               
                 1101 
                 2997408 
                 ANLN 
                 CACGACACGCTTGGTCGTTGAAGCG 
               
               
                 1102 
                 2997408 
                 ANLN 
                 CCGGTCAGGTCCTCCAGAATCACGA 
               
               
                 1103 
                 2997408 
                 ANLN 
                 AACCTAGAATGTGTAATAGTAACAG 
               
               
                 1104 
                 2997408 
                 ANLN 
                 CGTTGAAGCGGGAACAACCTAGAAT 
               
               
                 1105 
                 2997409 
                 ANLN 
                 CGCTCTCGATGACCCGATAAACAAG 
               
               
                 1106 
                 2997409 
                 ANLN 
                 ATTCTCTCGCTCTCGATGACCCGAT 
               
               
                 1107 
                 2997409 
                 ANLN 
                 TCGATGACCCGATAAACAAGGTCCT 
               
               
                 1108 
                 2997409 
                 ANLN 
                 ATGACCCGATAAACAAGGTCCTTTT 
               
               
                 1109 
                 2997414 
                 ANLN 
                 AGAATAACCTGAATAGGTCTACTAC 
               
               
                 1110 
                 2997414 
                 ANLN 
                 CAAAACCACGGACCGTAGCTTCTAC 
               
               
                 1111 
                 2997414 
                 ANLN 
                 GACCTTTGACATATAGAATAACCTG 
               
               
                 1112 
                 2997414 
                 ANLN 
                 CCGTAGCTTCTACCACACAAGAAAG 
               
               
                 1113 
                 2997417 
                 ANLN 
                 GACCCCGAGTAATATGACAACAAAC 
               
               
                 1114 
                 2997417 
                 ANLN 
                 AACCGACAACCGAGTACACACGGAT 
               
               
                 1115 
                 2997417 
                 ANLN 
                 ACCGTTCTCGATGGTCAACTATAAA 
               
               
                 1116 
                 2997417 
                 ANLN 
                 GCATAGTATCCTTAAGTACCGACGG 
               
               
                 1117 
                 2997418 
                 ANLN 
                 GTATCCTTCCTATTTAGACCGATTA 
               
               
                 1118 
                 2997418 
                 ANLN 
                 CCTTCCTATTTAGACCGATTAACAT 
               
               
                 1119 
                 2997418 
                 ANLN 
                 ATCCTTCCTATTTAGACCGATTAAC 
               
               
                 1120 
                 2997418 
                 ANLN 
                 CCTATTTAGACCGATTAACATGGTC 
               
               
                 1121 
                 2997419 
                 ANLN 
                 CACGTTCTGCGTTGTGAAAACTTAA 
               
               
                 1122 
                 2997419 
                 ANLN 
                 AGGCTGGTGTTTCTCTTCTACTGGC 
               
               
                 1123 
                 2997419 
                 ANLN 
                 TGGCTCTCTGAGAACAGTCGGTTAC 
               
               
                 1124 
                 2997419 
                 ANLN 
                 TCGGTTACGTCCCTGTGTGAGACAC 
               
               
                 1125 
                 2997422 
                 ANLN 
                 TTCTCGCCCTAGAGACCTACGTTTT 
               
               
                 1126 
                 2997422 
                 ANLN 
                 ACCTACGTTTTTGAGTTAGTTCAAG 
               
               
                 1127 
                 2997422 
                 ANLN 
                 TCAAGAACAACTATAAGCGGAGACC 
               
               
                 1128 
                 2997422 
                 ANLN 
                 ACCGACAGACGTCTATGATTTCTTC 
               
               
                 1129 
                 2997423 
                 ANLN 
                 ACGATGTTTGGATAACCTTTCGGAA 
               
               
                 1130 
                 2997423 
                 ANLN 
                 CGATGTTTGGATAACCTTTCGGAAT 
               
               
                 1131 
                 2997423 
                 ANLN 
                 AACGATGTTTGGATAACCTTTCGGA 
               
               
                 1132 
                 2997424 
                 ANLN 
                 GACGCATCGAATGTCTGAATCGTAT 
               
               
                 1133 
                 2997424 
                 ANLN 
                 ATGCTTTCCCAAACACGGTTATAAG 
               
               
                 1134 
                 2997424 
                 ANLN 
                 AGAGTCATCAAAAAAGCTTTCCGAC 
               
               
                 1135 
                 2997424 
                 ANLN 
                 CAGAAGAACCTCGACATCCAGAACT 
               
               
                 1136 
                 3012979 
                 GNG11 
                 CGACGTCAGTGTAGGACGCGCCCAC 
               
               
                 1137 
                 3012979 
                 GNG11 
                 GAGTCCAGGATCCTTCGACCCCGTG 
               
               
                 1138 
                 3012979 
                 GNG11 
                 GCACTGTTCGCAGGGCCTCTTTCGG 
               
               
                 1139 
                 3012979 
                 GNG11 
                 GGTCCGGAAGTCAACAAAGCCCTGC 
               
               
                 1140 
                 3012980 
                 GNG11 
                 ACTTTTACCTTCAACTCGTCGAAGC 
               
               
                 1141 
                 3012980 
                 GNG11 
                 TCAACTCGTCGAAGCGTTTCTTCAC 
               
               
                 1142 
                 3012980 
                 GNG11 
                 ACCTTCAACTCGTCGAAGCGTTTCT 
               
               
                 1143 
                 3012980 
                 GNG11 
                 TCGTCGAAGCGTTTCTTCACTTCAA 
               
               
                 1144 
                 3012981 
                 GNG11 
                 TCTCCTAGGAGATCATTTCCCTTAA 
               
               
                 1145 
                 3012981 
                 GNG11 
                 ACCTCTCCTAGGAGATCATTTCCCT 
               
               
                 1146 
                 3012981 
                 GNG11 
                 CTCCTAGGAGATCATTTCCCTTAAG 
               
               
                 1147 
                 3012981 
                 GNG11 
                 CCTCTCCTAGGAGATCATTTCCCTT 
               
               
                 1148 
                 3012982 
                 GNG11 
                 CTGTGAAGAAAGTCATATAACGAAC 
               
               
                 1149 
                 3012982 
                 GNG11 
                 CACGATGAGTAGAAACGAGTGATAC 
               
               
                 1150 
                 3012982 
                 GNG11 
                 CTTGTAATGAACTCGTACTGTGAAG 
               
               
                 1151 
                 3012982 
                 GNG11 
                 ACCCTCTTTGACGTAGGATTCACCT 
               
               
                 1152 
                 3012983 
                 GNG11 
                 GAACCCGTACCGTGATGAGGTCAAG 
               
               
                 1153 
                 3012983 
                 GNG11 
                 GAACCTGGAGACGTGAGTACGAACG 
               
               
                 1154 
                 3012983 
                 GNG11 
                 CGAAACTCTCGGTCATGAATAAGGA 
               
               
                 1155 
                 3012983 
                 GNG11 
                 GGAGACCTTGCACAAACTAGATTGG 
               
               
                 1156 
                 3012985 
                 GNG11 
                 GTAAATAAGGCCAATGACCGTTCCG 
               
               
                 1157 
                 3012985 
                 GNG11 
                 CATGTGAGGGTTCAGGATCGAAAAC 
               
               
                 1158 
                 3012985 
                 GNG11 
                 GGGATTGAACAACCCTCAACGCTAA 
               
               
                 1159 
                 3012985 
                 GNG11 
                 GGTCGGTTGTACATCTTCACGTTAT 
               
               
                 1160 
                 3428784 
                 DRAM1 
                 GAGGCATCAGCGCAGGCGAACCTCG 
               
               
                 1161 
                 3428784 
                 DRAM1 
                 TGGCAGGCACTCACATGCGCGGGCC 
               
               
                 1162 
                 3428784 
                 DRAM1 
                 GCCCGGCGAAACACTGAAGTGAGCA 
               
               
                 1163 
                 3428784 
                 DRAM1 
                 TGAGCAAAGCGTTGTTCGGGCCCGT 
               
               
                 1164 
                 3428785 
                 DRAM1 
                 CGACCCGCGTCGTGAGGCAGCCGCC 
               
               
                 1165 
                 3428785 
                 DRAM1 
                 ACCCGCGTCGTGAGGCAGCCGCCGC 
               
               
                 1166 
                 3428785 
                 DRAM1 
                 GGCGACCCGCGTCGTGAGGCAGCCG 
               
               
                 1167 
                 3428785 
                 DRAM1 
                 CCCGCGTCGTGAGGCAGCCGCCGCC 
               
               
                 1168 
                 3428786 
                 DRAM1 
                 GGAAGTAATAGAGGATGCACCAGCG 
               
               
                 1169 
                 3428786 
                 DRAM1 
                 TGGACCAGCAGTCGGCGGAAGTAAT 
               
               
                 1170 
                 3428786 
                 DRAM1 
                 GACACGAAGGACTCCCCTTACCGAA 
               
               
                 1171 
                 3428786 
                 DRAM1 
                 TAGAGGATGCACCAGCGGCACGAGA 
               
               
                 1172 
                 3428798 
                 DRAM1 
                 AAACCTAAATACTATTTGAAGAGAC 
               
               
                 1173 
                 3428798 
                 DRAM1 
                 AACCTAAATACTATTTGAAGAGACG 
               
               
                 1174 
                 3428798 
                 DRAM1 
                 AAAACCTAAATACTATTTGAAGAGA 
               
               
                 1175 
                 3428798 
                 DRAM1 
                 ACCTAAATACTATTTGAAGAGACGT 
               
               
                 1176 
                 3428799 
                 DRAM1 
                 AATTGAACCACAGAAATCACGAACC 
               
               
                 1177 
                 3428799 
                 DRAM1 
                 GGACGATAAAGTCGTGAGGACAAAA 
               
               
                 1178 
                 3428799 
                 DRAM1 
                 ATCATGTCTTCGTTTTAGTTTGGAC 
               
               
                 1179 
                 3428799 
                 DRAM1 
                 CGTCGGTGCTACATATGTTCTATGT 
               
               
                 1180 
                 3428800 
                 DRAM1 
                 ACCTCACATACACAGACTTCTCTCG 
               
               
                 1181 
                 3428800 
                 DRAM1 
                 CGTGTGAATACGGTAATATCGGTAA 
               
               
                 1182 
                 3428800 
                 DRAM1 
                 GTCAATACTCCTCACCACCTCACAT 
               
               
                 1183 
                 3428800 
                 DRAM1 
                 CTCCGTGTGAATACGGTAATATCGG 
               
               
                 1184 
                 3428802 
                 DRAM1 
                 GGGTCACCTTGTCAGAGAGCTGTAC 
               
               
                 1185 
                 3428802 
                 DRAM1 
                 AGACGGCAAAGAACGCGTCGACAGT 
               
               
                 1186 
                 3428802 
                 DRAM1 
                 CACATGTGCGAGGATGTCAGGTAGT 
               
               
                 1187 
                 3428802 
                 DRAM1 
                 AGAGCTGTACGGTGTATGCCTACCA 
               
               
                 1188 
                 3428806 
                 DRAM1 
                 GTGATTAAAGGTATTGGTTCGACCT 
               
               
                 1189 
                 3428806 
                 DRAM1 
                 TGATTAAAGGTATTGGTTCGACCTC 
               
               
                 1190 
                 3428806 
                 DRAM1 
                 GATTAAAGGTATTGGTTCGACCTCA 
               
               
                 1191 
                 3428809 
                 DRAM1 
                 ACTCAGAAAAAGCCGATTTAAGACA 
               
               
                 1192 
                 3428809 
                 DRAM1 
                 TCATACATGTAATTTCACTCAGAAA 
               
               
                 1193 
                 3428809 
                 DRAM1 
                 GTAATTTCACTCAGAAAAAGCCGAT 
               
               
                 1194 
                 3428809 
                 DRAM1 
                 TCACTCAGAAAAAGCCGATTTAAGA 
               
               
                 1195 
                 3428812 
                 DRAM1 
                 GTGGGATTCCTATAGGTGTCTTTAG 
               
               
                 1196 
                 3428812 
                 DRAM1 
                 CAGTGGGATTCCTATAGGTGTCTTT 
               
               
                 1197 
                 3428812 
                 DRAM1 
                 TCACAGTGGGATTCCTATAGGTGTC 
               
               
                 1198 
                 3428812 
                 DRAM1 
                 CACAGTGGGATTCCTATAGGTGTCT 
               
               
                 1199 
                 3428813 
                 DRAM1 
                 GAGTGAGTCACTTACAGCGTCCGGT 
               
               
                 1200 
                 3428813 
                 DRAM1 
                 TGGGACTAATAACCCTACGTAGACG 
               
               
                 1201 
                 3428813 
                 DRAM1 
                 CGAGAACGACGATTAACGGGTAAGC 
               
               
                 1202 
                 3428813 
                 DRAM1 
                 GGACGAGTACTCCAGCGTGGAAAAC 
               
               
                 1203 
                 3428814 
                 DRAM1 
                 GTCGGTTCTTCTTGAAGACCCAAGT 
               
               
                 1204 
                 3428814 
                 DRAM1 
                 TCGGTTCTTCTTGAAGACCCAAGTC 
               
               
                 1205 
                 3428815 
                 DRAM1 
                 CCGACCTACAGGGTGTTGTGATATT 
               
               
                 1206 
                 3428815 
                 DRAM1 
                 CAGTTCGGGAAACACAATTCGTTCT 
               
               
                 1207 
                 3428815 
                 DRAM1 
                 TGAGGTAGAAAAGTGGGTTTAGTAC 
               
               
                 1208 
                 3428815 
                 DRAM1 
                 ACGAGGAAGAGAAGTACGGACACCG 
               
               
                 1209 
                 3428816 
                 DRAM1 
                 ACACCGGTTCACTCTAGTCGGGAGT 
               
               
                 1210 
                 3428816 
                 DRAM1 
                 TCGTCGGGTACATCTGTCGAAGCCT 
               
               
                 1211 
                 3428816 
                 DRAM1 
                 CAAGCCCCATCGAGGAGTAATTGAT 
               
               
                 1212 
                 3428816 
                 DRAM1 
                 GATCTCGTATTTGGGTACACACCGG 
               
               
                 1213 
                 3428817 
                 DRAM1 
                 AAGAAATTCTGCGTAGTATTTACCA 
               
               
                 1214 
                 3428817 
                 DRAM1 
                 ACGAAAGAAATTCTGCGTAGTATTT 
               
               
                 1215 
                 3428817 
                 DRAM1 
                 GAAAGAAATTCTGCGTAGTATTTAC 
               
               
                 1216 
                 3428817 
                 DRAM1 
                 GAAATTCTGCGTAGTATTTACCAAA 
               
               
                 1217 
                 3428818 
                 DRAM1 
                 TCTGAAAACAAGAGCCGCGAGGAGT 
               
               
                 1218 
                 3428818 
                 DRAM1 
                 AGGAGTGCTACCTCAAAGTACGAAG 
               
               
                 1219 
                 3428818 
                 DRAM1 
                 GTGTTAATCTAACCCTCGAGGAACT 
               
               
                 1220 
                 3428818 
                 DRAM1 
                 ACGGAGTGAAGCTCGTCTGAAAACA 
               
               
                 1221 
                 3428832 
                 DRAM1 
                 TATTTTGGTATAAACTGACGTGGAA 
               
               
                 1222 
                 3428832 
                 DRAM1 
                 ATACTTGGTGTGACTTTGCTGGAAG 
               
               
                 1223 
                 3428832 
                 DRAM1 
                 ATCAGTTCACGACGTATTACAAAAC 
               
               
                 1224 
                 3428832 
                 DRAM1 
                 TCAACTACCGTTGCTACCAATGAGT 
               
               
                 1225 
                 3454842 
                 BIN2 
                 GGGACCCAAGAGTCATCCTTACGAC 
               
               
                 1226 
                 3454842 
                 BIN2 
                 CTCTTTGATGGTTCTGAGGAGGACG 
               
               
                 1227 
                 3454842 
                 BIN2 
                 AGTCTCCCTATATTCTCGGTCGTAG 
               
               
                 1228 
                 3454842 
                 BIN2 
                 ACGACCACGACAGATTTCTGGACCG 
               
               
                 1229 
                 3454844 
                 BIN2 
                 CTGGTCGAAGTTCAGAGGTACCATG 
               
               
                 1230 
                 3454844 
                 BIN2 
                 TCTGGTCGAAGTTCAGAGGTACCAT 
               
               
                 1231 
                 3454844 
                 BIN2 
                 TGGTCGAAGTTCAGAGGTACCATGG 
               
               
                 1232 
                 3454844 
                 BIN2 
                 GGTCGAAGTTCAGAGGTACCATGGT 
               
               
                 1233 
                 3454845 
                 BIN2 
                 ATTCGAATAGAGTCGATTGAGGAGC 
               
               
                 1234 
                 3454845 
                 BIN2 
                 CCTATTATTCGAATAGAGTCGATTG 
               
               
                 1235 
                 3454845 
                 BIN2 
                 ATTATTCGAATAGAGTCGATTGAGG 
               
               
                 1236 
                 3454845 
                 BIN2 
                 TTCCTATTATTCGAATAGAGTCGAT 
               
               
                 1237 
                 3454846 
                 BIN2 
                 TTGGTGGTCTCTTCGGTCATTCTTG 
               
               
                 1238 
                 3454846 
                 BIN2 
                 AACATGAAGGGGGTGGAATTACTGT 
               
               
                 1239 
                 3454846 
                 BIN2 
                 TCGGTCATTCTTGAGGACTCCGGTT 
               
               
                 1240 
                 3454846 
                 BIN2 
                 CTTTTGTAGGTGTTAGTCTTGGGAC 
               
               
                 1241 
                 3454847 
                 BIN2 
                 ATGGAAGGTCGGGATGTCGGAGACC 
               
               
                 1242 
                 3454847 
                 BIN2 
                 GTCGGGATCCCGGAGGAACCCCTGA 
               
               
                 1243 
                 3454847 
                 BIN2 
                 CCTGGAGGGATCTCCAGAGAGGATT 
               
               
                 1244 
                 3454847 
                 BIN2 
                 ACCCTGACGTTCAGGATCCTGGAGG 
               
               
                 1245 
                 3454848 
                 BIN2 
                 TCTCTCGGAGATAGGTCTCCTGGAG 
               
               
                 1246 
                 3454848 
                 BIN2 
                 CTTCTCTCGGAGATAGGTCTCCTGG 
               
               
                 1247 
                 3454848 
                 BIN2 
                 TTCTCTCGGAGATAGGTCTCCTGGA 
               
               
                 1248 
                 3454849 
                 BIN2 
                 TGAGGTAGTGGTCCGCCTCGGGACT 
               
               
                 1249 
                 3454849 
                 BIN2 
                 AGAGGATGGTGACTTTCCCGGTTCA 
               
               
                 1250 
                 3454849 
                 BIN2 
                 GGTCGAGGTGTTGAGGTAGTGGTCC 
               
               
                 1251 
                 3454849 
                 BIN2 
                 GATGGTGACTTTCCCGGTTCAGGGT 
               
               
                 1252 
                 3454850 
                 BIN2 
                 CAGAGGTCAGGAGAATGGAGTGGAT 
               
               
                 1253 
                 3454850 
                 BIN2 
                 TGTCGATGTCAGAGGTCAGGAGAAT 
               
               
                 1254 
                 3454850 
                 BIN2 
                 CTTGTCGATGTCAGAGGTCAGGAGA 
               
               
                 1255 
                 3454850 
                 BIN2 
                 AAGCTTGTCGATGTCAGAGGTCAGG 
               
               
                 1256 
                 3454851 
                 BIN2 
                 GTCGTCCGCGAGAAATCAGTAAAGA 
               
               
                 1257 
                 3454851 
                 BIN2 
                 TCCGCGAGAAATCAGTAAAGAGGGG 
               
               
                 1258 
                 3454851 
                 BIN2 
                 CGTCCGCGAGAAATCAGTAAAGAGG 
               
               
                 1259 
                 3454851 
                 BIN2 
                 CGCGAGAAATCAGTAAAGAGGGGGT 
               
               
                 1260 
                 3454853 
                 BIN2 
                 GTAAAGGTTGAACTCCCTACAGAAG 
               
               
                 1261 
                 3454853 
                 BIN2 
                 TAACCGACGATACACTGGTAGAAGG 
               
               
                 1262 
                 3454853 
                 BIN2 
                 TGAACTCCCTACAGAAGATGTCCCT 
               
               
                 1263 
                 3454853 
                 BIN2 
                 AGCATAACCGACGATACACTGGTAG 
               
               
                 1264 
                 3454854 
                 BIN2 
                 TAAATCCTCGGAACCACCGACCAAA 
               
               
                 1265 
                 3454854 
                 BIN2 
                 ACGGAATGAGCATACACAAACACCA 
               
               
                 1266 
                 3454854 
                 BIN2 
                 TACCGAAAGTAAATCCTCGGAACCA 
               
               
                 1267 
                 3454854 
                 BIN2 
                 GAAAGGGTACGGAATGAGCATACAC 
               
               
                 1268 
                 3454855 
                 BIN2 
                 CTTCTCAAGTTGTTTCGGGTCTGAC 
               
               
                 1269 
                 3454855 
                 BIN2 
                 TCTTGATGATCTCCTCGACGGATAA 
               
               
                 1270 
                 3454855 
                 BIN2 
                 CTTCTAGACTTGGTTCTTGATGATC 
               
               
                 1271 
                 3454855 
                 BIN2 
                 TCCTCGACGGATAAGAAATATTATC 
               
               
                 1272 
                 3454856 
                 BIN2 
                 AGCCTTTGAGCACCTGATACTGTCA 
               
               
                 1273 
                 3454856 
                 BIN2 
                 CCAGCCTTTGAGCACCTGATACTGT 
               
               
                 1274 
                 3454856 
                 BIN2 
                 CCCAGCCTTTGAGCACCTGATACTG 
               
               
                 1275 
                 3454856 
                 BIN2 
                 GCCCCAGCCTTTGAGCACCTGATAC 
               
               
                 1276 
                 3454857 
                 BIN2 
                 TACAACGGGTCAAGTCACTTTAATT 
               
               
                 1277 
                 3454857 
                 BIN2 
                 ATACAACGGGTCAAGTCACTTTAAT 
               
               
                 1278 
                 3454857 
                 BIN2 
                 ACAACGGGTCAAGTCACTTTAATTC 
               
               
                 1279 
                 3454858 
                 BIN2 
                 TTCACCTCGGAAGTGGTCGGAGACT 
               
               
                 1280 
                 3454858 
                 BIN2 
                 GTGTGACACGTAAACACATCGGAGT 
               
               
                 1281 
                 3454858 
                 BIN2 
                 CACCTAGGGAGATTAAAACTGGGAG 
               
               
                 1282 
                 3454858 
                 BIN2 
                 CTGGAACACGGGACAAGAATTAGAG 
               
               
                 1283 
                 3454859 
                 BIN2 
                 GTCGCTCACCCTGCCAGTACTCCTC 
               
               
                 1284 
                 3454859 
                 BIN2 
                 TGTCGTCGCTCACCCTGCCAGTACT 
               
               
                 1285 
                 3454859 
                 BIN2 
                 ACGTACTTTCAAGTTTTTCTCACAG 
               
               
                 1286 
                 3454859 
                 BIN2 
                 TAGATGTCGTCGCTCACCCTGCCAG 
               
               
                 1287 
                 3454860 
                 BIN2 
                 ACTTCTTGAAGGAATCACGTCAGTT 
               
               
                 1288 
                 3454860 
                 BIN2 
                 TTCTTGAAGGAATCACGTCAGTTTC 
               
               
                 1289 
                 3454860 
                 BIN2 
                 CTTCCGGTGTTCGACATGTTCCTGG 
               
               
                 1290 
                 3454860 
                 BIN2 
                 GGTGTTCGACATGTTCCTGGACTTC 
               
               
                 1291 
                 3454862 
                 BIN2 
                 CTTGCTAAACTTGTTTCGCGATCGT 
               
               
                 1292 
                 3454862 
                 BIN2 
                 CTAAACTTGTTTCGCGATCGTTGAA 
               
               
                 1293 
                 3454862 
                 BIN2 
                 TGCTAAACTTGTTTCGCGATCGTTG 
               
               
                 1294 
                 3454862 
                 BIN2 
                 ACTTGCTAAACTTGTTTCGCGATCG 
               
               
                 1295 
                 3454863 
                 BIN2 
                 GGATACCCTTCCAGATCGAGCTTTG 
               
               
                 1296 
                 3454863 
                 BIN2 
                 GCACATCGGTCTGAAGCAATGAAGT 
               
               
                 1297 
                 3454863 
                 BIN2 
                 CTCGTGACGAAACTCGGGACCCTTC 
               
               
                 1298 
                 3454863 
                 BIN2 
                 GGTCGAGAGGGCTCAACTAAATAGT 
               
               
                 1299 
                 3454864 
                 BIN2 
                 ACGTCTTCTTCAAATCGTCCCGGGT 
               
               
                 1300 
                 3454864 
                 BIN2 
                 GCCGCGCCGGCCGGAGAAGCGGTTC 
               
               
                 1301 
                 3454864 
                 BIN2 
                 TCTTCTTCAAATCGTCCCGGGTCCT 
               
               
                 1302 
                 3454864 
                 BIN2 
                 CACGTCTTCTTCAAATCGTCCCGGG 
               
               
                 1303 
                 3454865 
                 BIN2 
                 CGGCCCTCGGGCGTGAAGGAGGAGC 
               
               
                 1304 
                 3454865 
                 BIN2 
                 TCTTTTGGTGTCCCGCGCCCCGGTC 
               
               
                 1305 
                 3454865 
                 BIN2 
                 AGTCTTTTGGTGTCCCGCGCCCCGG 
               
               
                 1306 
                 3454865 
                 BIN2 
                 GCCCTCGGGCGTGAAGGAGGAGCCC 
               
               
                 1307 
                 3454866 
                 BIN2 
                 CCGAATCTCGGATGGACCTCGTTCT 
               
               
                 1308 
                 3454866 
                 BIN2 
                 AGGGATGGTCAAGGTCCGAATCTCG 
               
               
                 1309 
                 3454866 
                 BIN2 
                 GAGTCTCTTGGATTTGCACAAAAGC 
               
               
                 1310 
                 3454866 
                 BIN2 
                 TGCGTCACATGTACCGCCGAAGCGT 
               
               
                 1311 
                 3536337 
                 CDKN3 
                 ATCTCCGGCTCAGAAGCCGGTGGGT 
               
               
                 1312 
                 3536337 
                 CDKN3 
                 GCCTCATTCTTTGGTCTTCGCCTAG 
               
               
                 1313 
                 3536337 
                 CDKN3 
                 GTGGAGTGTCTTCCTGCTTGGTCAC 
               
               
                 1314 
                 3536337 
                 CDKN3 
                 AGCCGGTGGGTTTCCGCCTCATTCT 
               
               
                 1315 
                 3536338 
                 CDKN3 
                 ACCAGAGCTGCACCCCGCCGGTCGC 
               
               
                 1316 
                 3536338 
                 CDKN3 
                 CGCCGTGACCAGAGCTGCACCCCGC 
               
               
                 1317 
                 3536338 
                 CDKN3 
                 GTGACCAGAGCTGCACCCCGCCGGT 
               
               
                 1318 
                 3536338 
                 CDKN3 
                 CCTCCGCCGTGACCAGAGCTGCACC 
               
               
                 1319 
                 3536343 
                 CDKN3 
                 AACATTTAAATTTCTACAATCTTCT 
               
               
                 1320 
                 3536343 
                 CDKN3 
                 ACATTTAAATTTCTACAATCTTCTT 
               
               
                 1321 
                 3536344 
                 CDKN3 
                 TGTTCTGTATAAACAAAAGACGTGG 
               
               
                 1322 
                 3536344 
                 CDKN3 
                 ACACCATATGTTCTGTATAAACAAA 
               
               
                 1323 
                 3536344 
                 CDKN3 
                 TTCTGTATAAACAAAAGACGTGGTC 
               
               
                 1324 
                 3536344 
                 CDKN3 
                 ACCATATGTTCTGTATAAACAAAAG 
               
               
                 1325 
                 3536345 
                 CDKN3 
                 AGGGTTTGGAAGACCTAGAGATGGT 
               
               
                 1326 
                 3536345 
                 CDKN3 
                 GGGTTTGGAAGACCTAGAGATGGTC 
               
               
                 1327 
                 3536346 
                 CDKN3 
                 TGGGTAGTAGTAGGTTAGCGTCTAC 
               
               
                 1328 
                 3536346 
                 CDKN3 
                 AGTAGTAGGTTAGCGTCTACCTCCC 
               
               
                 1329 
                 3536346 
                 CDKN3 
                 GTTACACCTTAATAGTGGGTAGTAG 
               
               
                 1330 
                 3536346 
                 CDKN3 
                 TAATAGTGGGTAGTAGTAGGTTAGC 
               
               
                 1331 
                 3536347 
                 CDKN3 
                 CTTTATTACCTTCTCGAATGTTGGA 
               
               
                 1332 
                 3536357 
                 CDKN3 
                 AGTGGTCTCGTTCGGTATCTGTCGG 
               
               
                 1333 
                 3536357 
                 CDKN3 
                 CCTAGGCCCCGTTATGTCTGGTAGT 
               
               
                 1334 
                 3536357 
                 CDKN3 
                 GTCGGACGCTCTGGATTCTCCTAGG 
               
               
                 1335 
                 3536357 
                 CDKN3 
                 GACAGACTGTGTTATAGTGGTCTCG 
               
               
                 1336 
                 3536358 
                 CDKN3 
                 GGTCAGGCAAAACCCTTACCTAGGA 
               
               
                 1337 
                 3536358 
                 CDKN3 
                 TGAAGAGTCAAAAACGGGGTCAGGC 
               
               
                 1338 
                 3536358 
                 CDKN3 
                 CAGGCAAAACCCTTACCTAGGAGAG 
               
               
                 1339 
                 3536358 
                 CDKN3 
                 GCAAAACCCTTACCTAGGAGAGTGG 
               
               
                 1340 
                 3536359 
                 CDKN3 
                 TTACTCTACCAATAACAATTATGTT 
               
               
                 1341 
                 3536359 
                 CDKN3 
                 GTTACTCTACCAATAACAATTATGT 
               
               
                 1342 
                 3536359 
                 CDKN3 
                 CTGTTACTCTACCAATAACAATTAT 
               
               
                 1343 
                 3536359 
                 CDKN3 
                 TGTTACTCTACCAATAACAATTATG 
               
               
                 1344 
                 3536360 
                 CDKN3 
                 TATGTTAATAGAAGTACTCAAAGCC 
               
               
                 1345 
                 3536360 
                 CDKN3 
                 TGTTAATAGAAGTACTCAAAGCCCT 
               
               
                 1346 
                 3536360 
                 CDKN3 
                 GTTATGTTAATAGAAGTACTCAAAG 
               
               
                 1347 
                 3536360 
                 CDKN3 
                 GTTAATAGAAGTACTCAAAGCCCTG 
               
               
                 1348 
                 3536361 
                 CDKN3 
                 AAGTGTTAGTTCTAGACATAGTTCT 
               
               
                 1349 
                 3536361 
                 CDKN3 
                 TGTTAGTTCTAGACATAGTTCTATT 
               
               
                 1350 
                 3536361 
                 CDKN3 
                 GTGTTAGTTCTAGACATAGTTCTAT 
               
               
                 1351 
                 3536361 
                 CDKN3 
                 TAAGTGTTAGTTCTAGACATAGTTC 
               
               
                 1352 
                 3536362 
                 CDKN3 
                 ACGTCTATAAGGATTTCAAAATAAC 
               
               
                 1353 
                 3536362 
                 CDKN3 
                 TTACTTTGGTGGTCACAATAGTTGA 
               
               
                 1354 
                 3536362 
                 CDKN3 
                 TTACATGTACACGTCTATAAGGATT 
               
               
                 1355 
                 3536362 
                 CDKN3 
                 CTTTACAGTCAAGAGATCGTATTAA 
               
               
                 1356 
                 3599812 
                 KIF23 
                 GGCGCGGAATCGGCGCTTCAAGATC 
               
               
                 1357 
                 3599812 
                 KIF23 
                 ACCGGGCAAACTTTACGCGGTCCGC 
               
               
                 1358 
                 3599812 
                 KIF23 
                 CCGAAGCGTCTCGTGGCGCGGAATC 
               
               
                 1359 
                 3599812 
                 KIF23 
                 CCCGAGAATCGCAGCGGCGGCCGAA 
               
               
                 1360 
                 3599813 
                 KIF23 
                 AGGGCGTACGCGCAAACCCGCCGCA 
               
               
                 1361 
                 3599813 
                 KIF23 
                 GTCGGCAGGGCGTACGCGCAAACCC 
               
               
                 1362 
                 3599813 
                 KIF23 
                 GCGTCAGAAGCGGTCGGTCGGCAGG 
               
               
                 1363 
                 3599813 
                 KIF23 
                 AAGAACGACGGCCAGGATTGCAGGG 
               
               
                 1364 
                 3599815 
                 KIF23 
                 CCCGATGTCTGAGTTGGCTTTACCT 
               
               
                 1365 
                 3599815 
                 KIF23 
                 CCCGAAAGGACTAGTTCTCACAACG 
               
               
                 1366 
                 3599815 
                 KIF23 
                 GTCGAAGTATGAGGACTCCCGATGT 
               
               
                 1367 
                 3599815 
                 KIF23 
                 ATCCCACGCGGGTGACCCGAAAGGA 
               
               
                 1368 
                 3599816 
                 KIF23 
                 TGGTGGGTCTTCCTTGAGAAACTAC 
               
               
                 1369 
                 3599816 
                 KIF23 
                 TTCATAAACCGTGAGTGTGGTGGGT 
               
               
                 1370 
                 3599816 
                 KIF23 
                 TTACTGGAGTAAGTACCGTTTTTAC 
               
               
                 1371 
                 3599816 
                 KIF23 
                 CTACAACACCGATTAGGGAACCAGT 
               
               
                 1372 
                 3599817 
                 KIF23 
                 GAGTGTGTTACTGACCAAGAGGTCC 
               
               
                 1373 
                 3599817 
                 KIF23 
                 GGAGCAACAAACCTGTACTAGAAAT 
               
               
                 1374 
                 3599817 
                 KIF23 
                 GTATACCACACTGCCCTTCACCTTT 
               
               
                 1375 
                 3599817 
                 KIF23 
                 ATCCCAGTAAAGTTCGATTTGCTAT 
               
               
                 1376 
                 3599818 
                 KIF23 
                 TTTCTCTTCGATACGGGTTAGGTTT 
               
               
                 1377 
                 3599818 
                 KIF23 
                 TATATGTCACACTCCAACTACGGAA 
               
               
                 1378 
                 3599818 
                 KIF23 
                 CTACGGAATAATCTTGCAGTCTTTT 
               
               
                 1379 
                 3599818 
                 KIF23 
                 CAAAAGTTTAGATTACTATCCTTAT 
               
               
                 1380 
                 3599819 
                 KIF23 
                 TTTTACCTGAATATTGCATATGTTA 
               
               
                 1381 
                 3599819 
                 KIF23 
                 AATTTTACCTGAATATTGCATATGT 
               
               
                 1382 
                 3599819 
                 KIF23 
                 CTGAATATTGCATATGTTAACTTGA 
               
               
                 1383 
                 3599819 
                 KIF23 
                 ACCTGAATATTGCATATGTTAACTT 
               
               
                 1384 
                 3599820 
                 KIF23 
                 ATACTATTGACATGTTCTTAAGACG 
               
               
                 1385 
                 3599820 
                 KIF23 
                 CTTCTCCACGGCAAACTAGGGTATT 
               
               
                 1386 
                 3599820 
                 KIF23 
                 TCTATCACAGATACCACATAAACAG 
               
               
                 1387 
                 3599820 
                 KIF23 
                 TGCTGTTCATCTAGGTCTCAAACGT 
               
               
                 1388 
                 3599822 
                 KIF23 
                 CAGTGAACCGCAAAATCAGGATCAG 
               
               
                 1389 
                 3599822 
                 KIF23 
                 ATAAAGAGACCTCATAATATGCAAT 
               
               
                 1390 
                 3599822 
                 KIF23 
                 CTATGGTCGTAGAGTATTAAATCCT 
               
               
                 1391 
                 3599822 
                 KIF23 
                 TCAGGATCAGAATTTACTTCTATGG 
               
               
                 1392 
                 3599823 
                 KIF23 
                 TACAACGTCCTACATGTCTTCAACT 
               
               
                 1393 
                 3599823 
                 KIF23 
                 GGAGGTGTTAGATTTAACGAAGCAC 
               
               
                 1394 
                 3599823 
                 KIF23 
                 AACGAAGCACTTCTATTCTTGGTAT 
               
               
                 1395 
                 3599823 
                 KIF23 
                 AACTTCACTTTAGATGACTCCTCCG 
               
               
                 1396 
                 3599824 
                 KIF23 
                 AAACTGAATAATCTTTCGTACATAT 
               
               
                 1397 
                 3599824 
                 KIF23 
                 AGTGGATCTCAACGATGATTCAAAC 
               
               
                 1398 
                 3599824 
                 KIF23 
                 CGATGATTCAAACTACCGTTAAAAA 
               
               
                 1399 
                 3599824 
                 KIF23 
                 ACTACTTATAGTGGATCTCAACGAT 
               
               
                 1400 
                 3599825 
                 KIF23 
                 TAATTTAATCAAGTCCGAGGGAACC 
               
               
                 1401 
                 3599825 
                 KIF23 
                 TGGGTAAACTTAGCACTCAGGTCGG 
               
               
                 1402 
                 3599825 
                 KIF23 
                 CTCTGCATAACGATTATGGGTAAAC 
               
               
                 1403 
                 3599825 
                 KIF23 
                 GCAAGGGTATCGCACAAGTTGTAAT 
               
               
                 1404 
                 3599826 
                 KIF23 
                 GTCTTCCCTTGTCTAATGCACTTCG 
               
               
                 1405 
                 3599826 
                 KIF23 
                 CACTTTCTTGATTGGCCTGGTCTCG 
               
               
                 1406 
                 3599826 
                 KIF23 
                 GAACCATCTAGAACGACCTTCACTT 
               
               
                 1407 
                 3599826 
                 KIF23 
                 TCTTGTTTAGTGATATTCAGTCAAC 
               
               
                 1408 
                 3599828 
                 KIF23 
                 GTTTCAATTGGGTAGACAAGTTCTT 
               
               
                 1409 
                 3599828 
                 KIF23 
                 ACGCCTACTAGCACACACACTTGGG 
               
               
                 1410 
                 3599828 
                 KIF23 
                 CCAAGGTATAGCTCTAAGTTTCAAT 
               
               
                 1411 
                 3599828 
                 KIF23 
                 AGTTCTTGATGAAACTACCCCTTCC 
               
               
                 1412 
                 3599830 
                 KIF23 
                 TGGTAACCAATGACTGCACCAAAAC 
               
               
                 1413 
                 3599830 
                 KIF23 
                 GTAACCAATGACTGCACCAAAACGT 
               
               
                 1414 
                 3599830 
                 KIF23 
                 GGTAACCAATGACTGCACCAAAACG 
               
               
                 1415 
                 3599830 
                 KIF23 
                 TAACCAATGACTGCACCAAAACGTC 
               
               
                 1416 
                 3599831 
                 KIF23 
                 CTATAGTTGCTACTCGTCTGTGAAG 
               
               
                 1417 
                 3599831 
                 KIF23 
                 TCTGTGAAGGTTCCGACTAACTTCG 
               
               
                 1418 
                 3599831 
                 KIF23 
                 TAACTTCGGAATCTCTTTGCTGTAT 
               
               
                 1419 
                 3599831 
                 KIF23 
                 GGAAACGGTAGTACGCTTTAAAACC 
               
               
                 1420 
                 3599832 
                 KIF23 
                 TTACGAAAATTTCGAAACAATGTTC 
               
               
                 1421 
                 3599832 
                 KIF23 
                 GATTACGAAAATTTCGAAACAATGT 
               
               
                 1422 
                 3599832 
                 KIF23 
                 ATTACGAAAATTTCGAAACAATGTT 
               
               
                 1423 
                 3599833 
                 KIF23 
                 TTCTTTTGGTGTACGTTCCCTTTGA 
               
               
                 1424 
                 3599836 
                 KIF23 
                 TCTATTTGCGTTAAACGTTGTCCTT 
               
               
                 1425 
                 3599836 
                 KIF23 
                 TGTTGATGATAGATACTCCTTCTAT 
               
               
                 1426 
                 3599836 
                 KIF23 
                 ACCACTGTCTTTGCTGTTACTTCAC 
               
               
                 1427 
                 3599836 
                 KIF23 
                 ACTGTTTGCGTCTAATCTTCGGTCC 
               
               
                 1428 
                 3599837 
                 KIF23 
                 CATCTCACCGTCGGTTTGTCGACCT 
               
               
                 1429 
                 3599837 
                 KIF23 
                 TCGCATCTCACCGTCGGTTTGTCGA 
               
               
                 1430 
                 3599837 
                 KIF23 
                 CGACCTCTACGTCTTATTTGAGACC 
               
               
                 1431 
                 3599837 
                 KIF23 
                 CTCACCGTCGGTTTGTCGACCTCTA 
               
               
                 1432 
                 3599838 
                 KIF23 
                 GTCTCTCTGGGAGAGCCCTCGCTCT 
               
               
                 1433 
                 3599838 
                 KIF23 
                 CTCGCTCTAGCTCTTTTTCAATGAG 
               
               
                 1434 
                 3599838 
                 KIF23 
                 TTCGACTTTGTTGACTTCCGATAAC 
               
               
                 1435 
                 3599838 
                 KIF23 
                 GACTTCCGATAACAATGGCTTGGAT 
               
               
                 1436 
                 3599839 
                 KIF23 
                 CCCTCCACCAAGGATGTAAGTCTTT 
               
               
                 1437 
                 3599839 
                 KIF23 
                 GTAGATAACGTTCCGCATCCGTCGT 
               
               
                 1438 
                 3599839 
                 KIF23 
                 GTCGGTGTCGATGTATCCGCGAGAT 
               
               
                 1439 
                 3599839 
                 KIF23 
                 TCCGCGAGATTGAGAACGTCGTCGT 
               
               
                 1440 
                 3599841 
                 KIF23 
                 AGACAAAACAAATCTTCGGATCTTT 
               
               
                 1441 
                 3599841 
                 KIF23 
                 GGAGAGTTATCGTCCCTATTTATAA 
               
               
                 1442 
                 3599841 
                 KIF23 
                 AACACCTGTATTATCTAATGGAGAG 
               
               
                 1443 
                 3599841 
                 KIF23 
                 TCCTTTCTGAACGTCGTAATGGTCT 
               
               
                 1444 
                 3599842 
                 KIF23 
                 ATTTAATTAAGACCCAATACGAACA 
               
               
                 1445 
                 3599842 
                 KIF23 
                 TTAATTAAGACCCAATACGAACAAA 
               
               
                 1446 
                 3599842 
                 KIF23 
                 AATTAAGACCCAATACGAACAAAGA 
               
               
                 1447 
                 3599842 
                 KIF23 
                 TAATTAAGACCCAATACGAACAAAG 
               
               
                 1448 
                 3599843 
                 KIF23 
                 CGGAGGCTACCCCTCTAACTTTGAT 
               
               
                 1449 
                 3599843 
                 KIF23 
                 TCTGCTAGTGCGAGACGTCCTCTGT 
               
               
                 1450 
                 3599843 
                 KIF23 
                 ACCCATCTAGTATTCGGGCGGAGAT 
               
               
                 1451 
                 3599843 
                 KIF23 
                 GGAGTACGGTAGTGTCATAGACAAC 
               
               
                 1452 
                 3599845 
                 KIF23 
                 GTTCCCCACCACCTGTTAGACAAGT 
               
               
                 1453 
                 3599845 
                 KIF23 
                 TTTTGTTCCCCACCACCTGTTAGAC 
               
               
                 1454 
                 3599845 
                 KIF23 
                 CAAATGACTATAACTCTGAAATTTC 
               
               
                 1455 
                 3599845 
                 KIF23 
                 CCCACCACCTGTTAGACAAGTCAAA 
               
               
                 1456 
                 3599849 
                 KIF23 
                 CTTTTTAATTTATAAACAGACGGAT 
               
               
                 1457 
                 3599850 
                 KIF23 
                 ATGGACCTACTGGATTTCTGGAAAG 
               
               
                 1458 
                 3599850 
                 KIF23 
                 CTGGAAAGACCGAGTGTTGTAAACA 
               
               
                 1459 
                 3599850 
                 KIF23 
                 GATAACTCTCCTCGACTAGAAAAAG 
               
               
                 1460 
                 3599850 
                 KIF23 
                 TGGATCCACACCTCGGACGATTTAT 
               
               
                 1461 
                 3599851 
                 KIF23 
                 ACCTATAGTCGTAGTGCGTGTTGGG 
               
               
                 1462 
                 3599851 
                 KIF23 
                 CTATAGTCGTAGTGCGTGTTGGGTT 
               
               
                 1463 
                 3599851 
                 KIF23 
                 CCTATAGTCGTAGTGCGTGTTGGGT 
               
               
                 1464 
                 3599852 
                 KIF23 
                 AACTTTTAGTGCCTGGAGTCGATGT 
               
               
                 1465 
                 3599852 
                 KIF23 
                 TACCAAGGTTTCTGTTGATCATAAG 
               
               
                 1466 
                 3599852 
                 KIF23 
                 GAGCTTTCGGTACGGTCTTCGTCAG 
               
               
                 1467 
                 3599852 
                 KIF23 
                 TCTCGTTTCGAAAGGGATACCAAGG 
               
               
                 1468 
                 3599853 
                 KIF23 
                 TGTAAATCTATACGGTTTTCTTAAT 
               
               
                 1469 
                 3599853 
                 KIF23 
                 AAATCTATACGGTTTTCTTAATTTT 
               
               
                 1470 
                 3599853 
                 KIF23 
                 ACTGTAAATCTATACGGTTTTCTTA 
               
               
                 1471 
                 3599853 
                 KIF23 
                 AGACTGTAAATCTATACGGTTTTCT 
               
               
                 1472 
                 3726377 
                 EME1 
                 CTCCTCAACGGTTGTAAACGGAAAG 
               
               
                 1473 
                 3726377 
                 EME1 
                 CATCACCAACTGTAGAGTCTAACAC 
               
               
                 1474 
                 3726377 
                 EME1 
                 TCAATAAAAGTGGTGGACAGGGTCT 
               
               
                 1475 
                 3726377 
                 EME1 
                 GTCGGTCAGTCCAACGATTCGTCAC 
               
               
                 1476 
                 3726378 
                 EME1 
                 AGGTACTATGGGGTCTCTCCTCACG 
               
               
                 1477 
                 3726378 
                 EME1 
                 ACGTCGTCTATTGTTCCTGGACTAG 
               
               
                 1478 
                 3726378 
                 EME1 
                 GACTAGAATCTAGGTACGACAGTCG 
               
               
                 1479 
                 3726378 
                 EME1 
                 TCGGGAAAGGTTTCTAGGGACTTCA 
               
               
                 1480 
                 3726379 
                 EME1 
                 TACGTCGTGACCAATGGTCCTACTT 
               
               
                 1481 
                 3726379 
                 EME1 
                 TGTTCGTTCCGTCTTCCTTTCGTGG 
               
               
                 1482 
                 3726379 
                 EME1 
                 TGTGTAGTAACATCACGACCTAGGT 
               
               
                 1483 
                 3726379 
                 EME1 
                 TCTTTTGGTTCGGCTCAGTCTTCCA 
               
               
                 1484 
                 3726381 
                 EME1 
                 CGTGACGTCTGGTACCTCACGGCGA 
               
               
                 1485 
                 3726381 
                 EME1 
                 GGATCCTCGTGACGTCTGGTACCTC 
               
               
                 1486 
                 3726381 
                 EME1 
                 CCACCCCCGGTCGAGGATCCTCGTG 
               
               
                 1487 
                 3726381 
                 EME1 
                 TTCCACCCCCGGTCGAGGATCCTCG 
               
               
                 1488 
                 3726382 
                 EME1 
                 TCCGACACGGAACGTCACAGTGAAC 
               
               
                 1489 
                 3726382 
                 EME1 
                 ACACGGAACGTCACAGTGAACCTCC 
               
               
                 1490 
                 3726382 
                 EME1 
                 GCGTCCGACACGGAACGTCACAGTG 
               
               
                 1491 
                 3726382 
                 EME1 
                 CGACACGGAACGTCACAGTGAACCT 
               
               
                 1492 
                 3726383 
                 EME1 
                 GTAAACACAGGTACTAGCTGTTACC 
               
               
                 1493 
                 3726383 
                 EME1 
                 CCTCGGTTGTCATGACCACAACGAG 
               
               
                 1494 
                 3726383 
                 EME1 
                 TCCGTAAACACAGGTACTAGCTGTT 
               
               
                 1495 
                 3726383 
                 EME1 
                 GTCATGACCACAACGAGGCCCGTCT 
               
               
                 1496 
                 3726384 
                 EME1 
                 CCTTCGGACCTGTCGTGATACTTTC 
               
               
                 1497 
                 3726385 
                 EME1 
                 CTTCCTTTGCGAAGTCCCGAAACAT 
               
               
                 1498 
                 3726385 
                 EME1 
                 CGTCCCTTTCGAGACAGTGACCACT 
               
               
                 1499 
                 3726386 
                 EME1 
                 CAGTGAGACGTTCCATCAGGTAGAG 
               
               
                 1500 
                 3726386 
                 EME1 
                 AAAGTACAATTTTCCCCGTCGAGAA 
               
               
                 1501 
                 3726386 
                 EME1 
                 CCCTACGAGACCAGGTCAGAAGAAG 
               
               
                 1502 
                 3726386 
                 EME1 
                 ATAAGTAACGTCTACATCCAGTGAG 
               
               
                 1503 
                 3726387 
                 EME1 
                 GGACCTCGACGACAAGAAACTAAAG 
               
               
                 1504 
                 3726387 
                 EME1 
                 AGAAACTAAAGGAGGGGACGTGGTC 
               
               
                 1505 
                 3726387 
                 EME1 
                 CTCGACGACAAGAAACTAAAGGAGG 
               
               
                 1506 
                 3726387 
                 EME1 
                 CGACGACAAGAAACTAAAGGAGGGG 
               
               
                 1507 
                 3726388 
                 EME1 
                 TACCATAGGTCCCATCTGCGACTTC 
               
               
                 1508 
                 3726388 
                 EME1 
                 TCTCCGGTCGTATCCCAGGTACCAT 
               
               
                 1509 
                 3726388 
                 EME1 
                 AGGTACCATAGGTCCCATCTGCGAC 
               
               
                 1510 
                 3726388 
                 EME1 
                 GTATCCCAGGTACCATAGGTCCCAT 
               
               
                 1511 
                 3726389 
                 EME1 
                 GACCTTTCTCGACCGGCTGAAGTGT 
               
               
                 1512 
                 3726389 
                 EME1 
                 GACCGGCTGAAGTGTACGCGTAAGT 
               
               
                 1513 
                 3726389 
                 EME1 
                 CGGGTCCGAGTTTAACACGTCTCGA 
               
               
                 1514 
                 3726389 
                 EME1 
                 TCCGAGTTTAACACGTCTCGACCTT 
               
               
                 1515 
                 3726390 
                 EME1 
                 GTCCGACTATAGTATCCGGTCCAAT 
               
               
                 1516 
                 3726390 
                 EME1 
                 ACTCCGGACTTCTCTAACTGAACAG 
               
               
                 1517 
                 3726390 
                 EME1 
                 GGTATCCGGTTCAATGGTCCTAATT 
               
               
                 1518 
                 3726390 
                 EME1 
                 AAAGTCAACGGTGAACTCCCCTTGT 
               
               
                 1519 
                 3726391 
                 EME1 
                 ACGTCAACACTTACGGATAGGGAGG 
               
               
                 1520 
                 3726391 
                 EME1 
                 CCTGAGCGTGATCAGACCTCCTCTG 
               
               
                 1521 
                 3726391 
                 EME1 
                 TAAGTCGTCGACTTGGCTCAGTCGG 
               
               
                 1522 
                 3726391 
                 EME1 
                 TCGAGGCTCTACTTTGATGGAAGAG 
               
               
                 1523 
                 3726392 
                 EME1 
                 CTTGCGGTCTTAAACGAGCGTCTGT 
               
               
                 1524 
                 3726392 
                 EME1 
                 CACTGTAGGTGAAGAGCGGCGTAAC 
               
               
                 1525 
                 3726392 
                 EME1 
                 CTGGTCTTGATAGGTCCGCATAGAT 
               
               
                 1526 
                 3726392 
                 EME1 
                 TAGTCGTCACAAAAAGCCTATTTCT 
               
               
                 1527 
                 3726393 
                 EME1 
                 ACCGTAAATTACAAGGAGAGGACCG 
               
               
                 1528 
                 3726393 
                 EME1 
                 GGTTCCTTGCCCTAATACTACTGAT 
               
               
                 1529 
                 3726393 
                 EME1 
                 CTACTGATACGCCTGAAGATATAAC 
               
               
                 1530 
                 3726393 
                 EME1 
                 CTCCGGGTCAGAAAGAACCCAGAAT 
               
               
                 1531 
                 3756194 
                 TOP2A 
                 GCCCCTGTTGTAAACTAGGTTCTAG 
               
               
                 1532 
                 3756194 
                 TOP2A 
                 ACGAGTCGTTACTCGATAATCTAAG 
               
               
                 1533 
                 3756194 
                 TOP2A 
                 TCTGGACAGATGTAACAATATACAC 
               
               
                 1534 
                 3756194 
                 TOP2A 
                 GACCTAACGTCTTCTGAGCCCCTGT 
               
               
                 1535 
                 3756195 
                 TOP2A 
                 TCACTGGTAGAGTACCCGTAACAAA 
               
               
                 1536 
                 3756195 
                 TOP2A 
                 AAGAGTTTAGTAGTCTCCGGCTTCT 
               
               
                 1537 
                 3756195 
                 TOP2A 
                 GACTAGTGAAGTCGCATTTCGTCAC 
               
               
                 1538 
                 3756195 
                 TOP2A 
                 TGTGAAACCGACACAGATATTGAAC 
               
               
                 1539 
                 3756196 
                 TOP2A 
                 TAGACATGCCCGTTTCTTTGGATAT 
               
               
                 1540 
                 3756196 
                 TOP2A 
                 GGTATACCTGAAACTGAGTCGACAC 
               
               
                 1541 
                 3756196 
                 TOP2A 
                 CGAGGAGCCCGTTTTAGACATGCCC 
               
               
                 1542 
                 3756196 
                 TOP2A 
                 GTTCCCCCTCTCACTACTGAAGGTA 
               
               
                 1543 
                 3756197 
                 TOP2A 
                 ACAAAGCTTTCGTCAGTGTTCGTTC 
               
               
                 1544 
                 3756197 
                 TOP2A 
                 GACCACAGAGAGTTTTCGGACTAGG 
               
               
                 1545 
                 3756197 
                 TOP2A 
                 ACGGTTTTGGTTCTTAGCGGCGTTT 
               
               
                 1546 
                 3756197 
                 TOP2A 
                 AGCGGCGTTTTCCTTCGGTAGGTGA 
               
               
                 1547 
                 3756198 
                 TOP2A 
                 TCAAGGATTTTTCTTACACTGTCAC 
               
               
                 1548 
                 3756198 
                 TOP2A 
                 CAAGGATTTTTCTTACACTGTCACT 
               
               
                 1549 
                 3756198 
                 TOP2A 
                 GATTTTTCTTACACTGTCACTTCTT 
               
               
                 1550 
                 3756198 
                 TOP2A 
                 AGGATTTTTCTTACACTGTCACTTC 
               
               
                 1551 
                 3756199 
                 TOP2A 
                 ACATGGTGACAGAAGTTCGGGAGGA 
               
               
                 1552 
                 3756199 
                 TOP2A 
                 CCGTCACATGGTGACAGAAGTTCGG 
               
               
                 1553 
                 3756199 
                 TOP2A 
                 TTCGGGAGGACGATGTGTAAAGGGT 
               
               
                 1554 
                 3756199 
                 TOP2A 
                 TCGGGAGGACGATGTGTAAAGGGTC 
               
               
                 1555 
                 3756200 
                 TOP2A 
                 AATCATTGTTTCTTGACTTTGGTGT 
               
               
                 1556 
                 3756200 
                 TOP2A 
                 CTTTGGTGTCTTTTCACAGCACAGT 
               
               
                 1557 
                 3756200 
                 TOP2A 
                 TTTGGTGTCTTTTCACAGCACAGTC 
               
               
                 1558 
                 3756200 
                 TOP2A 
                 ATCATTGTTTCTTGACTTTGGTGTC 
               
               
                 1559 
                 3756201 
                 TOP2A 
                 ACTACTTCTAAAACAGGGTAGTCTA 
               
               
                 1560 
                 3756202 
                 TOP2A 
                 TGTTTGATGTAACCGTAAATTCGGT 
               
               
                 1561 
                 3756202 
                 TOP2A 
                 TCTCTTTAGGGACCAGACTAAGTCT 
               
               
                 1562 
                 3756202 
                 TOP2A 
                 CATTAAAACTACAGGGAGGTGCTCT 
               
               
                 1563 
                 3756202 
                 TOP2A 
                 AGTCTATCCTCGTCACTGCTTTCAT 
               
               
                 1564 
                 3756203 
                 TOP2A 
                 ACACCTTGATCTTCCGGATTTTGTT 
               
               
                 1565 
                 3756203 
                 TOP2A 
                 GATCTTCCGGATTTTGTTTCTAATC 
               
               
                 1566 
                 3756203 
                 TOP2A 
                 TCTACCACACCTTGATCTTCCGGAT 
               
               
                 1567 
                 3756203 
                 TOP2A 
                 TTTTATGACTTCCTTCGGGAGTTCT 
               
               
                 1568 
                 3756204 
                 TOP2A 
                 TTGTTCTACTTGTTCAGCCTGAAGG 
               
               
                 1569 
                 3756204 
                 TOP2A 
                 CCAGTTTCTCAGTAAGGTGCTTATT 
               
               
                 1570 
                 3756204 
                 TOP2A 
                 ACGGAAGAGGCGCACCAGTTTCTCA 
               
               
                 1571 
                 3756204 
                 TOP2A 
                 AAGGTGCTTATTGGTATCTTTACTT 
               
               
                 1572 
                 3756206 
                 TOP2A 
                 GGAAGTTGATAGAAGAACTATACGG 
               
               
                 1573 
                 3756206 
                 TOP2A 
                 ACTATACGGGGAAACCATAAATTGG 
               
               
                 1574 
                 3756206 
                 TOP2A 
                 ACTGAGGCATTGTCTAAGACCTGGT 
               
               
                 1575 
                 3756206 
                 TOP2A 
                 GTCTAAGACCTGGTTGGAAGTTGAT 
               
               
                 1576 
                 3756207 
                 TOP2A 
                 TACTTCTCTCACTGTTGCTTTTCCT 
               
               
                 1577 
                 3756207 
                 TOP2A 
                 ACTTCTCTCACTGTTGCTTTTCCTT 
               
               
                 1578 
                 3756207 
                 TOP2A 
                 TTACTTCTCTCACTGTTGCTTTTCC 
               
               
                 1579 
                 3756207 
                 TOP2A 
                 CTTCTCTCACTGTTGCTTTTCCTTT 
               
               
                 1580 
                 3756208 
                 TOP2A 
                 AAGTCTCCCCTATACTAAGCCTAGG 
               
               
                 1581 
                 3756208 
                 TOP2A 
                 AAGACTAAGTCTCCCCTATACTAAG 
               
               
                 1582 
                 3756208 
                 TOP2A 
                 CTATACTAAGCCTAGGACACTTCCG 
               
               
                 1583 
                 3756208 
                 TOP2A 
                 TAATTAATTTCAAGACTAAGTCTCC 
               
               
                 1584 
                 3756209 
                 TOP2A 
                 CTCTGAAAAAACTTGAGTCTGAATT 
               
               
                 1585 
                 3756209 
                 TOP2A 
                 TTAGTCCGAGCGAAATAGAATCTCT 
               
               
                 1586 
                 3756209 
                 TOP2A 
                 TTACCGAGGATCCTTACGAACCACG 
               
               
                 1587 
                 3756209 
                 TOP2A 
                 CGAAAAACTGGTGCATCCGACAAAT 
               
               
                 1588 
                 3756210 
                 TOP2A 
                 TGTTTCAGAAGTTTGAGGTTTGATC 
               
               
                 1589 
                 3756210 
                 TOP2A 
                 GGAGGAGAGTATTGTCTGATATCCC 
               
               
                 1590 
                 3756210 
                 TOP2A 
                 CGTCTCTCTCAACCTGATGTGTTTC 
               
               
                 1591 
                 3756210 
                 TOP2A 
                 CTGATATCCCTTATGGTATGTCTAT 
               
               
                 1592 
                 3756211 
                 TOP2A 
                 ACCGAGGTTTAGTTATACACTAATC 
               
               
                 1593 
                 3756211 
                 TOP2A 
                 TGTTGGTAACTTTAGAGTCTCGAAG 
               
               
                 1594 
                 3756211 
                 TOP2A 
                 AGTTCCCATGATAACTTCTTGACCG 
               
               
                 1595 
                 3756211 
                 TOP2A 
                 AGTCTCGAAGGGCAGTCTTGTACCT 
               
               
                 1596 
                 3756212 
                 TOP2A 
                 GCACAACTCGGACTTACCATGTAAG 
               
               
                 1597 
                 3756212 
                 TOP2A 
                 CATGACCCACCAGGACGTTTTAGGG 
               
               
                 1598 
                 3756212 
                 TOP2A 
                 CCGAGCTAACAATAAAGGTGGTTTT 
               
               
                 1599 
                 3756212 
                 TOP2A 
                 GGGTTGAAACTACACGCACTTTAAC 
               
               
                 1600 
                 3756213 
                 TOP2A 
                 CGTTCCTAAGACGATCAGGTGCTAT 
               
               
                 1601 
                 3756213 
                 TOP2A 
                 CTGGTAATAGTTAAACCGAGTCTTA 
               
               
                 1602 
                 3756213 
                 TOP2A 
                 GTCGGGTAACCAGTCAAACCATGGT 
               
               
                 1603 
                 3756213 
                 TOP2A 
                 GGTCCGATGTACCACCGTTCCTAAG 
               
               
                 1604 
                 3756214 
                 TOP2A 
                 CTTCATTTCCAACGGGTTAATCGAC 
               
               
                 1605 
                 3756214 
                 TOP2A 
                 ACTGTTCGCTCTTCATTTCCAACGG 
               
               
                 1606 
                 3756214 
                 TOP2A 
                 ACAAATGAACGAAGTTTGCCTTACT 
               
               
                 1607 
                 3756214 
                 TOP2A 
                 GTTTGCCTTACTGTTCGCTCTTCAT 
               
               
                 1608 
                 3756215 
                 TOP2A 
                 AGTTTAAGACTATTGCTCTCTAGAT 
               
               
                 1609 
                 3756215 
                 TOP2A 
                 TCTAGATAGGGAAGATACCACCTAC 
               
               
                 1610 
                 3756215 
                 TOP2A 
                 GAAGTAGTTGTTCCTTGAATAGAAC 
               
               
                 1611 
                 3756215 
                 TOP2A 
                 AGACTGTATATTACTGAAGTAGTTG 
               
               
                 1612 
                 3756216 
                 TOP2A 
                 CTACTAGCTTTCCTTACCAATTGAT 
               
               
                 1613 
                 3756216 
                 TOP2A 
                 GTTGCTTTCAATGAACCCGAAGGAC 
               
               
                 1614 
                 3756216 
                 TOP2A 
                 CAATTGATTAAAGTACCTCCTATCT 
               
               
                 1615 
                 3756216 
                 TOP2A 
                 TTGTCTATCTACTAGCTTTCCTTAC 
               
               
                 1616 
                 3756217 
                 TOP2A 
                 GGTCGTGTAGTTTCCTTCGATTTCT 
               
               
                 1617 
                 3756217 
                 TOP2A 
                 CTTTTCTGTAGCATAGGTCAAGTTT 
               
               
                 1618 
                 3756217 
                 TOP2A 
                 CTTCGATTTCTTATGAAACGTCTAT 
               
               
                 1619 
                 3756217 
                 TOP2A 
                 AGCATAGGTCAAGTTTATAAGACCA 
               
               
                 1620 
                 3756218 
                 TOP2A 
                 TTCTCACCTTCTCAAGATGAGGTTT 
               
               
                 1621 
                 3756218 
                 TOP2A 
                 TCTCACCTTCTCAAGATGAGGTTTA 
               
               
                 1622 
                 3756218 
                 TOP2A 
                 CTTCTCACCTTCTCAAGATGAGGTT 
               
               
                 1623 
                 3756219 
                 TOP2A 
                 AGACGCTGTAGCAAAAGACCTCCTT 
               
               
                 1624 
                 3756219 
                 TOP2A 
                 ACGCTGTAGCAAAAGACCTCCTTAA 
               
               
                 1625 
                 3756219 
                 TOP2A 
                 ACCGGGAGAGAAGACGCTGTAGCAA 
               
               
                 1626 
                 3756219 
                 TOP2A 
                 GAGAGAAGACGCTGTAGCAAAAGAC 
               
               
                 1627 
                 3756220 
                 TOP2A 
                 TTATAGTAGTTCTAACACCCAGAAG 
               
               
                 1628 
                 3756220 
                 TOP2A 
                 GTAACTTCTGCGAAGCAATACCCTT 
               
               
                 1629 
                 3756220 
                 TOP2A 
                 TTCTAACACCCAGAAGTCATGTTCT 
               
               
                 1630 
                 3756220 
                 TOP2A 
                 CTAAGTAACTTCTGCGAAGCAATAC 
               
               
                 1631 
                 3756221 
                 TOP2A 
                 ACAAGCTCTTCGAAGAGTATTCGTC 
               
               
                 1632 
                 3756221 
                 TOP2A 
                 ACCCTCTCTGTTTATACCCCAAAAG 
               
               
                 1633 
                 3756221 
                 TOP2A 
                 TTTTATGAGTTACAAGCTCTTCGAA 
               
               
                 1634 
                 3756222 
                 TOP2A 
                 ACTCCCTCTAAGTCGGTTTTGAAAC 
               
               
                 1635 
                 3756222 
                 TOP2A 
                 CCCTCTAAGTCGGTTTTGAAACCGA 
               
               
                 1636 
                 3756222 
                 TOP2A 
                 GAGGTGACTCACATGCGAATAGGAC 
               
               
                 1637 
                 3756222 
                 TOP2A 
                 GCGAATAGGACTGACTCCCTCTAAG 
               
               
                 1638 
                 3756223 
                 TOP2A 
                 CTTAGTTCCCTTAAGGGTTTGAGCT 
               
               
                 1639 
                 3756223 
                 TOP2A 
                 CAATTTGTTCTTCACAAGTCGACAT 
               
               
                 1640 
                 3756223 
                 TOP2A 
                 GTAACCGACACCATAACATCTTTCG 
               
               
                 1641 
                 3756223 
                 TOP2A 
                 ACATCTTTCGTATGATTTGACCCAC 
               
               
                 1642 
                 3756224 
                 TOP2A 
                 AACTTTTGGGTTGGAAACTGAGAGT 
               
               
                 1643 
                 3756224 
                 TOP2A 
                 TTTTGTACTGAAATGTTGGGTTCTC 
               
               
                 1644 
                 3756224 
                 TOP2A 
                 TTGGGTTGGAAACTGAGAGTCTGTT 
               
               
                 1645 
                 3756224 
                 TOP2A 
                 ACATTTACGGAATTAACTTTTGGGT 
               
               
                 1646 
                 3756225 
                 TOP2A 
                 ACCACAACGTCATTTTCGTGTAGTC 
               
               
                 1647 
                 3756225 
                 TOP2A 
                 CTAACACTGATTTGAACAACTACAA 
               
               
                 1648 
                 3756225 
                 TOP2A 
                 TGTTCCCACCACAACGTCATTTTCG 
               
               
                 1649 
                 3756225 
                 TOP2A 
                 CGACTAGTCTAACACTGATTTGAAC 
               
               
                 1650 
                 3756226 
                 TOP2A 
                 GGTGTCCACCCTTCACACAAATTGA 
               
               
                 1651 
                 3756226 
                 TOP2A 
                 TTTCCTAAAGCATCAATACACCTGT 
               
               
                 1652 
                 3756226 
                 TOP2A 
                 GTTCAACCTACTTTGACCATTGAGG 
               
               
                 1653 
                 3756226 
                 TOP2A 
                 TCCGAAAGTCGTTTAATCGAAACAG 
               
               
                 1654 
                 3756227 
                 TOP2A 
                 ATATGTACATAGTGGAAAGTCGGAC 
               
               
                 1655 
                 3756227 
                 TOP2A 
                 ATAACGACCTAGGTGGTTTCTACAG 
               
               
                 1656 
                 3756227 
                 TOP2A 
                 TTACGTTTCGGACCTGTTTCTATAA 
               
               
                 1657 
                 3756227 
                 TOP2A 
                 AACAACGTGATTACCAGTCTTCTCG 
               
               
                 1658 
                 3756228 
                 TOP2A 
                 CCGATACCTCGGTTTAACACATTGT 
               
               
                 1659 
                 3756228 
                 TOP2A 
                 CATTGTATAAGTCATGGTTTAAATG 
               
               
                 1660 
                 3756228 
                 TOP2A 
                 ACCGATACCTCGGTTTAACACATTG 
               
               
                 1661 
                 3756229 
                 TOP2A 
                 ACTTTTCTACATACAGGGTCGAGAG 
               
               
                 1662 
                 3756229 
                 TOP2A 
                 AAACCTGTCGAGGATTGAAGATCAT 
               
               
                 1663 
                 3756229 
                 TOP2A 
                 GTCGAGGATTGAAGATCATTGATAC 
               
               
                 1664 
                 3756229 
                 TOP2A 
                 GAGTATAAACCTGTCGAGGATTGAA 
               
               
                 1665 
                 3756230 
                 TOP2A 
                 GAACATAATCTCAGTGTTAACTAGG 
               
               
                 1666 
                 3756230 
                 TOP2A 
                 CCTGGGTTTTTACAGAACATAATCT 
               
               
                 1667 
                 3756230 
                 TOP2A 
                 ATTACGACGCCTGTTGTTTGTTTCC 
               
               
                 1668 
                 3756230 
                 TOP2A 
                 ACGCCTGTTGTTTGTTTCCCTGGGT 
               
               
                 1669 
                 3756232 
                 TOP2A 
                 GCGGGTCTGTGGATGTAACCAAGAC 
               
               
                 1670 
                 3756232 
                 TOP2A 
                 GTGGATGTAACCAAGACACCTTAAT 
               
               
                 1671 
                 3756232 
                 TOP2A 
                 ACCAAGACACCTTAATCACTGGGTC 
               
               
                 1672 
                 3756232 
                 TOP2A 
                 CTTGTATAAAACGAGGCGGGTCTGT 
               
               
                 1673 
                 3756234 
                 TOP2A 
                 AGAACTCGGGGAAGTGCTGGCAGTG 
               
               
                 1674 
                 3756234 
                 TOP2A 
                 AAGAACTCGGGGAAGTGCTGGCAGT 
               
               
                 1675 
                 3756234 
                 TOP2A 
                 GAACTCGGGGAAGTGCTGGCAGTGG 
               
               
                 1676 
                 3756234 
                 TOP2A 
                 CAAGAACTCGGGGAAGTGCTGGCAG 
               
               
                 1677 
                 3756235 
                 TOP2A 
                 CAGGACGGACAAATCAGCGAAAGTC 
               
               
                 1678 
                 3756235 
                 TOP2A 
                 CCCAGGACGGACAAATCAGCGAAAG 
               
               
                 1679 
                 3756235 
                 TOP2A 
                 AAGTTCACCTCGAGAGGATTGGCTG 
               
               
                 1680 
                 3756235 
                 TOP2A 
                 TTGGCTGCGCGCAGACACCTCTTCG 
               
               
                 1681 
                 3756237 
                 TOP2A 
                 AATTTATCCTTAAGTATGGTCCCTG 
               
               
                 1682 
                 3756237 
                 TOP2A 
                 TTATCCTTAAGTATGGTCCCTGTTT 
               
               
                 1683 
                 3756237 
                 TOP2A 
                 ATCCTTAAGTATGGTCCCTGTTTCG 
               
               
                 1684 
                 3756237 
                 TOP2A 
                 CCTTAAGTATGGTCCCTGTTTCGTC 
               
               
                 1685 
                 3757155 
                 KRT14 
                 ACCGTTAGTTATGTCGAAGTAATAG 
               
               
                 1686 
                 3757155 
                 KRT14 
                 ATCCTCCGGGGGGCACACCTGTGTC 
               
               
                 1687 
                 3757156 
                 KRT14 
                 GCGGTTTAGGCGTGGTTCCAGTACC 
               
               
                 1688 
                 3757156 
                 KRT14 
                 TCGGCGGTTTAGGCGTGGTTCCAGT 
               
               
                 1689 
                 3757156 
                 KRT14 
                 CGGTTTAGGCGTGGTTCCAGTACCT 
               
               
                 1690 
                 3757156 
                 KRT14 
                 AGGTCGGCGGTTTAGGCGTGGTTCC 
               
               
                 1691 
                 3757157 
                 KRT14 
                 ACCCTCGGGAGCAGACTTTCTTTAC 
               
               
                 1692 
                 3757157 
                 KRT14 
                 ACTCGAGATCACGACAGTGGGTCAA 
               
               
                 1693 
                 3757157 
                 KRT14 
                 GAGAACGAAGATGCACCACAGACAC 
               
               
                 1694 
                 3757157 
                 KRT14 
                 GACTCTGGTGAGGTAACCCACTTAT 
               
               
                 1695 
                 3757160 
                 KRT14 
                 GACCTCCTCTGGTTTCCAGCGATGA 
               
               
                 1696 
                 3757160 
                 KRT14 
                 TCTAGGTCCTCTACTAACCGTCGCA 
               
               
                 1697 
                 3757160 
                 KRT14 
                 TCCTCTGGTTTCCAGCGATGACGTA 
               
               
                 1698 
                 3757160 
                 KRT14 
                 CTGGTTTCCAGCGATGACGTACGTC 
               
               
                 1699 
                 3757162 
                 KRT14 
                 GTTCTCGCTCTAGAGCCTCGAGGCC 
               
               
                 1700 
                 3757162 
                 KRT14 
                 CGTCTTGGACCTCTAACTCGACGTC 
               
               
                 1701 
                 3757162 
                 KRT14 
                 ACCGGTGGTTGTCGCTCGACCACGT 
               
               
                 1702 
                 3757162 
                 KRT14 
                 CCTCGAGGCCGCGTGGTACGTCTTG 
               
               
                 1703 
                 3757164 
                 KRT14 
                 CCTCTACCTGCGACGTGGACCGCAC 
               
               
                 1704 
                 3757164 
                 KRT14 
                 CGGTCCACCCACCTCTACAGTTACA 
               
               
                 1705 
                 3757164 
                 KRT14 
                 CTACTTACGGGACTCTCCGGTCCAC 
               
               
                 1706 
                 3757164 
                 KRT14 
                 AGACTTGCTCTACGCACTGGTCATA 
               
               
                 1707 
                 3757167 
                 KRT14 
                 CACAGAGTATGGAAAAGAGACCCCA 
               
               
                 1708 
                 3757167 
                 KRT14 
                 CTACCCACAGAGTATGGAAAAGAGA 
               
               
                 1709 
                 3757167 
                 KRT14 
                 ATGGAAAAGAGACCCCAGTAAGGTC 
               
               
                 1710 
                 3757167 
                 KRT14 
                 AGTATGGAAAAGAGACCCCAGTAAG 
               
               
                 1711 
                 3757169 
                 KRT14 
                 TCGGTGTCACCTGTTACGGTTACAG 
               
               
                 1712 
                 3757169 
                 KRT14 
                 ACTGTTACGGGCAGACCGGCGCCTA 
               
               
                 1713 
                 3757169 
                 KRT14 
                 ACCGGCGCCTACTGAAGGCGTGGTT 
               
               
                 1714 
                 3757169 
                 KRT14 
                 CGGTTACAGGAAGACGTCTAACTGT 
               
               
                 1715 
                 3757172 
                 KRT14 
                 ACCCCCTCCTATACCACCACCGGAA 
               
               
                 1716 
                 3757172 
                 KRT14 
                 CCGAAACCACCACCGAAACGACCAC 
               
               
                 1717 
                 3757172 
                 KRT14 
                 ACCGGAACCACGACCGAACCCACCA 
               
               
                 1718 
                 3757172 
                 KRT14 
                 GAAACGACCACCACTACCCGAAGAC 
               
               
                 1719 
                 3757174 
                 KRT14 
                 TGAGTCGGTTGACGAGCGAGCGAGT 
               
               
                 1720 
                 3757174 
                 KRT14 
                 AAGAGAAGTGAGTCGGTTGACGAGC 
               
               
                 1721 
                 3757174 
                 KRT14 
                 AAGTGAGTCGGTTGACGAGCGAGCG 
               
               
                 1722 
                 3757174 
                 KRT14 
                 TGGGCTCGTGGAAGAGAAGTGAGTC 
               
               
                 1723 
                 3757199 
                 KRT14 
                 CTCTTCCACTGGTACGTCTTGGAGT 
               
               
                 1724 
                 3757199 
                 KRT14 
                 CACTGGTACGTCTTGGAGTTACTGG 
               
               
                 1725 
                 3757199 
                 KRT14 
                 TTCCACTGGTACGTCTTGGAGTTAC 
               
               
                 1726 
                 3757199 
                 KRT14 
                 CGTCTTGGAGTTACTGGCGGACCGG 
               
               
                 1727 
                 3815758 
                 MUM1 
                 CGTCGCCAACCGCCCGCCCAGGAGG 
               
               
                 1728 
                 3815758 
                 MUM1 
                 GACGCCGGAGGAACGGGCCCGAACC 
               
               
                 1729 
                 3815758 
                 MUM1 
                 GCCCAGGAGGCGACAACGCCGGCGA 
               
               
                 1730 
                 3815758 
                 MUM1 
                 CCGCCGCGCCTGCCGTCGCCAACCG 
               
               
                 1731 
                 3815759 
                 MUM1 
                 ACTCTGGACCCTCATGCAACACGGT 
               
               
                 1732 
                 3815759 
                 MUM1 
                 TGTGTAACCGCACTCTGGACCCTCA 
               
               
                 1733 
                 3815759 
                 MUM1 
                 TGTAACCGCACTCTGGACCCTCATG 
               
               
                 1734 
                 3815759 
                 MUM1 
                 CCTCATGCAACACGGTTTAGTAACG 
               
               
                 1735 
                 3815762 
                 MUM1 
                 ACCGGGCTTGGCGCTGAAGTTGTTT 
               
               
                 1736 
                 3815762 
                 MUM1 
                 ACACGTTTAGGAGAGAGATCTCCTT 
               
               
                 1737 
                 3815762 
                 MUM1 
                 TTCCTTATAAAAGATCGACACGTTT 
               
               
                 1738 
                 3815762 
                 MUM1 
                 AAACCGGGCTTGGCGCTGAAGTTGT 
               
               
                 1739 
                 3815763 
                 MUM1 
                 TGTCAACTTCGGGTCGGGTGAGAAT 
               
               
                 1740 
                 3815763 
                 MUM1 
                 AAGGGCACATCTAAAGACTATGAAG 
               
               
                 1741 
                 3815763 
                 MUM1 
                 CAAAGAATTAGTCACGGTACGGTCC 
               
               
                 1742 
                 3815763 
                 MUM1 
                 GGTTTGCTCCGTAAGACACTCTAGA 
               
               
                 1743 
                 3815764 
                 MUM1 
                 TTCCGTTTATTGACTACTGGTCCGC 
               
               
                 1744 
                 3815764 
                 MUM1 
                 TGCAGACACTGTCCGGGTAGTTAAA 
               
               
                 1745 
                 3815764 
                 MUM1 
                 TGGTCCGCCGTGTAACAAGACGAGG 
               
               
                 1746 
                 3815764 
                 MUM1 
                 CGGACAGTGAGATTTGGTCGCAAAT 
               
               
                 1747 
                 3815765 
                 MUM1 
                 CCACGTAGACAGCACTCTTAAGGGT 
               
               
                 1748 
                 3815765 
                 MUM1 
                 CGTGGCCCTTCCACATCTAGTAGAT 
               
               
                 1749 
                 3815765 
                 MUM1 
                 ACTAGGGCGCATCAGGTTCCGTAAC 
               
               
                 1750 
                 3815765 
                 MUM1 
                 TCGACGGAGACTTCGAGCGAACCAG 
               
               
                 1751 
                 3815766 
                 MUM1 
                 GAGTGTGAAAGGGACGCCGACCCTT 
               
               
                 1752 
                 3815766 
                 MUM1 
                 AGTGTGAAAGGGACGCCGACCCTTC 
               
               
                 1753 
                 3815767 
                 MUM1 
                 CATTGGAGTCCGTCTACTTAAGGAT 
               
               
                 1754 
                 3815767 
                 MUM1 
                 TGGTCCCAAGAACGACGGACATTGG 
               
               
                 1755 
                 3815767 
                 MUM1 
                 ACTTTTACAGAACCGCCGCAACCGA 
               
               
                 1756 
                 3815767 
                 MUM1 
                 CACATTGCAGCTAAAACAGAGACGT 
               
               
                 1757 
                 3815769 
                 MUM1 
                 TTGCGCTTAGGGGACTCGACTTCCT 
               
               
                 1758 
                 3815769 
                 MUM1 
                 ATAAGAACTGCGGGTCTTACCAGTC 
               
               
                 1759 
                 3815769 
                 MUM1 
                 CTTAAACGGGGATCTTGGTGAGGAT 
               
               
                 1760 
                 3815769 
                 MUM1 
                 TGAGGATAAGAACTGCGGGTCTTAC 
               
               
                 1761 
                 3815770 
                 MUM1 
                 GAGACGTATTGAATCCGGCCCGACT 
               
               
                 1762 
                 3815770 
                 MUM1 
                 TAGTAGAACCTACCGCAGCAGGAAC 
               
               
                 1763 
                 3815770 
                 MUM1 
                 CCGTGGGTAACAAACTCCGTGACAG 
               
               
                 1764 
                 3815770 
                 MUM1 
                 CGTAATACGGGCGACTCAACACTAT 
               
               
                 1765 
                 3815771 
                 MUM1 
                 TGTCTGCCAGCGAAGCGCACCGAGA 
               
               
                 1766 
                 3815771 
                 MUM1 
                 CCAAGGACGCCGTGGGGACCTTCTT 
               
               
                 1767 
                 3815771 
                 MUM1 
                 CTTGACCGGATGTCTGCCAGCGAAG 
               
               
                 1768 
                 3815771 
                 MUM1 
                 GAGACCTGCAAGACTCGCTCCCGAG 
               
               
                 1769 
                 3815772 
                 MUM1 
                 CGGTACACACGTTGTTTCGGACAGT 
               
               
                 1770 
                 3815772 
                 MUM1 
                 GGTCTACAGAAGGAACGGGCCTAAG 
               
               
                 1771 
                 3815772 
                 MUM1 
                 CAACCCGTCAAGGTCTGGAGTGTCC 
               
               
                 1772 
                 3815772 
                 MUM1 
                 CTCGTACAGAGGAGCGGGACACTAA 
               
               
                 1773 
                 3815773 
                 MUM1 
                 TCTCAGGTACCCCAGATTAAGGTAC 
               
               
                 1774 
                 3815773 
                 MUM1 
                 CCTTCTGCTCCTCGGTGGTTCTCAG 
               
               
                 1775 
                 3815773 
                 MUM1 
                 ACGGTCAGAAGGCTTCTCAGGTACC 
               
               
                 1776 
                 3815773 
                 MUM1 
                 CCCCAGATTAAGGTACGCAAGATAG 
               
               
                 1777 
                 3815774 
                 MUM1 
                 CCTTACGATCAGACCGTATTTGTAT 
               
               
                 1778 
                 3815774 
                 MUM1 
                 ACTTCATCCTTACGATCAGACCGTA 
               
               
                 1779 
                 3815774 
                 MUM1 
                 CATCCTTACGATCAGACCGTATTTG 
               
               
                 1780 
                 3815774 
                 MUM1 
                 ATCCTTACGATCAGACCGTATTTGT 
               
               
                 1781 
                 3815775 
                 MUM1 
                 TTTCGCAGTCCGTCTCTCTATTCTT 
               
               
                 1782 
                 3815775 
                 MUM1 
                 CAGTTTTCGCAGTCCGTCTCTCTAT 
               
               
                 1783 
                 3815775 
                 MUM1 
                 TCGTTCACACGATATGTAGCTTCCT 
               
               
                 1784 
                 3815775 
                 MUM1 
                 TCCTGTGTACTTGGGCTTTTACTTT 
               
               
                 1785 
                 3815778 
                 MUM1 
                 CCGACCACACAGAGGGAGTAGTGGC 
               
               
                 1786 
                 3815778 
                 MUM1 
                 TTCGGTCCCTCCTGAAGTTGGTCCT 
               
               
                 1787 
                 3815778 
                 MUM1 
                 GTAGTGGCTGATGTCCCAGGCCAAT 
               
               
                 1788 
                 3815778 
                 MUM1 
                 CCTGAAGTTGGTCCTGTAGCCGACC 
               
               
                 1789 
                 3815780 
                 MUM1 
                 GGCTTTTAGGTAGGTCGTCCTGCAG 
               
               
                 1790 
                 3815780 
                 MUM1 
                 AACCCCTGGTTCGAAGGAGTTGACT 
               
               
                 1791 
                 3815780 
                 MUM1 
                 CGAAGGAGTTGACTCGTTCCCCTCG 
               
               
                 1792 
                 3815780 
                 MUM1 
                 GAACCCCTGGTTCGAAGGAGTTGAC 
               
               
                 1793 
                 3815781 
                 MUM1 
                 GTGGACGCCCGGTAGGATTTCTCGT 
               
               
                 1794 
                 3815781 
                 MUM1 
                 ACTTCATGGACGTCCCGCAGATGGT 
               
               
                 1795 
                 3815781 
                 MUM1 
                 AGTAAGACCTGCACGAAGACGGGCT 
               
               
                 1796 
                 3815781 
                 MUM1 
                 ACTCGAGGTCGGTCATGCACTGGAC 
               
               
                 1797 
                 3815783 
                 MUM1 
                 ACGAACAGTGTCGATTCCCACGAAG 
               
               
                 1798 
                 3815783 
                 MUM1 
                 CTCTGAGACGAGACTTGGCTTACCT 
               
               
                 1799 
                 3815783 
                 MUM1 
                 AAGAATTGGCGTCCGGTGAACCCCG 
               
               
                 1800 
                 3815783 
                 MUM1 
                 GTCCCTAAGTACCTGATCCAAACGT 
               
               
                 1801 
                 3815784 
                 MUM1 
                 ACCTGCTCCACCTGATGTTCTGCCG 
               
               
                 1802 
                 3815784 
                 MUM1 
                 GTAGTTCCCCGGAAGCGACTCGATG 
               
               
                 1803 
                 3815784 
                 MUM1 
                 TTCTGCCGACTCCTCTTCATGTAGT 
               
               
                 1804 
                 3815784 
                 MUM1 
                 CGGTAGTAGACACGCTAGAGACGCC 
               
               
                 1805 
                 3815786 
                 MUM1 
                 CCGGGTCGACCGAATGGTTTTGTCC 
               
               
                 1806 
                 3815786 
                 MUM1 
                 CTCGCGGATTAGGACAGAGACCCGT 
               
               
                 1807 
                 3815786 
                 MUM1 
                 AAAGGACGACCTAGAAGTACCAAGG 
               
               
                 1808 
                 3815786 
                 MUM1 
                 TGTAGGCACACGAATCGACGGGAAC 
               
               
                 1809 
                 3815787 
                 MUM1 
                 GGGCAATCCTCAAGTAGTGTCGAAG 
               
               
                 1810 
                 3815787 
                 MUM1 
                 AACGGCTGTAGTTTTGGGCAATCCT 
               
               
                 1811 
                 3815787 
                 MUM1 
                 GCGGCCCCTGTACGAGTTTTATTGT 
               
               
                 1812 
                 3815787 
                 MUM1 
                 GGTCAACGGTACTTTCGGAGGGCAC 
               
               
                 1813 
                 3815790 
                 MUM1 
                 CTTTATAAACTGTTGGTCGAGGAAC 
               
               
                 1814 
                 3815790 
                 MUM1 
                 TCTTTATAAACTGTTGGTCGAGGAA 
               
               
                 1815 
                 3815790 
                 MUM1 
                 CGAGGAACTTCTCGCCTTGGCCGCG 
               
               
                 1816 
                 3815790 
                 MUM1 
                 AACTTCTCGCCTTGGCCGCGGCAGC 
               
               
                 1817 
                 3815791 
                 MUM1 
                 GACCGCCACCTTCGCGGAGGTCACA 
               
               
                 1818 
                 3815791 
                 MUM1 
                 GGACCGCCACCTTCGCGGAGGTCAC 
               
               
                 1819 
                 3815791 
                 MUM1 
                 CGGACCGCCACCTTCGCGGAGGTCA 
               
               
                 1820 
                 3815791 
                 MUM1 
                 CCGCCACCTTCGCGGAGGTCACACG 
               
               
                 1821 
                 3815792 
                 MUM1 
                 CCTCTTAGGTAAAGCAATTGTGACT 
               
               
                 1822 
                 3815792 
                 MUM1 
                 CGACACCAAAGAGGGCTGCACGTGT 
               
               
                 1823 
                 3815792 
                 MUM1 
                 CTTCGCATAAGTGACACGCGGTCAT 
               
               
                 1824 
                 3815792 
                 MUM1 
                 CTAGAGCATACACACCGTAGACTAT 
               
               
                 1825 
                 3815793 
                 MUM1 
                 GGCGGACGCTGTCAAGGTCTTAAAC 
               
               
                 1826 
                 3815793 
                 MUM1 
                 TCTTAAACGAGAGGGTGAGTCACAC 
               
               
                 1827 
                 3815793 
                 MUM1 
                 TCAGTGGCGCCAGAGTCAGTAGCCG 
               
               
                 1828 
                 3815793 
                 MUM1 
                 GCGTCGGAAACATACCTCCGGGTTG 
               
               
                 1829 
                 3815794 
                 MUM1 
                 AAACTCCCCGACACTGGGAGAAGGG 
               
               
                 1830 
                 3815794 
                 MUM1 
                 TACAGGTCCCAAGGTCCCGGGCCAC 
               
               
                 1831 
                 3815794 
                 MUM1 
                 ACGAAACTCCCCGACACTGGGAGAA 
               
               
                 1832 
                 3815794 
                 MUM1 
                 CGGAACGAAACTCCCCGACACTGGG 
               
               
                 1833 
                 3815795 
                 MUM1 
                 GTCGGCTGCTGTCGGTGGCCTCTCC 
               
               
                 1834 
                 3815795 
                 MUM1 
                 CTCCTCTAGCCTTGTGCTAACAGAG 
               
               
                 1835 
                 3815795 
                 MUM1 
                 TTCCTGAGAGCATAGCCCGGGAACC 
               
               
                 1836 
                 3815795 
                 MUM1 
                 CCTGCTTCGGCGTTCCTGAGAGCAT 
               
               
                 1837 
                 3815796 
                 MUM1 
                 GTCCTTTGGGCCGGCACCGGACCGT 
               
               
                 1838 
                 3815796 
                 MUM1 
                 ACTGGAAACAAAGTGAACGGAGACG 
               
               
                 1839 
                 3815796 
                 MUM1 
                 GAGCTGAGGCTCTCGTCCTTTGGGC 
               
               
                 1840 
                 3815796 
                 MUM1 
                 TGAACGGAGACGAGCTGAGGCTCTC 
               
               
                 1841 
                 3815797 
                 MUM1 
                 CGCCCCGAGTCGTCGCAACGTACAT 
               
               
                 1842 
                 3815797 
                 MUM1 
                 GCCGGTCATGGTGGCGGACTCCGCC 
               
               
                 1843 
                 3815797 
                 MUM1 
                 GGGACGACCAGCGACAAAGCCCCTG 
               
               
                 1844 
                 3815797 
                 MUM1 
                 CCTCGTCACCCCGTGTGGGGCCTCC 
               
               
                 1845 
                 3815798 
                 MUM1 
                 AGTACCTTTTAGGAGGCCTCGGCGG 
               
               
                 1846 
                 3815798 
                 MUM1 
                 GCCCGGAGCATGACGGAGTACCTTT 
               
               
                 1847 
                 3815798 
                 MUM1 
                 ACGGAGTACCTTTTAGGAGGCCTCG 
               
               
                 1848 
                 3815798 
                 MUM1 
                 AGCATGACGGAGTACCTTTTAGGAG 
               
               
                 1849 
                 3815799 
                 MUM1 
                 GGAACGGTTCAACAAGCTCCACCTT 
               
               
                 1850 
                 3815799 
                 MUM1 
                 CTCCACCTTAATTTGTGGAGGGTCT 
               
               
                 1851 
                 3815799 
                 MUM1 
                 CTCATCCTGTGTAACGGTACCAAAA 
               
               
                 1852 
                 3815799 
                 MUM1 
                 GACGACAACACTTCATGAAAATAGG 
               
               
                 1853 
                 3908359 
                 SULF2 
                 TAAGCGGAACCGGTTGGGAAGAAAC 
               
               
                 1854 
                 3908359 
                 SULF2 
                 GATCGTTGAGGGATCACCGCAAAAA 
               
               
                 1855 
                 3908359 
                 SULF2 
                 AAATTGTCTACTGCCTCTATTAGGG 
               
               
                 1856 
                 3908359 
                 SULF2 
                 GGGAAGAAACACATAGTCCATCAGA 
               
               
                 1857 
                 3908360 
                 SULF2 
                 CCTCATCTACCAACATCTAACTGAT 
               
               
                 1858 
                 3908360 
                 SULF2 
                 TATGATGGTCAGTTGTAGAAAAACC 
               
               
                 1859 
                 3908360 
                 SULF2 
                 AGATGGTATGAAGTTCCCTGATGTC 
               
               
                 1860 
                 3908360 
                 SULF2 
                 TAAGTTCTATGATGGTCAGTTGTAG 
               
               
                 1861 
                 3908361 
                 SULF2 
                 CGGTTACTGGTCGTCAACCATACTT 
               
               
                 1862 
                 3908361 
                 SULF2 
                 AGAAACAATACAGGGTCTTGACTAC 
               
               
                 1863 
                 3908361 
                 SULF2 
                 AGGGAGCGTCAACACCTGTAAAGAC 
               
               
                 1864 
                 3908361 
                 SULF2 
                 ACAGGTCTATGGTAAAGAGGATCAT 
               
               
                 1865 
                 3908362 
                 SULF2 
                 AAACCTAATATGGAGTGGTCGACGT 
               
               
                 1866 
                 3908362 
                 SULF2 
                 AGAGGGTTCCCGCTTTCAGTAACCT 
               
               
                 1867 
                 3908362 
                 SULF2 
                 TCGTCAGGACAAGATTTAGGAGAAT 
               
               
                 1868 
                 3908362 
                 SULF2 
                 ACCACAGTTATTTGCGAGACACCGG 
               
               
                 1869 
                 3908364 
                 SULF2 
                 TCAAAGTCGCAGCTTTCACCGGTCT 
               
               
                 1870 
                 3908364 
                 SULF2 
                 CAAAGTCGCAGCTTTCACCGGTCTT 
               
               
                 1871 
                 3908364 
                 SULF2 
                 CGTCAAAGTCGCAGCTTTCACCGGT 
               
               
                 1872 
                 3908364 
                 SULF2 
                 AAAGTCGCAGCTTTCACCGGTCTTT 
               
               
                 1873 
                 3908365 
                 SULF2 
                 GACGTGGACAATAGAACTCTTTGAC 
               
               
                 1874 
                 3908365 
                 SULF2 
                 TCAGAGTAGAGACACTCAGACGTGG 
               
               
                 1875 
                 3908365 
                 SULF2 
                 GTCCTAGTGGGTGGTTTCTATCCAC 
               
               
                 1876 
                 3908365 
                 SULF2 
                 CCACAGTGGATCCTCTGGAAGAAAC 
               
               
                 1877 
                 3908366 
                 SULF2 
                 TACCTCCTTCGATACTCGTTATGTC 
               
               
                 1878 
                 3908368 
                 SULF2 
                 GGACTTTGGTACAACTGATTTCTAC 
               
               
                 1879 
                 3908368 
                 SULF2 
                 ACGGGTCCTTTGTGTGCCTTAAGGC 
               
               
                 1880 
                 3908368 
                 SULF2 
                 GCCTTAAGGCAGAGTAAAGTAACAG 
               
               
                 1881 
                 3908368 
                 SULF2 
                 CTCTCTCCTTGTGGACGTGGTTGAC 
               
               
                 1882 
                 3908369 
                 SULF2 
                 CTACAGGAGTTGGTCGATGTGCATG 
               
               
                 1883 
                 3908369 
                 SULF2 
                 GTTGGTCGATGTGCATGTCGAGTAC 
               
               
                 1884 
                 3908369 
                 SULF2 
                 GGGGCCTGAGCTTTGTACCTGGACC 
               
               
                 1885 
                 3908369 
                 SULF2 
                 GGTCGATGTGCATGTCGAGTACCTC 
               
               
                 1886 
                 3908371 
                 SULF2 
                 ATCTCATGAAACTAGAGTTGTGTCT 
               
               
                 1887 
                 3908371 
                 SULF2 
                 GGTCGCGGTTGTTATTGTGCATGAC 
               
               
                 1888 
                 3908371 
                 SULF2 
                 ACGTACTCCTGGTAGTTACTCTGAG 
               
               
                 1889 
                 3908371 
                 SULF2 
                 CACTTAAACGTTGACCGAAGGATCT 
               
               
                 1890 
                 3908373 
                 SULF2 
                 GTCCGGAGTGCACGAAGTGGGTGCT 
               
               
                 1891 
                 3908373 
                 SULF2 
                 AGTGCACGAAGTGGGTGCTGTTGGT 
               
               
                 1892 
                 3908373 
                 SULF2 
                 ACCGTCTGCCGCGGAAAGACCTGTG 
               
               
                 1893 
                 3908373 
                 SULF2 
                 TGCTGTTGGTCGTGACCGTCTGCCG 
               
               
                 1894 
                 3908374 
                 SULF2 
                 AGTTCGCGGACGTCTTGTTGCTGTG 
               
               
                 1895 
                 3908374 
                 SULF2 
                 ACGAGTTCGCGGACGTCTTGTTGCT 
               
               
                 1896 
                 3908374 
                 SULF2 
                 GACGAGTTCGCGGACGTCTTGTTGC 
               
               
                 1897 
                 3908374 
                 SULF2 
                 GGACGTCTTGTTGCTGTGCACGTCG 
               
               
                 1898 
                 3908375 
                 SULF2 
                 ACCGACAACGCCCTCGTCTTCGCGT 
               
               
                 1899 
                 3908375 
                 SULF2 
                 ACAACGCCCTCGTCTTCGCGTTCTT 
               
               
                 1900 
                 3908375 
                 SULF2 
                 GACAACGCCCTCGTCTTCGCGTTCT 
               
               
                 1901 
                 3908375 
                 SULF2 
                 CCACACCGACAACGCCCTCGTCTTC 
               
               
                 1902 
                 3908377 
                 SULF2 
                 TCTCCGAGGTCAGACGTAGGAAAGT 
               
               
                 1903 
                 3908377 
                 SULF2 
                 GTGTTTCCGGCGGAGTTCGTGTCTC 
               
               
                 1904 
                 3908377 
                 SULF2 
                 CTCCGAGGTCAGACGTAGGAAAGTC 
               
               
                 1905 
                 3908377 
                 SULF2 
                 TGTTTCCGGCGGAGTTCGTGTCTCC 
               
               
                 1906 
                 3908381 
                 SULF2 
                 CTTTTTCGCCGGTCTTCTTACACTG 
               
               
                 1907 
                 3908381 
                 SULF2 
                 TCGCCGGTCTTCTTACACTGACAGT 
               
               
                 1908 
                 3908381 
                 SULF2 
                 TTCGCCGGTCTTCTTACACTGACAG 
               
               
                 1909 
                 3908381 
                 SULF2 
                 CCGGTCTTCTTACACTGACAGTGTT 
               
               
                 1910 
                 3908382 
                 SULF2 
                 GTCTTGTTTTAATTCTTGGACTCCC 
               
               
                 1911 
                 3908382 
                 SULF2 
                 TAATTCTTGGACTCCCTTCAGGCTC 
               
               
                 1912 
                 3908382 
                 SULF2 
                 GACGTCTTGTTTTAATTCTTGGACT 
               
               
                 1913 
                 3908382 
                 SULF2 
                 GGGACGTCTTGTTTTAATTCTTGGA 
               
               
                 1914 
                 3908388 
                 SULF2 
                 GACCTGGACATGTTCAGGGACGTCC 
               
               
                 1915 
                 3908388 
                 SULF2 
                 GGATCTCTTGCTGTGTCAGGTCACA 
               
               
                 1916 
                 3908388 
                 SULF2 
                 GGTCACACTGGACCTGGACATGTTC 
               
               
                 1917 
                 3908388 
                 SULF2 
                 AGGATCTCTTGCTGTGTCAGGTCAC 
               
               
                 1918 
                 3908390 
                 SULF2 
                 GTCAGCGAGGTAGGCGAGTCACCGG 
               
               
                 1919 
                 3908390 
                 SULF2 
                 TGTTCCGGTCGATACAGGCGTCAGC 
               
               
                 1920 
                 3908390 
                 SULF2 
                 GCTTTGGAGTGGTTCGCCGTGACCG 
               
               
                 1921 
                 3908390 
                 SULF2 
                 TGCCGTCCCACATGGTGCATCCGGA 
               
               
                 1922 
                 3908391 
                 SULF2 
                 GCCCCTGATGTTCGAGTCGGACCGG 
               
               
                 1923 
                 3908391 
                 SULF2 
                 GACGTGGACACTGTCGCCCCTGATG 
               
               
                 1924 
                 3908391 
                 SULF2 
                 GTTGGAGCACGGGTTCATGATGCCC 
               
               
                 1925 
                 3908391 
                 SULF2 
                 TCGACTTCGACGTATTCACGTTCCC 
               
               
                 1926 
                 3908393 
                 SULF2 
                 GACTCATGGTCTGCCGCACACTCGT 
               
               
                 1927 
                 3908393 
                 SULF2 
                 TGGACACAGTCGCACGACTCATGGT 
               
               
                 1928 
                 3908393 
                 SULF2 
                 TGGTCGCACACTTCCTGGACACAGT 
               
               
                 1929 
                 3908393 
                 SULF2 
                 CTGCGGGTCCTCCTCTTGAAAGACG 
               
               
                 1930 
                 3908394 
                 SULF2 
                 TCCCAGACCGCCCTGAGGAAGAACC 
               
               
                 1931 
                 3908394 
                 SULF2 
                 TTCTACTCCCAGACCGCCCTGAGGA 
               
               
                 1932 
                 3908394 
                 SULF2 
                 TACTCCCAGACCGCCCTGAGGAAGA 
               
               
                 1933 
                 3908394 
                 SULF2 
                 ACTCCCAGACCGCCCTGAGGAAGAA 
               
               
                 1934 
                 3908395 
                 SULF2 
                 CCTGCCCTTTAGGTAGGAGTTCGAC 
               
               
                 1935 
                 3908395 
                 SULF2 
                 TGTAGCAGGAGTTGTAACTGGACCG 
               
               
                 1936 
                 3908395 
                 SULF2 
                 ATGGACGCCTATACCTGCCCTTTAG 
               
               
                 1937 
                 3908395 
                 SULF2 
                 CTGTAACGTCCGGACCTGTATGGAC 
               
               
                 1938 
                 3908397 
                 SULF2 
                 ACTCAAACTGTAGTCCCAGGGCAAG 
               
               
                 1939 
                 3908397 
                 SULF2 
                 TGTGCATGTAGCATATGTGGCGGCT 
               
               
                 1940 
                 3908397 
                 SULF2 
                 GTGCCAATGGTGTAGCCGGTCAAAC 
               
               
                 1941 
                 3908397 
                 SULF2 
                 GCCCGCTCGACCTGTTGTGCATGTA 
               
               
                 1942 
                 3908400 
                 SULF2 
                 ACAGCCACCTGCTGAGGTACCTCTG 
               
               
                 1943 
                 3908400 
                 SULF2 
                 GGTTGTACGAGGTCGCCTTCGCGAA 
               
               
                 1944 
                 3908400 
                 SULF2 
                 CTTCGCGAACGTCTGGGAGTACAGC 
               
               
                 1945 
                 3908400 
                 SULF2 
                 TTGTGACCTAGTACGCGATGTGCCC 
               
               
                 1946 
                 3908401 
                 SULF2 
                 TGCAGGTTCTTCTACATGGGCGTGT 
               
               
                 1947 
                 3908401 
                 SULF2 
                 TCTGGAGTAGTGGTTACTGTCGCAC 
               
               
                 1948 
                 3908401 
                 SULF2 
                 AGGAGTACCAGTAGTCGGTACGTCG 
               
               
                 1949 
                 3908401 
                 SULF2 
                 ACTGTCGCACTCGAAGAAGGCGTGC 
               
               
                 1950 
                 3908407 
                 SULF2 
                 ACCTGGATTGGTCCGGGAGGTAAAC 
               
               
                 1951 
                 3908407 
                 SULF2 
                 GTGACGTGAGACTACTTAGACCACT 
               
               
                 1952 
                 3908407 
                 SULF2 
                 CACACTGTCTGAAGGGTGACTACGT 
               
               
                 1953 
                 3908407 
                 SULF2 
                 CCGAAGGACTGATTTGAGGTCTCAC 
               
               
                 1954 
                 3908417 
                 SULF2 
                 CCGTGTCGTGCTCTCGGCGTGGAAA 
               
               
                 1955 
                 3908417 
                 SULF2 
                 CGCGTGAAGTAGTTGCGGAAGCACT 
               
               
                 1956 
                 3908417 
                 SULF2 
                 CCACTACTTGTTCTGGGCCGCGTAG 
               
               
                 1957 
                 3908417 
                 SULF2 
                 GCGTGGAAACGGCACATGGAGTTAT 
               
               
                 1958 
                 3908426 
                 SULF2 
                 TTCGAGCCGGAAGGACAGCGTGGTG 
               
               
                 1959 
                 3908426 
                 SULF2 
                 AGCGTGGTGGCGGACTTTCCGTCCA 
               
               
                 1960 
                 3908426 
                 SULF2 
                 AACGACAGGCGTTGACACAAGAGGG 
               
               
                 1961 
                 3908426 
                 SULF2 
                 GTCCAAAGTCTCCCTGGCGTCCTTG 
               
               
                 1962 
                 3908435 
                 SULF2 
                 CGCCTCAGGGGACGCGGGTCGCCGG 
               
               
                 1963 
                 3908435 
                 SULF2 
                 CAGGGGACGCGGGTCGCCGGGCCGG 
               
               
                 1964 
                 3908435 
                 SULF2 
                 GGGGACGCGGGTCGCCGGGCCGGCC 
               
               
                 1965 
                 3908435 
                 SULF2 
                 CTCAGGGGACGCGGGTCGCCGGGCC 
               
               
                 1966 
                 3908436 
                 SULF2 
                 GCCTCCGTAGCCCTCCAGCTCTCGG 
               
               
                 1967 
                 3908436 
                 SULF2 
                 GCGCCGGTCGGCTCAGGCCTCCGTA 
               
               
                 1968 
                 3908436 
                 SULF2 
                 CAAGTGACGGGGCAGGCCTCGACCT 
               
               
                 1969 
                 3908436 
                 SULF2 
                 ACACGCAGACACACAGGGCCGCTCC 
               
               
                 1970 
                 3908437 
                 SULF2 
                 TGTGCACGTGTGTTCCGAGACCGAG 
               
               
                 1971 
                 3908437 
                 SULF2 
                 CTACCGGGAGGACTTAAATAGTGCT 
               
               
                 1972 
                 3908437 
                 SULF2 
                 CTAAGTGCAGCAAAGGTCGGTTCAC 
               
               
                 1973 
                 3908437 
                 SULF2 
                 CCGCGGCCGGAGAGGTTACCGTTTA 
               
               
                 1974 
                 3978625 
                 APEX2 
                 CGACCCTCCACAAGGTCGGGAAATT 
               
               
                 1975 
                 3978625 
                 APEX2 
                 CCGCGCCCGACCCTCCACAAGGTCG 
               
               
                 1976 
                 3978625 
                 APEX2 
                 GACCCTCCACAAGGTCGGGAAATTC 
               
               
                 1977 
                 3978625 
                 APEX2 
                 CAACCGCGCCCGACCCTCCACAAGG 
               
               
                 1978 
                 3978626 
                 APEX2 
                 CGACCTACGCCTATAGCAGACAGAG 
               
               
                 1979 
                 3978626 
                 APEX2 
                 TCGACCTTGTAGTTACCCTAAGCCT 
               
               
                 1980 
                 3978626 
                 APEX2 
                 CCGCGTAAAACCTGCTCGACCTACG 
               
               
                 1981 
                 3978626 
                 APEX2 
                 TAGTCCTTGGGTCGTTGACACGGCG 
               
               
                 1982 
                 3978629 
                 APEX2 
                 GACATTCCTGTTACGATGGGGTCAC 
               
               
                 1983 
                 3978629 
                 APEX2 
                 TCCTTGAGGCCCGAGACCTATCACT 
               
               
                 1984 
                 3978629 
                 APEX2 
                 ATACCTTTGTACCTACTCAAATGGG 
               
               
                 1985 
                 3978629 
                 APEX2 
                 CCGGACTCACCGGACAAACGGTGGG 
               
               
                 1986 
                 3978630 
                 APEX2 
                 CGCGAAGATAGCAAACGACGTTTAG 
               
               
                 1987 
                 3978630 
                 APEX2 
                 ATTCCTCTTCTGGAACTGGGATTAG 
               
               
                 1988 
                 3978630 
                 APEX2 
                 GGACTCGCCGATCAGAAATTCTACG 
               
               
                 1989 
                 3978630 
                 APEX2 
                 CGTTTAGGCTCGTCTTCGGGAGGAC 
               
               
                 1990 
                 3978634 
                 APEX2 
                 ACCTACCTGTCGAACGAGTCATTGA 
               
               
                 1991 
                 3978634 
                 APEX2 
                 ACGGAGAGTACATCCCGGGAAGTAG 
               
               
                 1992 
                 3978634 
                 APEX2 
                 TATCGATGGCGACGAAGGTTGGTTT 
               
               
                 1993 
                 3978634 
                 APEX2 
                 ACGAGTCATTGAACCCCACGGTCAG 
               
               
                 1994 
                 3978635 
                 APEX2 
                 GAGACACGGACGTTTTGTCACGGGT 
               
               
                 1995 
                 3978635 
                 APEX2 
                 CCCCTGTCCTGGGACCAGTATCTGT 
               
               
                 1996 
                 3978635 
                 APEX2 
                 GTAGAGTTGATACCGAGGGCCGAAC 
               
               
                 1997 
                 3978635 
                 APEX2 
                 TCCGTGGGTCGAGTTCTAGGAAGCG 
               
               
                 1998 
                 3978636 
                 APEX2 
                 CTCGACGGATCGGATGGTGACTACT 
               
               
                 1999 
                 3978636 
                 APEX2 
                 AGTTTGGGCCCATGTCTGTACGGTT 
               
               
                 2000 
                 3978636 
                 APEX2 
                 GTTTCAGGACACAACCTCGTCAGCT 
               
               
                 2001 
                 3978636 
                 APEX2 
                 CGGGTCAGTCCAACCGAGATCGTCT 
               
               
                 2002 
                 3978637 
                 APEX2 
                 ACTCTTCCTCAATGCCTGGAGTAAG 
               
               
                 2003 
                 3978637 
                 APEX2 
                 ACTTCTTCGGTCCTGGGTTGAACCC 
               
               
                 2004 
                 3978637 
                 APEX2 
                 CTCGGTACACACTACGCATGACACT 
               
               
                 2005 
                 3978637 
                 APEX2 
                 GAACCCGGCGGCGAAGATGTACACA 
               
               
                 2006 
                 3978638 
                 APEX2 
                 AGGAACAACCACTCGAAGAACACGG 
               
               
                 2007 
                 3978638 
                 APEX2 
                 AACACGGAATTAGGACACTGGGTCG 
               
               
                 2008 
                 3978638 
                 APEX2 
                 GGCTTCATGTGCCTGTGATCGACGG 
               
               
                 2009 
                 3978638 
                 APEX2 
                 GGACGTGTACTAGACTCCGGTCGAG 
               
               
                 2010 
                 3978639 
                 APEX2 
                 ATGAGGTATTTCAACTCAGTCTCTT 
               
               
                 2011 
                 3978639 
                 APEX2 
                 ACCTCCATGAGGTATTTCAACTCAG 
               
               
                 2012 
                 3978639 
                 APEX2 
                 ACCTGTAACACCTCCATGAGGTATT 
               
               
                 2013 
                 3978639 
                 APEX2 
                 GTGAAACCTGTAACACCTCCATGAG 
               
               
                 2014 
                 3978641 
                 APEX2 
                 GACACTGGACCTTTCACCCTCGTAA 
               
               
                 2015 
                 3978641 
                 APEX2 
                 AACTTTTACCCTGACCATCTGGTCC 
               
               
                 2016 
                 3978641 
                 APEX2 
                 ACCCTCGTAACGAAACTTGTGTCAC 
               
               
                 2017 
                 3978641 
                 APEX2 
                 TGTGTCACGAACGAGATCGGTTCGG 
               
               
                 2018 
                 3978642 
                 APEX2 
                 GTGACACATCAAAAACCCGTAAAGG 
               
               
                 2019 
                 3978642 
                 APEX2 
                 GATCGAGAAACGTTGAGTGACACAT 
               
               
                 2020 
                 3978642 
                 APEX2 
                 GTCACTTCGCAGTTAGGGACCTAAA 
               
               
                 2021 
                 3978642 
                 APEX2 
                 CGTGAACAGACAAGGGACAGGTTAT 
               
            
           
         
       
     
     Probes/Primers 
     The present invention provides for a probe set for predicting response of a subject to post-operative radiation therapy for prostate cancer comprising a plurality of probes, wherein (i) the probes in the set are capable of detecting an expression level of at least one target selected from Table 1 or Table 2; and (ii) the expression level determines whether or not the subject will benefit from post-operative radiation therapy with at least about 40% specificity. 
     The probe set may comprise one or more polynucleotide probes. Individual polynucleotide probes comprise a nucleotide sequence derived from the nucleotide sequence of the target sequences or complementary sequences thereof. The nucleotide sequence of the polynucleotide probe is designed such that it corresponds to, or is complementary to the target sequences. The polynucleotide probe can specifically hybridize under either stringent or lowered stringency hybridization conditions to a region of the target sequences, to the complement thereof, or to a nucleic acid sequence (such as a cDNA) derived therefrom. 
     The selection of the polynucleotide probe sequences and determination of their uniqueness may be carried out in silico using techniques known in the art, for example, based on a BLASTN search of the polynucleotide sequence in question against gene sequence databases, such as the Human Genome Sequence, UniGene, dbEST or the non-redundant database at NCBI. In one embodiment of the invention, the polynucleotide probe is complementary to a region of a target mRNA derived from a target sequence in the probe set. Computer programs can also be employed to select probe sequences that may not cross hybridize or may not hybridize non-specifically. 
     In some instances, microarray hybridization of RNA, extracted from prostate cancer tissue samples and amplified, may yield a dataset that is then summarized and normalized by the fRMA technique. After removal (or filtration) of cross-hybridizing PSRs, and PSRs containing less than , the remaining PSRs can be used in further analysis. Following fRMA and filtration, the data can be decomposed into its principal components and an analysis of variance model is used to determine the extent to which a batch effect remains present in the first 10 principal components. 
     These remaining PSRs can then be subjected to filtration by a T-test between CR (clinical recurrence) and non-CR samples. Using a p-value cut-off of 0.01, the remaining features (e.g., PSRs) can be further refined. Feature selection can be performed by regularized logistic regression using the elastic-net penalty. The regularized regression may be bootstrapped over 1000 times using all training data; with each iteration of bootstrapping, features that have non-zero co-efficient following 3-fold cross validation can be tabulated. In some instances, features that were selected in at least 25% of the total runs were used for model building. 
     The polynucleotide probes of the present invention may range in length from about 15 nucleotides to the full length of the coding target or non-coding target. In one embodiment of the invention, the polynucleotide probes are at least about 15 nucleotides in length. In another embodiment, the polynucleotide probes are at least about 20 nucleotides in length. In a further embodiment, the polynucleotide probes are at least about 25 nucleotides in length. In another embodiment, the polynucleotide probes are between about 15 nucleotides and about 500 nucleotides in length. In other embodiments, the polynucleotide probes are between about 15 nucleotides and about 450 nucleotides, about 15 nucleotides and about 400 nucleotides, about 15 nucleotides and about 350 nucleotides, about 15 nucleotides and about 300 nucleotides, about 15 nucleotides and about 250 nucleotides, about 15 nucleotides and about 200 nucleotides in length. In some embodiments, the probes are at least 15 nucleotides in length. In some embodiments, the probes are at least 15 nucleotides in length. In some embodiments, the probes are at least 20 nucleotides, at least 25 nucleotides, at least 50 nucleotides, at least 75 nucleotides, at least 100 nucleotides, at least 125 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 225 nucleotides, at least 250 nucleotides, at least 275 nucleotides, at least 300 nucleotides, at least 325 nucleotides, at least 350 nucleotides, at least 375 nucleotides in length. 
     The polynucleotide probes of a probe set can comprise RNA, DNA, RNA or DNA mimetics, or combinations thereof, and can be single-stranded or double-stranded. Thus the polynucleotide probes can be composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as polynucleotide probes having non-naturally-occurring portions which function similarly. Such modified or substituted polynucleotide probes may provide desirable properties such as, for example, enhanced affinity for a target gene and increased stability. The probe set may comprise a coding target and/or a non-coding target. Preferably, the probe set comprises a combination of a coding target and non-coding target. 
     In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 5 coding targets and/or non-coding targets selected from Table 1 or Table 2. Alternatively, the probe set comprise a plurality of target sequences that hybridize to at least about 10 coding targets and/or non-coding targets selected from Table 1 or Table 2. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 15 coding targets and/or non-coding targets selected from Table 1 or Table 2. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 20 coding targets and/or non-coding targets selected from Table 1 or Table 2. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 24 coding targets and/or non-coding targets selected from Table 1 or Table 2. 
     The system of the present invention further provides for primers and primer pairs capable of amplifying target sequences defined by the probe set, or fragments or subsequences or complements thereof. The nucleotide sequences of the probe set may be provided in computer-readable media for in silico applications and as a basis for the design of appropriate primers for amplification of one or more target sequences of the probe set. 
     Primers based on the nucleotide sequences of target sequences can be designed for use in amplification of the target sequences. For use in amplification reactions such as PCR, a pair of primers can be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers may hybridize to specific sequences of the probe set under stringent conditions, particularly under conditions of high stringency, as known in the art. The pairs of primers are usually chosen so as to generate an amplification product of at least about 50 nucleotides, more usually at least about 100 nucleotides. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. These primers may be used in standard quantitative or qualitative PCR-based assays to assess transcript expression levels of RNAs defined by the probe set. Alternatively, these primers may be used in combination with probes, such as molecular beacons in amplifications using real-time PCR. 
     In one embodiment, the primers or primer pairs, when used in an amplification reaction, specifically amplify at least a portion of a nucleic acid sequence of a target selected from Table 2 (or subgroups thereof as set forth herein), an RNA form thereof, or a complement to either thereof. 
     A label can optionally be attached to or incorporated into a probe or primer polynucleotide to allow detection and/or quantitation of a target polynucleotide representing the target sequence of interest. The target polynucleotide may be the expressed target sequence RNA itself, a cDNA copy thereof, or an amplification product derived therefrom, and may be the positive or negative strand, so long as it can be specifically detected in the assay being used. Similarly, an antibody may be labeled. 
     In certain multiplex formats, labels used for detecting different targets may be distinguishable. The label can be attached directly (e.g., via covalent linkage) or indirectly, e.g., via a bridging molecule or series of molecules (e.g., a molecule or complex that can bind to an assay component, or via members of a binding pair that can be incorporated into assay components, e.g. biotin-avidin or streptavidin). Many labels are commercially available in activated forms which can readily be used for such conjugation (for example through amine acylation), or labels may be attached through known or determinable conjugation schemes, many of which are known in the art. 
     Labels useful in the invention described herein include any substance which can be detected when bound to or incorporated into the biomolecule of interest. Any effective detection method can be used, including optical, spectroscopic, electrical, piezoelectrical, magnetic, Raman scattering, surface plasmon resonance, colorimetric, calorimetric, etc. A label is typically selected from a chromophore, a lumiphore, a fluorophore, one member of a quenching system, a chromogen, a hapten, an antigen, a magnetic particle, a material exhibiting nonlinear optics, a semiconductor nanocrystal, a metal nanoparticle, an enzyme, an antibody or binding portion or equivalent thereof, an aptamer, and one member of a binding pair, and combinations thereof. Quenching schemes may be used, wherein a quencher and a fluorophore as members of a quenching pair may be used on a probe, such that a change in optical parameters occurs upon binding to the target introduce or quench the signal from the fluorophore. One example of such a system is a molecular beacon. Suitable quencher/fluorophore systems are known in the art. The label may be bound through a variety of intermediate linkages. For example, a polynucleotide may comprise a biotin-binding species, and an optically detectable label may be conjugated to biotin and then bound to the labeled polynucleotide. Similarly, a polynucleotide sensor may comprise an immunological species such as an antibody or fragment, and a secondary antibody containing an optically detectable label may be added. 
     Chromophores useful in the methods described herein include any substance which can absorb energy and emit light. For multiplexed assays, a plurality of different signaling chromophores can be used with detectably different emission spectra. The chromophore can be a lumophore or a fluorophore. Typical fluorophores include fluorescent dyes, semiconductor nanocrystals, lanthanide chelates, polynucleotide-specific dyes and green fluorescent protein. 
     In some embodiments, polynucleotides of the invention comprise at least 20 consecutive bases of the nucleic acid sequence of a target selected from Table 1 or Table 2 or a complement thereto. The polynucleotides may comprise at least 21, 22, 23, 24, 25, 27, 30, 32, 35, 40, 45, 50, or more consecutive bases of the nucleic acids sequence of a target selected from Table 1 or Table 2, as applicable. 
     The polynucleotides may be provided in a variety of formats, including as solids, in solution, or in an array. The polynucleotides may optionally comprise one or more labels, which may be chemically and/or enzymatically incorporated into the polynucleotide. 
     In some embodiments, one or more polynucleotides provided herein can be provided on a substrate. The substrate can comprise a wide range of material, either biological, nonbiological, organic, inorganic, or a combination of any of these. For example, the substrate may be a polymerized Langmuir Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, SiO 2 , SiN 4 , modified silicon, or any one of a wide variety of gels or polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, cross-linked polystyrene, polyacrylic, polylactic acid, polyglycolic acid, poly(lactide coglycolide), polyanhydrides, poly(methyl methacrylate), poly(ethylene-co-vinyl acetate), polysiloxanes, polymeric silica, latexes, dextran polymers, epoxies, polycarbonates, or combinations thereof. Conducting polymers and photoconductive materials can be used. 
     The substrate can take the form of an array, a photodiode, an optoelectronic sensor such as an optoelectronic semiconductor chip or optoelectronic thin-film semiconductor, or a biochip. The location(s) of probe(s) on the substrate can be addressable; this can be done in highly dense formats, and the location(s) can be microaddressable or nanoaddressable. 
     Diagnostic Samples 
     A biological sample containing prostate cancer cells is collected from a subject in need of treatment for prostate cancer to evaluate whether a patient will benefit from radiation therapy. Diagnostic samples for use with the systems and in the methods of the present invention comprise nucleic acids suitable for providing RNAs expression information. In principle, the biological sample from which the expressed RNA is obtained and analyzed for target sequence expression can be any material suspected of comprising cancerous tissue or cells. The diagnostic sample can be a biological sample used directly in a method of the invention. Alternatively, the diagnostic sample can be a sample prepared from a biological sample. 
     In one embodiment, the sample or portion of the sample comprising or suspected of comprising cancerous tissue or cells can be any source of biological material, including cells, tissue or fluid, including bodily fluids. Non-limiting examples of the source of the sample include an aspirate, a needle biopsy, a cytology pellet, a bulk tissue preparation or a section thereof obtained for example by surgery or autopsy, lymph fluid, blood, plasma, serum, tumors, and organs. In some embodiments, the sample is from urine. Alternatively, the sample is from blood, plasma or serum. In some embodiments, the sample is from saliva. 
     The samples may be archival samples, having a known and documented medical outcome, or may be samples from current patients whose ultimate medical outcome is not yet known. 
     In some embodiments, the sample may be dissected prior to molecular analysis. The sample may be prepared via macrodissection of a bulk tumor specimen or portion thereof, or may be treated via microdissection, for example via Laser Capture Microdissection (LCM). 
     The sample may initially be provided in a variety of states, as fresh tissue, fresh frozen tissue, fine needle aspirates, and may be fixed or unfixed. Frequently, medical laboratories routinely prepare medical samples in a fixed state, which facilitates tissue storage. A variety of fixatives can be used to fix tissue to stabilize the morphology of cells, and may be used alone or in combination with other agents. Exemplary fixatives include crosslinking agents, alcohols, acetone, Bouin’s solution, Zenker solution, Hely solution, osmic acid solution and Carnoy solution. 
     Crosslinking fixatives can comprise any agent suitable for forming two or more covalent bonds, for example an aldehyde. Sources of aldehydes typically used for fixation include formaldehyde, paraformaldehyde, glutaraldehyde or formalin. Preferably, the crosslinking agent comprises formaldehyde, which may be included in its native form or in the form of paraformaldehyde or formalin. One of skill in the art would appreciate that for samples in which crosslinking fixatives have been used special preparatory steps may be necessary including for example heating steps and proteinase-k digestion; see methods. 
     One or more alcohols may be used to fix tissue, alone or in combination with other fixatives. Exemplary alcohols used for fixation include methanol, ethanol and isopropanol. 
     Formalin fixation is frequently used in medical laboratories. Formalin comprises both an alcohol, typically methanol, and formaldehyde, both of which can act to fix a biological sample. 
     Whether fixed or unfixed, the biological sample may optionally be embedded in an embedding medium. Exemplary embedding media used in histology including paraffin, Tissue-Tek® V.I.P.TM, Paramat, Paramat Extra, Paraplast, Paraplast X-tra, Paraplast Plus, Peel Away Paraffin Embedding Wax, Polyester Wax, Carbowax Polyethylene Glycol, PolyfinTM, Tissue Freezing Medium TFMFM, Cryo-GefTM, and OCT Compound (Electron Microscopy Sciences, Hatfield, PA). Prior to molecular analysis, the embedding material may be removed via any suitable techniques, as known in the art. For example, where the sample is embedded in wax, the embedding material may be removed by extraction with organic solvent(s), for example xylenes. Kits are commercially available for removing embedding media from tissues. Samples or sections thereof may be subjected to further processing steps as needed, for example serial hydration or dehydration steps. 
     In some embodiments, the sample is a fixed, wax-embedded biological sample. Frequently, samples from medical laboratories are provided as fixed, wax-embedded samples, most commonly as formalin-fixed, paraffin embedded (FFPE) tissues. 
     Whatever the source of the biological sample, the target polynucleotide that is ultimately assayed can be prepared synthetically (in the case of control sequences), but typically is purified from the biological source and subjected to one or more preparative steps. The RNA may be purified to remove or diminish one or more undesired components from the biological sample or to concentrate it. Conversely, where the RNA is too concentrated for the particular assay, it may be diluted. 
     RNA Extraction 
     RNA can be extracted and purified from biological samples using any suitable technique. A number of techniques are known in the art, and several are commercially available (e.g., FormaPure nucleic acid extraction kit, Agencourt Biosciences, Beverly MA, High Pure FFPE RNA Micro Kit, Roche Applied Science, Indianapolis, IN). RNA can be extracted from frozen tissue sections using TRIzol (Invitrogen, Carlsbad, CA) and purified using RNeasy Protect kit (Qiagen, Valencia, CA). RNA can be further purified using DNAse I treatment (Ambion, Austin, TX) to eliminate any contaminating DNA. RNA concentrations can be made using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Rockland, DE). RNA can be further purified to eliminate contaminants that interfere with cDNA synthesis by cold sodium acetate precipitation. RNA integrity can be evaluated by running electropherograms, and RNA integrity number (RIN, a correlative measure that indicates intactness of mRNA) can be determined using the RNA 6000 PicoAssay for the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). 
     Kits 
     Kits for performing the desired method(s) are also provided, and comprise a container or housing for holding the components of the kit, one or more vessels containing one or more nucleic acid(s), and optionally one or more vessels containing one or more reagents. The reagents include those described herein, and those reagents useful for performing the methods described, including amplification reagents, and may include one or more probes, primers or primer pairs, enzymes (including polymerases and ligases), intercalating dyes, labeled probes, and labels that can be incorporated into amplification products. 
     In some embodiments, the kit comprises primers or primer pairs specific for those subsets and combinations of target sequences described herein. The primers or pairs of primers suitable for selectively amplifying the target sequences. The kit may comprise at least two, three, four or five primers or pairs of primers suitable for selectively amplifying one or more targets. The kit may comprise at least 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, or more primers or pairs of primers suitable for selectively amplifying one or more targets. 
     In some embodiments, the primers or primer pairs of the kit, when used in an amplification reaction, specifically amplify a non-coding target, coding target, exonic, or non-exonic target described herein, a nucleic acid sequence corresponding to a target selected from Table 1 or Table 2, an RNA form thereof, or a complement to either thereof. The kit may include a plurality of such primers or primer pairs which can specifically amplify a corresponding plurality of different amplify a non-coding target, coding target, exonic, or non-exonic transcript described herein, a nucleic acid sequence corresponding to a target selected from Table 1 or Table 2, RNA forms thereof, or complements thereto. At least two, three, four or five primers or pairs of primers suitable for selectively amplifying the one or more targets can be provided in kit form. In some embodiments, the kit comprises from five to fifty primers or pairs of primers suitable for amplifying the one or more targets. 
     The reagents may independently be in liquid or solid form. The reagents may be provided in mixtures. Control samples and/or nucleic acids may optionally be provided in the kit. Control samples may include tissue and/or nucleic acids obtained from or representative of tumor samples from patients showing no evidence of disease, as well as tissue and/or nucleic acids obtained from or representative of tumor samples from patients that develop systemic cancer. 
     The nucleic acids may be provided in an array format, and thus an array or microarray may be included in the kit. The kit optionally may be certified by a government agency for use in prognosing the disease outcome of cancer patients and/or for designating a treatment modality. 
     Instructions for using the kit to perform one or more methods of the invention can be provided with the container, and can be provided in any fixed medium. The instructions may be located inside or outside the container or housing, and/or may be printed on the interior or exterior of any surface thereof. A kit may be in multiplex form for concurrently detecting and/or quantitating one or more different target polynucleotides representing the expressed target sequences. 
     Amplification and Hybridization 
     Following sample collection and nucleic acid extraction, the nucleic acid portion of the sample comprising RNA that is or can be used to prepare the target polynucleotide(s) of interest can be subjected to one or more preparative reactions. These preparative reactions can include in vitro transcription (IVT), labeling, fragmentation, amplification and other reactions. mRNA can first be treated with reverse transcriptase and a primer to create cDNA prior to detection, quantitation and/or amplification; this can be done in vitro with purified mRNA or in situ, e.g., in cells or tissues affixed to a slide. 
     By “amplification” is meant any process of producing at least one copy of a nucleic acid, in this case an expressed RNA, and in many cases produces multiple copies. An amplification product can be RNA or DNA, and may include a complementary strand to the expressed target sequence. DNA amplification products can be produced initially through reverse translation and then optionally from further amplification reactions. The amplification product may include all or a portion of a target sequence, and may optionally be labeled. A variety of amplification methods are suitable for use, including polymerase-based methods and ligation-based methods. Exemplary amplification techniques include the polymerase chain reaction method (PCR), the lipase chain reaction (LCR), ribozyme-based methods, self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), the use of Q Beta replicase, reverse transcription, nick translation, and the like. 
     Asymmetric amplification reactions may be used to preferentially amplify one strand representing the target sequence that is used for detection as the target polynucleotide. In some cases, the presence and/or amount of the amplification product itself may be used to determine the expression level of a given target sequence. In other instances, the amplification product may be used to hybridize to an array or other substrate comprising sensor polynucleotides which are used to detect and/or quantitate target sequence expression. 
     The first cycle of amplification in polymerase-based methods typically forms a primer extension product complementary to the template strand. If the template is single-stranded RNA, a polymerase with reverse transcriptase activity is used in the first amplification to reverse transcribe the RNA to DNA, and additional amplification cycles can be performed to copy the primer extension products. The primers for a PCR must, of course, be designed to hybridize to regions in their corresponding template that can produce an amplifiable segment; thus, each primer must hybridize so that its 3′ nucleotide is paired to a nucleotide in its complementary template strand that is located 3′ from the 3′ nucleotide of the primer used to replicate that complementary template strand in the PCR. 
     The target polynucleotide can be amplified by contacting one or more strands of the target polynucleotide with a primer and a polymerase having suitable activity to extend the primer and copy the target polynucleotide to produce a full-length complementary polynucleotide or a smaller portion thereof. Any enzyme having a polymerase activity that can copy the target polynucleotide can be used, including DNA polymerases, RNA polymerases, reverse transcriptases, and enzymes having more than one type of polymerase or enzyme activity. The enzyme can be thermolabile or thermostable. Mixtures of enzymes can also be used. Exemplary enzymes include: DNA polymerases such as DNA Polymerase I (“Pol I”), the Klenow fragment of Pol I, T4, T7, Sequenase® T7, Sequenase® Version 2.0 T7, Tub, Taq, Tth, Pfic, Pfu, Tsp, Tfl, Tli and  Pyrococcus  sp GB-D DNA polymerases; RNA polymerases such as E.  coil , SP6, T3 and T7 RNA polymerases; and reverse transcriptases such as AMV, M-MuLV, MMLV, RNAse H MMLV (SuperScript®), SuperScript® II, ThermoScript®, HIV-1, and RAV2 reverse transcriptases. All of these enzymes are commercially available. Exemplary polymerases with multiple specificities include RAV2 and Tli (exo-) polymerases. Exemplary thermostable polymerases include Tub, Taq, Tth, Pfic, Pfu, Tsp, Tfl, Tli and  Pyrococcus  sp. GB-D DNA polymerases. 
     Suitable reaction conditions are chosen to permit amplification of the target polynucleotide, including pH, buffer, ionic strength, presence and concentration of one or more salts, presence and concentration of reactants and cofactors such as nucleotides and magnesium and/or other metal ions (e.g., manganese), optional cosolvents, temperature, thermal cycling profile for amplification schemes comprising a polymerase chain reaction, and may depend in part on the polymerase being used as well as the nature of the sample. Cosolvents include formamide (typically at from about 2 to about 10 %), glycerol (typically at from about 5 to about 10 %), and DMSO (typically at from about 0.9 to about 10 %). Techniques may be used in the amplification scheme in order to minimize the production of false positives or artifacts produced during amplification. These include “touchdown” PCR, hot-start techniques, use of nested primers, or designing PCR primers so that they form stem-loop structures in the event of primer-dimer formation and thus are not amplified. Techniques to accelerate PCR can be used, for example centrifugal PCR, which allows for greater convection within the sample, and comprising infrared heating steps for rapid heating and cooling of the sample. One or more cycles of amplification can be performed. An excess of one primer can be used to produce an excess of one primer extension product during PCR; preferably, the primer extension product produced in excess is the amplification product to be detected. A plurality of different primers may be used to amplify different target polynucleotides or different regions of a particular target polynucleotide within the sample. 
     An amplification reaction can be performed under conditions which allow an optionally labeled sensor polynucleotide to hybridize to the amplification product during at least part of an amplification cycle. When the assay is performed in this manner, real-time detection of this hybridization event can take place by monitoring for light emission or fluorescence during amplification, as known in the art. 
     Where the amplification product is to be used for hybridization to an array or microarray, a number of suitable commercially available amplification products are available. These include amplification kits available from NuGEN, Inc. (San Carlos, CA), including the WT-OvationTm System, WT-OvationTm System v2, WT-OvationTm Pico System, WT-OvationTm FFPE Exon Module, WT-OvationTm FFPE Exon Module RiboAmp and RiboAmp  Plus  RNA Amplification Kits (MDS Analytical Technologies (formerly Arcturus) (Mountain View, CA), Genisphere, Inc. (Hatfield, PA), including the RampUp PlusTM and SenseAmpTM RNA Amplification kits, alone or in combination. Amplified nucleic acids may be subjected to one or more purification reactions after amplification and labeling, for example using magnetic beads (e.g., RNAClean magnetic beads, Agencourt Biosciences). 
     Multiple RNA biomarkers can be analyzed using real-time quantitative multiplex RT-PCR platforms and other multiplexing technologies such as GenomeLab GeXP Genetic Analysis System (Beckman Coulter, Foster City, CA), SmartCycler® 9600 or GeneXpert® Systems (Cepheid, Sunnyvale, CA), ABI 7900 HT Fast Real Time PCR system (Applied Biosystems, Foster City, CA), LightCycler® 480 System (Roche Molecular Systems, Pleasanton, CA), xMAP 100 System (Luminex, Austin, TX) Solexa Genome Analysis System (Illumina, Hayward, CA), OpenArray Real Time qPCR (BioTrove, Woburn, MA) and BeadXpress System (Illumina, Hayward, CA). 
     Detection and/or Quantification of Target Sequences 
     Any method of detecting and/or quantitating the expression of the encoded target sequences can in principle be used in the invention. The expressed target sequences can be directly detected and/or quantitated, or may be copied and/or amplified to allow detection of amplified copies of the expressed target sequences or its complement. 
     Methods for detecting and/or quantifying a target can include Northern blotting, sequencing, array or microarray hybridization, serial analysis of gene expression (SAGE), by enzymatic cleavage of specific structures (e.g., an Invader® assay, Third Wave Technologies, e.g. as described in U.S. Pat. Nos. 5,846,717, 6,090,543; 6,001,567; 5,985,557; and 5,994,069) and amplification methods, e.g. RT-PCR, including in a TaqMan® assay (PE Biosystems, Foster City, Calif., e.g. as described in U.S. Pat. Nos. 5,962,233 and 5,538,848), and may be quantitative or semi-quantitative, and may vary depending on the origin, amount and condition of the available biological sample. Combinations of these methods may also be used. For example, nucleic acids may be amplified, labeled and subjected to microarray analysis. 
     In some instances, target sequences may be detected by sequencing. Sequencing methods may comprise whole genome sequencing or exome sequencing. Sequencing methods such as Maxim-Gilbert, chain-termination, or high-throughput systems may also be used. Additional, suitable sequencing techniques include classic dideoxy sequencing reactions (Sanger method) using labeled terminators or primers and gel separation in slab or capillary, sequencing by synthesis using reversibly terminated labeled nucleotides, pyrosequencing, 454 sequencing, allele specific hybridization to a library of labeled oligonucleotide probes, sequencing by synthesis using allele specific hybridization to a library of labeled clones that is followed by ligation, real time monitoring of the incorporation of labeled nucleotides during a polymerization step, and SOLiD sequencing. 
     Additional methods for detecting and/or quantifying a target include single-molecule sequencing (e.g., Helicos, PacBio), sequencing by synthesis (e.g., Illumina, Ion Torrent), sequencing by ligation (e.g., ABI SOLID), sequencing by hybridization (e.g., Complete Genomics), in situ hybridization, bead-array technologies (e.g., Luminex xMAP, Illumina BeadChips), branched DNA technology (e.g., Panomics, Genisphere). Sequencing methods may use fluorescent (e.g., Illumina) or electronic (e.g., Ion Torrent, Oxford Nanopore) methods of detecting nucleotides. 
     Reverse Transcription for QRT-PCR Analysis 
     Reverse transcription can be performed by any method known in the art. For example, reverse transcription may be performed using the Omniscript kit (Qiagen, Valencia, CA), Superscript III kit (Invitrogen, Carlsbad, CA), for RT-PCR. Target-specific priming can be performed in order to increase the sensitivity of detection of target sequences and generate target-specific cDNA. 
     TaqMan® Gene Expression Analysis 
     TaqMan®RT-PCR can be performed using Applied Biosystems Prism (ABI) 7900 HT instruments in a 51.11 volume with target sequence-specific cDNA equivalent to 1 ng total RNA. 
     Primers and probes concentrations for TaqMan analysis are added to amplify fluorescent amplicons using PCR cycling conditions such as 95° C. for 10 minutes for one cycle, 95° C. for 20 seconds, and 60° C. for 45 seconds for 40 cycles. A reference sample can be assayed to ensure reagent and process stability. Negative controls (e.g., no template) should be assayed to monitor any exogenous nucleic acid contamination. 
     Classification Arrays 
     The present invention contemplates that a probe set or probes derived therefrom may be provided in an array format. In the context of the present invention, an “array” is a spatially or logically organized collection of polynucleotide probes. An array comprising probes specific for a coding target, non-coding target, or a combination thereof may be used. Alternatively, an array comprising probes specific for two or more of the transcripts of a target selected from Table 2, or a product derived thereof, can be used. Desirably, an array may be specific for 5, 10, 15, 20, 25, 30 or more of the transcripts of a target selected from Table 2. Probes useful for the methods of the present invention are provided in Table 1. Expression of these sequences may be detected alone or in combination with other transcripts. In some embodiments, an array is used which comprises a wide range of sensor probes for prostate-specific expression products, along with appropriate control sequences. In some instances, the array may comprise the Human Exon 1.0 ST Array (HuEx 1.0 ST, Affymetrix, Inc., Santa Clara, CA.). 
     Typically the polynucleotide probes are attached to a solid substrate and are ordered so that the location (on the substrate) and the identity of each are known. The polynucleotide probes can be attached to one of a variety of solid substrates capable of withstanding the reagents and conditions necessary for use of the array. Examples include, but are not limited to, polymers, such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, polypropylene and polystyrene; ceramic; silicon; silicon dioxide; modified silicon; (fused) silica, quartz or glass; functionalized glass; paper, such as filter paper; diazotized cellulose; nitrocellulose filter; nylon membrane; and polyacrylamide gel pad. Substrates that are transparent to light are useful for arrays that may be used in an assay that involves optical detection. 
     Examples of array formats include membrane or filter arrays (for example, nitrocellulose, nylon arrays), plate arrays (for example, multiwell, such as a 24-, 96-, 256-, 384-, 864- or 1536-well, microtitre plate arrays), pin arrays, and bead arrays (for example, in a liquid “slurry”). Arrays on substrates such as glass or ceramic slides are often referred to as chip arrays or “chips.” Such arrays are well known in the art. In one embodiment of the present invention, the Cancer Prognosticarray is a chip. 
     Data Analysis 
     In some embodiments, one or more pattern recognition methods can be used in analyzing the expression level of target sequences. The pattern recognition method can comprise a linear combination of expression levels, or a nonlinear combination of expression levels. In some embodiments, expression measurements for RNA transcripts or combinations of RNA transcript levels are formulated into linear or non-linear models or algorithms (e.g., an ‘expression signature’) and converted into a likelihood score. This likelihood score may indicate the probability that a biological sample is from a patient who will benefit from radiation therapy. Additionally, a likelihood score may indicate the probability that a biological sample is from a patient who may exhibit no evidence of disease, who may exhibit systemic cancer, or who may exhibit biochemical recurrence. The likelihood score can be used to distinguish these disease states. The models and/or algorithms can be provided in machine readable format, and may be used to correlate expression levels or an expression profile with a disease state, and/or to designate a treatment modality for a patient or class of patients. 
     Assaying the expression level for a plurality of targets may comprise the use of an algorithm or classifier. Array data can be managed, classified, and analyzed using techniques known in the art. Assaying the expression level for a plurality of targets may comprise probe set modeling and data pre-processing. Probe set modeling and data pre-processing can be derived using the Robust Multi-Array (RMA) algorithm or variants GC-RMA, fRMA, Probe Logarithmic Intensity Error (PLIER) algorithm, or variant iterPLIER, or Single-Channel Array Normalization (SCAN) algorithm. Variance or intensity filters can be applied to pre-process data using the RMA algorithm, for example by removing target sequences with a standard deviation of &lt; 10 or a mean intensity of &lt; 100 intensity units of a normalized data range, respectively. 
     Alternatively, assaying the expression level for a plurality of targets may comprise the use of a machine learning algorithm. The machine learning algorithm may comprise a supervised learning algorithm. Examples of supervised learning algorithms may include Average One-Dependence Estimators (AODE), Artificial neural network (e.g., Backpropagation), Bayesian statistics (e.g., Naive Bayes classifier, Bayesian network, Bayesian knowledge base), Case-based reasoning, Decision trees, Inductive logic programming, Gaussian process regression, Group method of data handling (GMDH), Learning Automata, Learning Vector Quantization, Minimum message length (decision trees, decision graphs, etc.), Lazy learning, Instance-based learning Nearest Neighbor Algorithm, Analogical modeling, Probably approximately correct learning (PAC) learning, Ripple down rules, a knowledge acquisition methodology, Symbolic machine learning algorithms, Subsymbolic machine learning algorithms, Support vector machines, Random Forests, Ensembles of classifiers, Bootstrap aggregating (bagging), and Boosting. Supervised learning may comprise ordinal classification such as regression analysis and Information fuzzy networks (IFN). Alternatively, supervised learning methods may comprise statistical classification, such as AODE, Linear classifiers (e.g., Fisher’s linear discriminant, Logistic regression, Naive Bayes classifier, Perceptron, and Support vector machine), quadratic classifiers, k-nearest neighbor, Boosting, Decision trees (e.g., C4.5, Random forests), Bayesian networks, and Hidden Markov models. 
     The machine learning algorithms may also comprise an unsupervised learning algorithm. Examples of unsupervised learning algorithms may include artificial neural network, Data clustering, Expectation-maximization algorithm, Self-organizing map, Radial basis function network, Vector Quantization, Generative topographic map, Information bottleneck method, and IBSEAD. Unsupervised learning may also comprise association rule learning algorithms such as Apriori algorithm, Eclat algorithm and FP-growth algorithm. Hierarchical clustering, such as Single-linkage clustering and Conceptual clustering, may also be used. Alternatively, unsupervised learning may comprise partitional clustering such as K-means algorithm and Fuzzy clustering. 
     In some instances, the machine learning algorithms comprise a reinforcement learning algorithm. Examples of reinforcement learning algorithms include, but are not limited to, temporal difference learning, Q-learning and Learning Automata. Alternatively, the machine learning algorithm may comprise Data Pre-processing. 
     Preferably, the machine learning algorithms may include, but are not limited to, Average One-Dependence Estimators (AODE), Fisher’s linear discriminant, Logistic regression, Perceptron, Multilayer Perceptron, Artificial Neural Networks, Support vector machines, Quadratic classifiers, Boosting, Decision trees, C4.5, Bayesian networks, Hidden Markov models, High-Dimensional Discriminant Analysis, and Gaussian Mixture Models. The machine learning algorithm may comprise support vector machines, Naive Bayes classifier, k-nearest neighbor, high-dimensional discriminant analysis, or Gaussian mixture models. In some instances, the machine learning algorithm comprises Random Forests. 
     Therapeutic Regimens 
     Diagnosing, predicting, or monitoring a status or outcome of prostate cancer may comprise treating prostate cancer or preventing cancer progression. In addition, diagnosing, predicting, or monitoring a status or outcome of prostate cancer may comprise identifying or predicting which patients will be responders or non-responders to an anti-cancer therapy (e.g., radiation therapy). In some instances, diagnosing, predicting, or monitoring may comprise determining a therapeutic regimen. Determining a therapeutic regimen may comprise administering an anti-cancer therapy. Alternatively, determining a therapeutic regimen may comprise modifying, recommending, continuing or discontinuing an anti-cancer regimen. In some instances, if the sample expression patterns are consistent with the expression pattern for a known disease or disease outcome, the expression patterns can be used to designate one or more treatment modalities (e.g., therapeutic regimens, such as radiation therapy or other anti-cancer regimen). An anti-cancer regimen may comprise one or more anti-cancer therapies. Examples of anti-cancer therapies include surgery, chemotherapy, radiation therapy, immunotherapy/biological therapy, and photodynamic therapy. 
     For example, a patient is selected for treatment with radiation therapy if the patient is identified as likely to be responsive to radiation therapy based on an expression profile or PORTOS, as described herein. The radiation used in treatment can come from a machine outside the body (external-beam radiation therapy) or from radioactive material placed in the body near cancer cells (internal radiation therapy, more commonly called brachytherapy). Systemic radiation therapy uses a radioactive substance, given by mouth or into a vein that travels in the blood to tissues throughout the body. 
     External-beam radiation therapy may be delivered in the form of photon beams (either x-rays or gamma rays). A photon is the basic unit of light and other forms of electromagnetic radiation. An example of external-beam radiation therapy is called 3-dimensional conformal radiation therapy (3D-CRT). 3D-CRT may use computer software and advanced treatment machines to deliver radiation to very precisely shaped target areas. Many other methods of external-beam radiation therapy are currently being tested and used in cancer treatment. These methods include, but are not limited to, intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), Stereotactic radiosurgery (SRS), Stereotactic body radiation therapy (SBRT), and proton therapy. 
     Intensity-modulated radiation therapy (IMRT) is an example of external-beam radiation and may use hundreds of tiny radiation beam-shaping devices, called collimators, to deliver a single dose of radiation. The collimators can be stationary or can move during treatment, allowing the intensity of the radiation beams to change during treatment sessions. This kind of dose modulation allows different areas of a tumor or nearby tissues to receive different doses of radiation. IMRT is planned in reverse (called inverse treatment planning). In inverse treatment planning, the radiation doses to different areas of the tumor and surrounding tissue are planned in advance, and then a high-powered computer program calculates the required number of beams and angles of the radiation treatment. In contrast, during traditional (forward) treatment planning, the number and angles of the radiation beams are chosen in advance and computers calculate how much dose may be delivered from each of the planned beams. The goal of IMRT is to increase the radiation dose to the areas that need it and reduce radiation exposure to specific sensitive areas of surrounding normal tissue. 
     Another example of external-beam radiation is image-guided radiation therapy (IGRT). In IGRT, repeated imaging scans (CT, MRI, or PET) may be performed during treatment. These imaging scans may be processed by computers to identify changes in a tumor’s size and location due to treatment and to allow the position of the patient or the planned radiation dose to be adjusted during treatment as needed. Repeated imaging can increase the accuracy of radiation treatment and may allow reductions in the planned volume of tissue to be treated, thereby decreasing the total radiation dose to normal tissue. 
     Tomotherapy is a type of image-guided IMRT. A tomotherapy machine is a hybrid between a CT imaging scanner and an external-beam radiation therapy machine. The part of the tomotherapy machine that delivers radiation for both imaging and treatment can rotate completely around the patient in the same manner as a normal CT scanner. Tomotherapy machines can capture CT images of the patient’s tumor immediately before treatment sessions, to allow for very precise tumor targeting and sparing of normal tissue. 
     Stereotactic radiosurgery (SRS) can deliver one or more high doses of radiation to a small tumor. SRS uses extremely accurate image-guided tumor targeting and patient positioning. Therefore, a high dose of radiation can be given without excess damage to normal tissue. SRS can be used to treat small tumors with well-defined edges. It is most commonly used in the treatment of brain or spinal tumors and brain metastases from other cancer types. For the treatment of some brain metastases, patients may receive radiation therapy to the entire brain (called whole-brain radiation therapy) in addition to SRS. SRS requires the use of a head frame or other device to immobilize the patient during treatment to ensure that the high dose of radiation is delivered accurately. 
     Stereotactic body radiation therapy (SBRT) delivers radiation therapy in fewer sessions, using smaller radiation fields and higher doses than 3D-CRT in most cases. SBRT may treat tumors that lie outside the brain and spinal cord. Because these tumors are more likely to move with the normal motion of the body, and therefore cannot be targeted as accurately as tumors within the brain or spine, SBRT is usually given in more than one dose. SBRT can be used to treat small, isolated tumors, including cancers in the lung and liver. SBRT systems may be known by their brand names, such as the CyberKnife®. 
     In proton therapy, external-beam radiation therapy may be delivered by proton. Protons are a type of charged particle. Proton beams differ from photon beams mainly in the way they deposit energy in living tissue. Whereas photons deposit energy in small packets all along their path through tissue, protons deposit much of their energy at the end of their path (called the Bragg peak) and deposit less energy along the way. Use of protons may reduce the exposure of normal tissue to radiation, possibly allowing the delivery of higher doses of radiation to a tumor. 
     Other charged particle beams such as electron beams may be used to irradiate superficial tumors, such as skin cancer or tumors near the surface of the body, but they cannot travel very far through tissue. 
     Internal radiation therapy (brachytherapy) is radiation delivered from radiation sources (radioactive materials) placed inside or on the body. Several brachytherapy techniques are used in cancer treatment. Interstitial brachytherapy may use a radiation source placed within tumor tissue, such as within a prostate tumor. Intracavitary brachytherapy may use a source placed within a surgical cavity or a body cavity, such as the chest cavity, near a tumor. Episcleral brachytherapy, which may be used to treat melanoma inside the eye, may use a source that is attached to the eye. In brachytherapy, radioactive isotopes can be sealed in tiny pellets or “seeds.” These seeds may be placed in patients using delivery devices, such as needles, catheters, or some other type of carrier. As the isotopes decay naturally, they give off radiation that may damage nearby cancer cells. Brachytherapy may be able to deliver higher doses of radiation to some cancers than external-beam radiation therapy while causing less damage to normal tissue. 
     Brachytherapy can be given as a low-dose-rate or a high-dose-rate treatment. In low-dose-rate treatment, cancer cells receive continuous low-dose radiation from the source over a period of several days. In high-dose-rate treatment, a robotic machine attached to delivery tubes placed inside the body may guide one or more radioactive sources into or near a tumor, and then removes the sources at the end of each treatment session. High-dose-rate treatment can be given in one or more treatment sessions. An example of a high-dose-rate treatment is the MammoSite® system. Bracytherapy may be used to treat patients with breast cancer who have undergone breast-conserving surgery. 
     The placement of brachytherapy sources can be temporary or permanent. For permanent brachytherapy, the sources may be surgically sealed within the body and left there, even after all of the radiation has been given off. In some instances, the remaining material (in which the radioactive isotopes were sealed) does not cause any discomfort or harm to the patient. Permanent brachytherapy is a type of low-dose-rate brachytherapy. For temporary brachytherapy, tubes (catheters) or other carriers are used to deliver the radiation sources, and both the carriers and the radiation sources are removed after treatment. Temporary brachytherapy can be either low-dose-rate or high-dose-rate treatment. Brachytherapy may be used alone or in addition to external-beam radiation therapy to provide a “boost” of radiation to a tumor while sparing surrounding normal tissue. 
     In systemic radiation therapy, a patient may swallow or receive an injection of a radioactive substance, such as radioactive iodine or a radioactive substance bound to a monoclonal antibody. Radioactive iodine (131I) is a type of systemic radiation therapy commonly used to help treat cancer, such as thyroid cancer. Thyroid cells naturally take up radioactive iodine. For systemic radiation therapy for some other types of cancer, a monoclonal antibody may help target the radioactive substance to the right place. The antibody joined to the radioactive substance travels through the blood, locating and killing tumor cells. For example, the drug ibritumomab tiuxetan (Zevalin®) may be used for the treatment of certain types of B-cell non-Hodgkin lymphoma (NHL). The antibody part of this drug recognizes and binds to a protein found on the surface of B lymphocytes. The combination drug regimen of tositumomab and iodine I 131 tositumomab (Bexxar®) may be used for the treatment of certain types of cancer, such as NHL. In this regimen, nonradioactive tositumomab antibodies may be given to patients first, followed by treatment with tositumomab antibodies that have 131I attached. Tositumomab may recognize and bind to the same protein on B lymphocytes as ibritumomab. The nonradioactive form of the antibody may help protect normal B lymphocytes from being damaged by radiation from 131I. 
     Some systemic radiation therapy drugs relieve pain from cancer that has spread to the bone (bone metastases). This is a type of palliative radiation therapy. The radioactive drugs samarium-153-lexidronam (Quadramet®) and strontium-89 chloride (Metastron®) are examples of radiopharmaceuticals may be used to treat pain from bone metastases. 
     In addition, patients, especially those not identified as likely to benefit from radiation therapy, may be administered other cancer treatments such as, but not limited to, surgery, chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any combination thereof. 
     Surgical oncology uses surgical methods to diagnose, stage, and treat cancer, and to relieve certain cancer-related symptoms. Surgery may be used to remove the tumor (e.g., excisions, resections, debulking surgery), reconstruct a part of the body (e.g., restorative surgery), and/or to relieve symptoms such as pain (e.g., palliative surgery). Surgery may also include cryosurgery. Cryosurgery (also called cryotherapy) may use extreme cold produced by liquid nitrogen (or argon gas) to destroy abnormal tissue. Cryosurgery can be used to treat external tumors, such as those on the skin. For external tumors, liquid nitrogen can be applied directly to the cancer cells with a cotton swab or spraying device. Cryosurgery may also be used to treat tumors inside the body (internal tumors and tumors in the bone). For internal tumors, liquid nitrogen or argon gas may be circulated through a hollow instrument called a cryoprobe, which is placed in contact with the tumor. An ultrasound or MRI may be used to guide the cryoprobe and monitor the freezing of the cells, thus limiting damage to nearby healthy tissue. A ball of ice crystals may form around the probe, freezing nearby cells. Sometimes more than one probe is used to deliver the liquid nitrogen to various parts of the tumor. The probes may be put into the tumor during surgery or through the skin (percutaneously). After cryosurgery, the frozen tissue thaws and may be naturally absorbed by the body (for internal tumors), or may dissolve and form a scab (for external tumors). 
     Chemotherapeutic agents may also be used for the treatment of prostate cancer. Examples of chemotherapeutic agents include alkylating agents, anti-metabolites, plant alkaloids and terpenoids, vinca alkaloids, podophyllotoxin, taxanes, topoisomerase inhibitors, and cytotoxic antibiotics. Cisplatin, carboplatin, and oxaliplatin are examples of alkylating agents. Other alkylating agents include mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide. Alkylating agents may impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. Alternatively, alkylating agents may chemically modify a cell’s DNA. 
     Anti-metabolites are another example of chemotherapeutic agents. Anti-metabolites may masquerade as purines or pyrimidines and may prevent purines and pyrimidines from becoming incorporated in to DNA during the “S” phase (of the cell cycle), thereby stopping normal development and division. Antimetabolites may also affect RNA synthesis. Examples of metabolites include azathioprine and mercaptopurine. 
     Alkaloids may be derived from plants and block cell division may also be used for the treatment of cancer. Alkyloids may prevent microtubule function. Examples of alkaloids are vinca alkaloids and taxanes. Vinca alkaloids may bind to specific sites on tubulin and inhibit the assembly of tubulin into microtubules (M phase of the cell cycle). The vinca alkaloids may be derived from the Madagascar periwinkle,  Catharanthus roseus  (formerly known as  Vinca rosea ). Examples of vinca alkaloids include, but are not limited to, vincristine, vinblastine, vinorelbine, or vindesine. Taxanes are diterpenes produced by the plants of the genus  Taxus  (yews). Taxanes may be derived from natural sources or synthesized artificially. Taxanes include paclitaxel (Taxol) and docetaxel (Taxotere). Taxanes may disrupt microtubule function. Microtubules are essential to cell division, and taxanes may stabilize GDP-bound tubulin in the microtubule, thereby inhibiting the process of cell division. Thus, in essence, taxanes may be mitotic inhibitors. Taxanes may also be radiosensitizing and often contain numerous chiral centers. 
     Alternative chemotherapeutic agents include podophyllotoxin. Podophyllotoxin is a plant-derived compound that may help with digestion and may be used to produce cytostatic drugs such as etoposide and teniposide. They may prevent the cell from entering the G1 phase (the start of DNA replication) and the replication of DNA (the S phase). 
     Topoisomerases are essential enzymes that maintain the topology of DNA. Inhibition of type I or type II topoisomerases may interfere with both transcription and replication of DNA by upsetting proper DNA supercoiling. Some chemotherapeutic agents may inhibit topoisomerases. For example, some type I topoisomerase inhibitors include camptothecins: irinotecan and topotecan. Examples of type II inhibitors include amsacrine, etoposide, etoposide phosphate, and teniposide. 
     Another example of chemotherapeutic agents is cytotoxic antibiotics. Cytotoxic antibiotics are a group of antibiotics that are used for the treatment of cancer because they may interfere with DNA replication and/or protein synthesis. Cytotoxic antiobiotics include, but are not limited to, actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin, and mitomycin. 
     Alternatively or additionally, the anti-cancer treatment may comprise immunotherapy (sometimes called, biological therapy, biotherapy, biologic therapy, or biological response modifier (BRM) therapy), which uses the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Immunotherapies include interferons, interleukins, colony-stimulating factors, monoclonal antibodies, vaccines, immune cell-based therapy, gene therapy, and nonspecific immunomodulating agents. 
     Interferons (IFNs) are types of cytokines that occur naturally in the body. Interferon alpha, interferon beta, and interferon gamma are examples of interferons that may be used in cancer treatment. 
     Like interferons, interleukins (ILs) are cytokines that occur naturally in the body and can be made in the laboratory. Many interleukins have been identified for the treatment of cancer. For example, interleukin-2 (IL-2 or aldesleukin), interleukin 7, and interleukin 12 have may be used as an anti-cancer treatment. IL-2 may stimulate the growth and activity of many immune cells, such as lymphocytes, that can destroy cancer cells. Interleukins may be used to treat a number of cancers, including leukemia, lymphoma, and brain, colorectal, ovarian, breast, kidney and prostate cancers. 
     Colony-stimulating factors (CSFs) (sometimes called hematopoietic growth factors) may also be used for the treatment of cancer. Some examples of CSFs include, but are not limited to, G-CSF (filgrastim) and GM-CSF (sargramostim). CSFs may promote the division of bone marrow stem cells and their development into white blood cells, platelets, and red blood cells. Bone marrow is critical to the body’s immune system because it is the source of all blood cells. Because anticancer drugs can damage the body’s ability to make white blood cells, red blood cells, and platelets, stimulation of the immune system by CSFs may benefit patients undergoing other anti-cancer treatment, thus CSFs may be combined with other anti-cancer therapies, such as chemotherapy. CSFs may be used to treat a large variety of cancers, including lymphoma, leukemia, multiple myeloma, melanoma, and cancers of the brain, lung, esophagus, breast, uterus, ovary, prostate, kidney, colon, and rectum. 
     Another type of immunotherapy includes monoclonal antibodies (MOABs or MoABs). These antibodies may be produced by a single type of cell and may be specific for a particular antigen. To create MOABs, a human cancer cells may be injected into mice. In response, the mouse immune system can make antibodies against these cancer cells. The mouse plasma cells that produce antibodies may be isolated and fused with laboratory-grown cells to create “hybrid” cells called hybridomas. Hybridomas can indefinitely produce large quantities of these pure antibodies, or MOABs. MOABs may be used in cancer treatment in a number of ways. For instance, MOABs that react with specific types of cancer may enhance a patient’s immune response to the cancer. MOABs can be programmed to act against cell growth factors, thus interfering with the growth of cancer cells. 
     MOABs may be linked to other anti-cancer therapies such as chemotherapeutics, radioisotopes (radioactive substances), other biological therapies, or other toxins. When the antibodies latch onto cancer cells, they deliver these anti-cancer therapies directly to the tumor, helping to destroy it. MOABs carrying radioisotopes may also prove useful in diagnosing certain cancers, such as colorectal, ovarian, and prostate. 
     Rituxan® (rituximab) and Herceptin® (trastuzumab) are examples of MOABs that may be used as a biological therapy. Rituxan may be used for the treatment of non-Hodgkin lymphoma. Herceptin can be used to treat metastatic breast cancer in patients with tumors that produce excess amounts of a protein called HER2. Alternatively, MOABs may be used to treat lymphoma, leukemia, melanoma, and cancers of the brain, breast, lung, kidney, colon, rectum, ovary, prostate, and other areas. 
     Cancer vaccines are another form of immunotherapy. Cancer vaccines may be designed to encourage the patient’s immune system to recognize cancer cells. Cancer vaccines may be designed to treat existing cancers (therapeutic vaccines) or to prevent the development of cancer (prophylactic vaccines). Therapeutic vaccines may be injected in a person after cancer is diagnosed. These vaccines may stop the growth of existing tumors, prevent cancer from recurring, or eliminate cancer cells not killed by prior treatments. Cancer vaccines given when the tumor is small may be able to eradicate the cancer. On the other hand, prophylactic vaccines are given to healthy individuals before cancer develops. These vaccines are designed to stimulate the immune system to attack viruses that can cause cancer. By targeting these cancer-causing viruses, development of certain cancers may be prevented. For example, cervarix and gardasil are vaccines to treat human papilloma virus and may prevent cervical cancer. Therapeutic vaccines may be used to treat melanoma, lymphoma, leukemia, and cancers of the brain, breast, lung, kidney, ovary, prostate, pancreas, colon, and rectum. Cancer vaccines can be used in combination with other anti-cancer therapies. 
     Immune cell-based therapy is also another form of immunotherapy. Adoptive cell transfer may include the transfer of immune cells such as dendritic cells, T cells (e.g., cytotoxic T cells), or natural killer (NK) cells to activate a cytotoxic response or attack cancer cells in a patient. Autologous immune cell-based therapy involves the transfer of a patient’s own immune cells after expansion in vitro. 
     Gene therapy is another example of a biological therapy. Gene therapy may involve introducing genetic material into a person’s cells to fight disease. Gene therapy methods may improve a patient’s immune response to cancer. For example, a gene may be inserted into an immune cell to enhance its ability to recognize and attack cancer cells. In another approach, cancer cells may be injected with genes that cause the cancer cells to produce cytokines and stimulate the immune system. 
     In some instances, biological therapy includes nonspecific immunomodulating agents. Nonspecific immunomodulating agents are substances that stimulate or indirectly augment the immune system. Often, these agents target key immune system cells and may cause secondary responses such as increased production of cytokines and immunoglobulins. Two nonspecific immunomodulating agents used in cancer treatment are bacillus Calmette-Guerin (BCG) and levamisole. BCG may be used in the treatment of superficial bladder cancer following surgery. BCG may work by stimulating an inflammatory, and possibly an immune, response. A solution of BCG may be instilled in the bladder. Levamisole is sometimes used along with fluorouracil (5-FU) chemotherapy in the treatment of stage III (Dukes′ C) colon cancer following surgery. Levamisole may act to restore depressed immune function. 
     Photodynamic therapy (PDT) is an anti-cancer treatment that may use a drug, called a photosensitizer or photosensitizing agent, and a particular type of light. When photosensitizers are exposed to a specific wavelength of light, they may produce a form of oxygen that kills nearby cells. A photosensitizer may be activated by light of a specific wavelength. This wavelength determines how far the light can travel into the body. Thus, photosensitizers and wavelengths of light may be used to treat different areas of the body with PDT. 
     In the first step of PDT for cancer treatment, a photosensitizing agent may be injected into the bloodstream. The agent may be absorbed by cells all over the body but may stay in cancer cells longer than it does in normal cells. Approximately 24 to 72 hours after injection, when most of the agent has left normal cells but remains in cancer cells, the tumor can be exposed to light. The photosensitizer in the tumor can absorb the light and produces an active form of oxygen that destroys nearby cancer cells. In addition to directly killing cancer cells, PDT may shrink or destroy tumors in two other ways. The photosensitizer can damage blood vessels in the tumor, thereby preventing the cancer from receiving necessary nutrients. PDT may also activate the immune system to attack the tumor cells. 
     The light used for PDT can come from a laser or other sources. Laser light can be directed through fiber optic cables (thin fibers that transmit light) to deliver light to areas inside the body. For example, a fiber optic cable can be inserted through an endoscope (a thin, lighted tube used to look at tissues inside the body) into the lungs or esophagus to treat cancer in these organs. Other light sources include light-emitting diodes (LEDs), which may be used for surface tumors, such as skin cancer. PDT is usually performed as an outpatient procedure. PDT may also be repeated and may be used with other therapies, such as surgery, radiation, or chemotherapy. 
     Extracorporeal photopheresis (ECP) is a type of PDT in which a machine may be used to collect the patient’s blood cells. The patient’s blood cells may be treated outside the body with a photosensitizing agent, exposed to light, and then returned to the patient. ECP may be used to help lessen the severity of skin symptoms of cutaneous T-cell lymphoma that has not responded to other therapies. ECP may be used to treat other blood cancers, and may also help reduce rejection after transplants. 
     Additionally, photosensitizing agent, such as porfimer sodium or Photofrin®, may be used in PDT to treat or relieve the symptoms of esophageal cancer and non-small cell lung cancer. Porfimer sodium may relieve symptoms of esophageal cancer when the cancer obstructs the esophagus or when the cancer cannot be satisfactorily treated with laser therapy alone. Porfimer sodium may be used to treat non-small cell lung cancer in patients for whom the usual treatments are not appropriate, and to relieve symptoms in patients with non-small cell lung cancer that obstructs the airways. Porfimer sodium may also be used for the treatment of precancerous lesions in patients with Barrett esophagus, a condition that can lead to esophageal cancer. 
     Laser therapy may use high-intensity light to treat cancer and other illnesses. Lasers can be used to shrink or destroy tumors or precancerous growths. Lasers are most commonly used to treat superficial cancers (cancers on the surface of the body or the lining of internal organs) such as basal cell skin cancer and the very early stages of some cancers, such as cervical, penile, vaginal, vulvar, and non-small cell lung cancer. 
     Lasers may also be used to relieve certain symptoms of cancer, such as bleeding or obstruction. For example, lasers can be used to shrink or destroy a tumor that is blocking a patient’s trachea (windpipe) or esophagus. Lasers also can be used to remove colon polyps or tumors that are blocking the colon or stomach. 
     Laser therapy is often given through a flexible endoscope (a thin, lighted tube used to look at tissues inside the body). The endoscope is fitted with optical fibers (thin fibers that transmit light). It is inserted through an opening in the body, such as the mouth, nose, anus, or vagina. Laser light is then precisely aimed to cut or destroy a tumor. 
     Laser-induced interstitial thermotherapy (LITT), or interstitial laser photocoagulation, also uses lasers to treat some cancers. LITT is similar to a cancer treatment called hyperthermia, which uses heat to shrink tumors by damaging or killing cancer cells. During LITT, an optical fiber is inserted into a tumor. Laser light at the tip of the fiber raises the temperature of the tumor cells and damages or destroys them. LITT is sometimes used to shrink tumors in the liver. 
     Laser therapy can be used alone, but most often it is combined with other treatments, such as surgery, chemotherapy, or radiation therapy. In addition, lasers can seal nerve endings to reduce pain after surgery and seal lymph vessels to reduce swelling and limit the spread of tumor cells. 
     Lasers used to treat cancer may include carbon dioxide (CO 2 ) lasers, argon lasers, and neodymium:yttrium-aluminum-garnet (Nd:YAG) lasers. Each of these can shrink or destroy tumors and can be used with endoscopes. CO 2  and argon lasers can cut the skin’s surface without going into deeper layers. Thus, they can be used to remove superficial cancers, such as skin cancer. In contrast, the Nd:YAG laser is more commonly applied through an endoscope to treat internal organs, such as the uterus, esophagus, and colon. Nd:YAG laser light can also travel through optical fibers into specific areas of the body during LITT. Argon lasers are often used to activate the drugs used in PDT. 
     For patients with systemic disease after a prostatectomy, systemic radiation therapy (e.g., samarium or strontium) may be combined with additional treatment modalities such as adjuvant chemotherapy (e.g., docetaxel, mitoxantrone, cabazitaxel, estramustine and prednisone), and/or hormone therapy including anti-androgen therapy (e.g., surgical castration, finasteride, flutamide, bicalutamide, niltamide, enzalutamide, ketoconazole and dutasteride); lutenizing hormone releasing hormone (LHRH) agonists, (leuprolide, goserelin, triptorelin and histrelin) and/or LHRH antagonists, also known as gonadotropin-releasing hormone antagonists, (degarelix, ganirelix, cetrorelix and abarelix). Such patients would likely be treated immediately with radiation therapy either alone or in combination with one or more other treatment modalities in order to eliminate presumed micro-metastatic disease. 
     Such patients can also be more closely monitored for signs of disease progression. For patients with biochemical recurrence only (BCR-only or elevated PSA that does not rapidly become manifested as systemic disease), only localized adjuvant therapy (e.g., radiation therapy of the prostate bed) or a short course of anti-androgen therapy would likely be administered. For patients with no evidence of disease (NED), adjuvant therapy would not likely be recommended by their physicians in order to avoid treatment-related side effects such as metabolic syndrome (e.g., hypertension, diabetes and/or weight gain), osteoporosis, proctitis, incontinence or impotence. Patients with NED could be designated for watchful waiting, or for no treatment. Patients with systemic disease, but who have successive PSA increases, could be designated for watchful waiting, increased monitoring, or lower dose or shorter duration radiation therapy. 
     Target sequences can be grouped so that information obtained about the set of target sequences in the group can be used to make or assist in making a clinically relevant judgment such as a diagnosis, prognosis, or treatment choice. 
     A patient report is also provided comprising a representation of measured expression levels of a plurality of target sequences in a biological sample from the patient, wherein the representation comprises expression levels of target sequences corresponding to any one, two, three, four, five, six, eight, ten, twenty, or more of the target sequences corresponding to a target selected from Table 1 or Table 2, the subsets described herein, or a combination thereof. In some embodiments, the representation of the measured expression level(s) may take the form of a linear or nonlinear combination of expression levels of the target sequences of interest. The patient report may further include a PORTOS. The patient report may be provided in a machine (e.g., a computer) readable format and/or in a hard (paper) copy. The report can also include standard measurements of expression levels of said plurality of target sequences from one or more sets of patients with known disease status and/or outcome. The report can be used to inform the patient and/or treating physician of the expression levels of the expressed target sequences, the likely medical diagnosis and/or implications, and optionally may recommend a treatment modality (e.g., radiation therapy) for the patient. 
     Also provided are representations of the gene expression profiles useful for treating, diagnosing, prognosticating, and otherwise assessing disease. In some embodiments, these profile representations are reduced to a medium that can be automatically read by a machine such as computer readable media (magnetic, optical, and the like). The articles can also include instructions for assessing the gene expression profiles in such media. For example, the articles may comprise a readable storage form having computer instructions for comparing gene expression profiles of the portfolios of genes described above and/or calculating a PORTOS based on the gene expression profiles. The articles may also have gene expression profiles digitally recorded therein so that they may be compared with gene expression data from patient samples. Alternatively, the profiles can be recorded in different representational format. A graphical recordation is one such format. Clustering algorithms can assist in the visualization of such data. 
     Prediction of Treatment Response to Radiation Therapy 
     A radiation response genomic signature can be utilized to predict whether or not a patient who has prostate cancer will benefit from radiation therapy. In particular, a post-operative radiation therapy outcome score (PORTOS) can be calculated based on the levels of expression of a plurality of genes selected from Table 2 to determine whether or not the subject is likely to benefit from post-operative radiation therapy (see Examples). A PORTOS greater than 0 (i.e., high PORTOS) indicates that a subject will benefit from post-operative radiation therapy, whereas a PORTOS of less than or equal to 0 (i.e., low PORTOS) indicates that a subject will not benefit from post-operative radiation therapy. Thus, patients with high PORTOS signature scores are more likely to benefit from radiation treatment after surgery and may be prescribed or administered radiation therapy. 
     III. Experimental 
     Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. 
     Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for. 
     EXAMPLES 
     Example 1: Development of a Genetic Signature to Predict Post-Operative Radiation Therapy Response in Prostate Cancer Patients. 
     DNA Damage Repair (DDR) genes and pathways are significantly associated with increased metastatic progression risk (Evans et al., Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer, JAMA Oncol. 2016 Jan 7:1-10). DDR genes were evaluated for their utility in a radiation response signature prostate cancer patients following prostatectomy. An 1800 gene compilation from Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) related to response to DNA damage and radiation and in the Human Exon Array platform were collected to identify a subset of genes having the most potential to predict response to radiation therapy (RT). 
     To develop a post-operative radiation therapy response signature, a 1:1 matching was performed for patients treated and untreated with RT within a year in the MCI case-control prostatectomy cohort (Erho et al., Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.  PLoS One  2013; 8: e66855). Prostate cancer patients considered “treated” received adjuvant or salvage post-operative radiation after radical prostatectomy and before the primary endpoint of metastasis. Matching between treated and untreated arms was performed on Gleason score, pre-operative prostate specific antigen (PSA), positive surgical margins (SM), extracapsular extension (ECE), seminal vesicle invasion (SVI), lymph node invasion (LNI), and androgen deprivation therapy (ADT). Gleason score was categorized into low (&lt;7), intermediate (7), and high (8-10). Similarly, PSA was stratified into low (&lt;10 ng/dL), intermediate (10-20 ng/dL), and high (&gt;20 ng/dL). SM, ECE, SVI, and LNI were treated as binary variables and defined by the respective institutions. The resulting matched training prostatectomy cohort (N=196) with whole-genome expression profiles was used to develop the radiation response signature. 
     Using the training cohort, each of the 1800 genes was ranked in order of its univariate interaction p-value in a Cox proportional hazards model. This ranked gene list was used to train a ridge-penalized Cox model, using metastasis as the endpoint, and with treatment and the interaction terms of treatment and each gene as the variables. Feature selection was performed by varying the number of included features from 10 to 25 (9 to 24 genes in addition to treatment) in order to range from approximately 10 to 4 events per variable in the training cohort. The final gene list was the model that minimized the interaction p-value in the training cohort. The predictions from the model are calculated by taking the difference of the predictions without RT and with RT, and converting to binary scores using a cutoff of 0. The resulting score is the Post-Operative Radiation Therapy Outcome Score (PORTOS) where patients with scores greater than 0 (high PORTOS) benefit from treatment, and patients with scores less than or equal to 0 (low PORTOS) do not benefit from treatment. As a result a 24-gene model was developed using ridge-penalized Cox regression to model the interactions of the genes and radiation therapy to generate the PORTOS [Table 2]. The model was then applied to the independent validation cohort.  
     
       
         
          TABLE 2
           
               
               
               
               
             
               
                 A list of the 24 genes in PORTOS model with their regression coefficients 
               
               
                 Gene 
                 Coefficient 
                 Gene 
                 Coefficient 
               
             
            
               
                 DRAM1 
                 -0.102 
                 HCLS1 
                 -0.008 
               
               
                 KRT14 
                 -0.847 
                 DTL 
                 1.161 
               
               
                 PTPN22 
                 -1.029 
                 IL7R 
                 0.135 
               
               
                 ZMAT3 
                 0.118 
                 UBA7 
                 0.291 
               
               
                 ARHGAP15 
                 -1.114 
                 NEK1 
                 0.678 
               
               
                 IL1B 
                 -1.502 
                 CDKN2AIP 
                 0.466 
               
               
                 ANLN 
                 -1.233 
                 APEX2 
                 0.671 
               
               
                 RPS27A 
                 0.364 
                 KIF23 
                 1.01 
               
               
                 MUM1 
                 0.444 
                 SULF2 
                 -0.288 
               
               
                 TOP2A 
                 1.378 
                 PLK2 
                 -1.294 
               
               
                 GNG11 
                 0.41 
                 EME1 
                 1.39 
               
               
                 CDKN3 
                 -0.848 
                 BIN2 
                 0.529 
               
            
           
         
       
     
     Example 2: PORTOS Is Predictive of Response to Radiation Therapy in Prostate Cancer Patients 
     In the matched training cohort, PORTOS was able to predict response to radiation therapy (RT) as evidenced by the significant interaction term (p&lt;0.0001,  FIG.  1 A ). In patients with high scores (PORTOS&gt;0), treated patients had better outcomes than untreated patients with a 10-year metastasis rate of 5% in RT treated patients and 63% in untreated patients (p&lt;0.0001, HR=0.12 [0.033-0.41],  FIGS.  1 B and  2 A ), whereas in patients with low scores (PORTOS&lt;0), untreated patients had better outcomes with a 10-year metastasis rate of 31%, compared to 57% in RT treated patients (p=0.0001, HR=2.5 [1.6-4.1],  FIGS.  1 B and  2 B ). These results showed that the PORTOS of the present invention was useful for predicting benefit from post-operative RT in patients with prostate cancer. These results also indicated that the methods of the present invention are useful for treating prostate cancer. These results further indicated that methods of the present invention are useful for predicting response to post-operative radiation therapy and treating a subject for prostate cancer. 
     Example 3: PORTOS Is Predictive of Response to Radiation Therapy in an Independent Validation of the Model 
     To independently validate the model, a matched cohort of treated and untreated radiation therapy (RT) patients was designed using a pooled cohort from four clinical sites (MCII, THU, TJU and DVA). These results were confirmed in an independent matched validation cohort, with a significant interaction term (p&lt;0.05,  FIG.  1 C ). Within the high PORTOS group, patients treated with RT had better outcomes than untreated patients (p=0.01, HR=0.19 [0.048-0.78],  FIG.  2 C ), with a 10-year metastasis rate of 4% in RT treated patients and 31% in untreated patients ( FIG.  1 D ). Within the low PORTOS group, untreated patients had outcomes similar as treated patients (p=0.77, HR=0.92 [0.56-1.5],  FIG.  2 D ) with 10-year metastasis rate of 31% in RT treated patients and 32% in untreated patients ( FIG.  1 D ). 
     These results provide further evidence that patients with high scores are more likely to benefit from radiation treatment after surgery. These results showed that the PORTOS was useful for predicting benefit from post-operative RT in patients with prostate cancer. These results further indicated that methods of the present invention are useful for predicting response to post-operative radiation therapy and treating a subject for prostate cancer. 
     Example 4: PORTOS is an Independent Predictor of Response to Radiation Therapy After Adjusting for Clinical Variables 
     To determine whether PORTOS is predictive, multivariable interaction analyses (MVA) to examine the interaction between PORTOS scores and RT treatment in a pooled set from multiple cohorts from different institutes was performed [Table 3]. Due to the differences in the baseline risks of cohorts, MVA adjusting was performed for clinical variables and institute. PORTOS was significantly interacting with RT (p &lt;0.05). 
     These results provide further evidence that patients with high scores are more likely to benefit from radiation treatment after surgery. These results showed that the PORTOS was useful for predicting benefit from post-operative RT in patients with prostate cancer. These results further indicated that methods of the present invention are useful for predicting response to post-operative radiation therapy and treating a subject for prostate cancer.  
     
       
         
          TABLE 3
           
               
               
               
               
             
               
                 MVA of PORTOS adjusted for clinical variables to predict response to RT 
               
             
            
               
                 Covariate 
                   
                 P-value 
                 HR [95% CI] 
               
               
                 RT 
                   
                 0.00411 
                 2.49 [1.34-4.65] 
               
               
                 PORTOS 
                   
                 8.26E-07 
                 0.36 [0.24-0.54] 
               
               
                 PSA 
                 &lt; 10 
                 Reference 
                   
               
               
                   
                 10-20 
                 0.179 
                 0.8 [0.58-1.11] 
               
               
                   
                 &gt; 20 
                 0.547 
                 1.13 [0.76-1.68] 
               
               
                 Gleason 
                 &lt;7 
                 Reference 
                   
               
               
                   
                 7 
                 0.134 
                 4.57 [0.63-33.39] 
               
               
                   
                 8-10 
                 0.0166 
                 11.38 [1.56-83.3] 
               
               
                 SMS 
                 0.787 1.04 [0.77-1.41] 
               
               
                 SVI 
                 4.37E-05 1.89 [1.39-2.56] 
               
               
                 ECE 
                 0.269 1.22 [0.86-1.74] 
               
               
                 LNI 
                 0.00226 1.69 [1.21-2.36] 
               
               
                 ADT 
                 0.0102 2.13 [1.2-3.8] 
               
            
           
           
               
               
               
               
             
               
                 Study 
                 DVA 
                 Reference 
                   
               
             
            
               
                   
                 JHMI 
                 9.86E-06 
                 11.6 [3.91-34.41] 
               
               
                   
                 Mayo Val 
                 0.000273 
                 6.32 [2.34-17.04] 
               
               
                   
                 TJU 
                 0.535 
                 1.5 [0.42-5.43] 
               
               
                 RT:PORTOS 
                 0.0203 
                 2.74 [1.17-6.41] 
               
            
           
         
       
     
     Example 5: Univariate and Pairwise Analysis of the 24 Target Genes in the Genetic Signature to Predict Post-Operative Radiation Therapy Response in Prostate Cancer Patients Across Different Endpoints 
     The 24 targets in the genetic signature described in Example 1 were assessed for their performance across a range of different metrics and endpoints in both the training and validation cohorts. 
     Table 4 shows univariate (UVA) and pairwise (MVA) analysis of the interaction between RT treatment and individual genes in the genetic signature in Example 1. Table 5 shows univariate (UVA) and pairwise (MVA) analysis of the interaction between pairwise combinations of genes in the genetic signature and radiation therapy (RT) treatment adjusted for clinical variables. The associated p-value provided in Table 4 and 5 gives a measure of the statistical significance of the corresponding metric. 
     As shown in Tables 4 and 5, the performance of the 24 genes in the genetic signature, individually and as pairwise combinations, were statistically significant in the training and validation cohorts for predicting response to RT treatment. These results showed that the targets of the present invention are useful for predicting benefit from post-operative RT in patients with prostate cancer. These results also indicated that the methods of the present invention are useful for treating prostate cancer. These results further indicated that methods of the present invention are useful for predicting response to post-operative radiation therapy and treating a subject for prostate cancer.  
     
       
         
          TABLE 4
           
               
               
               
               
             
               
                 Univariate and Multivariate Analysis of the 24 Target Genes from the Genetic Signature with Associated P-values. 
               
               
                 Gene 
                 UVA p-value of interaction of treatment and gene in Training Cohort 
                 UVA p-value of interaction of treatment and gene in Validation Cohort 
                 MVA p-value of interaction of treatment and gene adjusting for clinical variables Pooled in Validation Cohort 
               
             
            
               
                 DRAM1 
                 0.001 
                 0.361 
                 0.524 
               
               
                 KRT14 
                 0.001 
                 0.549 
                 0.046 
               
               
                 PTPN22 
                 0.005 
                 0.407 
                 0.004 
               
               
                 ZMAT3 
                 0.012 
                 0.275 
                 0.927 
               
               
                 ARHGAP15 
                 0.013 
                 0.478 
                 0.178 
               
               
                 IL1B 
                 0.013 
                 0.611 
                 0.891 
               
               
                 ANLN 
                 0.020 
                 0.492 
                 0.008 
               
               
                 RPS27A 
                 0.021 
                 0.386 
                 0.228 
               
               
                 MUM1 
                 0.029 
                 0.833 
                 0.530 
               
               
                 TOP2A 
                 0.032 
                 0.083 
                 0.239 
               
               
                 GNG11 
                 0.035 
                 0.171 
                 0.251 
               
               
                 CDKN3 
                 0.036 
                 0.691 
                 0.087 
               
               
                 HCLS1 
                 0.042 
                 0.778 
                 0.797 
               
               
                 DTL 
                 0.047 
                 0.607 
                 0.012 
               
               
                 IL7R 
                 0.050 
                 0.829 
                 0.076 
               
               
                 UBA7 
                 0.050 
                 0.905 
                 0.435 
               
               
                 NEK1 
                 0.053 
                 0.506 
                 0.893 
               
               
                 CDKN2AIP 
                 0.057 
                 0.589 
                 0.323 
               
               
                 APEX2 
                 0.059 
                 0.644 
                 0.703 
               
               
                 KIF23 
                 0.059 
                 0.437 
                 0.154 
               
               
                 SULF2 
                 0.061 
                 0.173 
                 0.178 
               
               
                 PLK2 
                 0.065 
                 0.231 
                 0.242 
               
               
                 EME1 
                 0.067 
                 0.031 
                 0.006 
               
               
                 BIN2 
                 0.071 
                 0.009 
                 0.000 
               
            
           
         
       
     
     
       
         
          TABLE 5
           
               
               
               
               
               
             
               
                 Univariate and Multivariable Analysis of pairwise combinations of the 24 Genes from the Genetic Signature with Associated P-values. 
               
               
                 Gene 1 
                 Gene 2 
                 UVA p-value of interaction of treatment and Genes 1 and 2 in Training Cohort 
                 UVA p-value of interaction of treatment and Genes 1 and 2 in Validation Cohort 
                 MVA p-value of interaction of treatment and genes 1 and 2 adjusting for clinical variables in Pooled Validation Cohort 
               
             
            
               
                 DRAM1 
                 KRT14 
                 0.000 
                 0.596 
                 0.058 
               
               
                 DRAM1 
                 PTPN22 
                 0.002 
                 0.370 
                 0.014 
               
               
                 DRAM1 
                 ZMAT3 
                 0.655 
                 0.081 
                 0.667 
               
               
                 DRAM1 
                 ARHGAP15 
                 0.005 
                 0.448 
                 0.705 
               
               
                 DRAM1 
                 IL1B 
                 0.007 
                 0.601 
                 0.807 
               
               
                 DRAM1 
                 ANLN 
                 0.006 
                 0.370 
                 0.115 
               
               
                 DRAM1 
                 RPS27A 
                 0.001 
                 0.190 
                 0.663 
               
               
                 DRAM1 
                 MUM1 
                 0.002 
                 0.979 
                 0.315 
               
               
                 DRAM1 
                 TOP2A 
                 0.044 
                 0.075 
                 0.911 
               
               
                 DRAM1 
                 GNG11 
                 0.007 
                 0.220 
                 0.363 
               
               
                 DRAM1 
                 CDKN3 
                 0.016 
                 0.807 
                 0.163 
               
               
                 DRAM1 
                 HCLS 1 
                 0.001 
                 0.393 
                 0.911 
               
               
                 DRAM1 
                 DTL 
                 0.015 
                 0.687 
                 0.028 
               
               
                 DRAM1 
                 IL7R 
                 0.434 
                 0.994 
                 0.120 
               
               
                 DRAM1 
                 UBA7 
                 0.452 
                 0.787 
                 0.751 
               
               
                 DRAM1 
                 NEK1 
                 0.031 
                 0.568 
                 0.449 
               
               
                 DRAM1 
                 CDKN2AIP 
                 0.019 
                 0.516 
                 0.198 
               
               
                 DRAM1 
                 APEX2 
                 0.017 
                 0.487 
                 0.249 
               
               
                 DRAM1 
                 KIF23 
                 0.148 
                 0.527 
                 0.542 
               
               
                 DRAM1 
                 SULF2 
                 0.008 
                 0.333 
                 0.368 
               
               
                 DRAM1 
                 PLK2 
                 0.039 
                 0.267 
                 0.041 
               
               
                 DRAM1 
                 EME1 
                 0.033 
                 0.041 
                 0.018 
               
               
                 DRAM1 
                 BIN2 
                 0.298 
                 0.015 
                 0.000 
               
               
                 KRT14 
                 PTPN22 
                 0.000 
                 0.882 
                 0.838 
               
               
                 KRT14 
                 ZMAT3 
                 0.002 
                 0.602 
                 0.055 
               
               
                 KRT14 
                 ARHGAP15 
                 0.000 
                 0.967 
                 0.196 
               
               
                 KRT14 
                 IL1B 
                 0.000 
                 0.664 
                 0.287 
               
               
                 KRT14 
                 ANLN 
                 0.000 
                 0.357 
                 0.276 
               
               
                 KRT14 
                 RPS27A 
                 0.000 
                 0.688 
                 0.087 
               
               
                 KRT14 
                 MUM1 
                 0.000 
                 0.616 
                 0.131 
               
               
                 KRT14 
                 TOP2A 
                 0.844 
                 0.360 
                 0.456 
               
               
                 KRT14 
                 GNG11 
                 0.000 
                 0.363 
                 0.041 
               
               
                 KRT14 
                 CDKN3 
                 0.000 
                 0.312 
                 0.248 
               
               
                 KRT14 
                 HCLS 1 
                 0.001 
                 0.547 
                 0.055 
               
               
                 KRT14 
                 DTL 
                 0.000 
                 0.506 
                 0.009 
               
               
                 KRT14 
                 IL7R 
                 0.004 
                 0.435 
                 0.023 
               
               
                 KRT14 
                 UBA7 
                 0.002 
                 0.507 
                 0.054 
               
               
                 KRT14 
                 NEK1 
                 0.000 
                 0.520 
                 0.343 
               
               
                 KRT14 
                 CDKN2AIP 
                 0.000 
                 0.832 
                 0.271 
               
               
                 KRT14 
                 APEX2 
                 0.000 
                 0.719 
                 0.142 
               
               
                 KRT14 
                 KIF23 
                 0.074 
                 0.314 
                 0.046 
               
               
                 KRT14 
                 SULF2 
                 0.000 
                 0.368 
                 0.039 
               
               
                 KRT14 
                 PLK2 
                 0.000 
                 0.106 
                 0.809 
               
               
                 KRT14 
                 EME1 
                 0.000 
                 0.035 
                 0.003 
               
               
                 KRT14 
                 BIN2 
                 0.011 
                 0.133 
                 0.003 
               
               
                 PTPN22 
                 ZMAT3 
                 0.010 
                 0.337 
                 0.010 
               
               
                 PTPN22 
                 ARHGAP15 
                 0.002 
                 0.368 
                 0.105 
               
               
                 PTPN22 
                 IL1B 
                 0.001 
                 0.601 
                 0.228 
               
               
                 PTPN22 
                 ANLN 
                 0.002 
                 0.102 
                 0.004 
               
               
                 PTPN22 
                 RPS27A 
                 0.001 
                 0.312 
                 0.007 
               
               
                 PTPN22 
                 MUM1 
                 0.001 
                 0.511 
                 0.007 
               
               
                 PTPN22 
                 TOP2A 
                 0.363 
                 0.071 
                 0.252 
               
               
                 PTPN22 
                 GNG11 
                 0.001 
                 0.785 
                 0.029 
               
               
                 PTPN22 
                 CDKN3 
                 0.001 
                 0.307 
                 0.005 
               
               
                 PTPN22 
                 HCLS1 
                 0.005 
                 0.412 
                 0.011 
               
               
                 PTPN22 
                 DTL 
                 0.000 
                 0.721 
                 0.610 
               
               
                 PTPN22 
                 IL7R 
                 0.020 
                 0.502 
                 0.022 
               
               
                 PTPN22 
                 UBA7 
                 0.019 
                 0.379 
                 0.005 
               
               
                 PTPN22 
                 NEK1 
                 0.003 
                 0.842 
                 0.016 
               
               
                 PTPN22 
                 CDKN2AIP 
                 0.001 
                 0.304 
                 0.003 
               
               
                 PTPN22 
                 APEX2 
                 0.001 
                 0.340 
                 0.004 
               
               
                 PTPN22 
                 KIF23 
                 0.281 
                 0.851 
                 0.080 
               
               
                 PTPN22 
                 SULF2 
                 0.002 
                 0.819 
                 0.041 
               
               
                 PTPN22 
                 PLK2 
                 0.003 
                 0.601 
                 0.003 
               
               
                 PTPN22 
                 EME1 
                 0.001 
                 0.207 
                 0.989 
               
               
                 PTPN22 
                 BIN2 
                 0.040 
                 0.610 
                 0.304 
               
               
                 ZMAT3 
                 ARHGAP15 
                 0.027 
                 0.409 
                 0.706 
               
               
                 ZMAT3 
                 IL1B 
                 0.022 
                 0.529 
                 0.795 
               
               
                 ZMAT3 
                 ANLN 
                 0.042 
                 0.495 
                 0.153 
               
               
                 ZMAT3 
                 RPS27A 
                 0.142 
                 0.338 
                 0.817 
               
               
                 ZMAT3 
                 MUM1 
                 0.176 
                 0.857 
                 0.377 
               
               
                 ZMAT3 
                 TOP2A 
                 0.023 
                 0.085 
                 0.967 
               
               
                 ZMAT3 
                 GNG11 
                 0.136 
                 0.280 
                 0.379 
               
               
                 ZMAT3 
                 CDKN3 
                 0.073 
                 0.729 
                 0.171 
               
               
                 ZMAT3 
                 HCLS 1 
                 0.021 
                 0.289 
                 0.558 
               
               
                 ZMAT3 
                 DTL 
                 0.117 
                 0.659 
                 0.023 
               
               
                 ZMAT3 
                 IL7R 
                 0.013 
                 0.982 
                 0.185 
               
               
                 ZMAT3 
                 UBA7 
                 0.017 
                 0.917 
                 0.906 
               
               
                 ZMAT3 
                 NEK1 
                 0.101 
                 0.575 
                 0.521 
               
               
                 ZMAT3 
                 CDKN2AIP 
                 0.145 
                 0.503 
                 0.252 
               
               
                 ZMAT3 
                 APEX2 
                 0.156 
                 0.600 
                 0.326 
               
               
                 ZMAT3 
                 KIF23 
                 0.033 
                 0.562 
                 0.516 
               
               
                 ZMAT3 
                 SULF2 
                 0.401 
                 0.331 
                 0.207 
               
               
                 ZMAT3 
                 PLK2 
                 0.097 
                 0.237 
                 0.036 
               
               
                 ZMAT3 
                 EME1 
                 0.118 
                 0.038 
                 0.014 
               
               
                 ZMAT3 
                 BIN2 
                 0.023 
                 0.020 
                 0.001 
               
               
                 ARHGAP15 
                 IL1B 
                 0.002 
                 0.509 
                 0.717 
               
               
                 ARHGAP15 
                 ANLN 
                 0.005 
                 0.259 
                 0.274 
               
               
                 ARHGAP15 
                 RPS27A 
                 0.001 
                 0.370 
                 0.525 
               
               
                 ARHGAP15 
                 MUM1 
                 0.002 
                 0.508 
                 0.415 
               
               
                 ARHGAP15 
                 TOP2A 
                 0.327 
                 0.052 
                 0.566 
               
               
                 ARHGAP15 
                 GNG11 
                 0.001 
                 0.847 
                 0.965 
               
               
                 ARHGAP15 
                 CDKN3 
                 0.004 
                 0.523 
                 0.320 
               
               
                 ARHGAP15 
                 HCLS1 
                 0.012 
                 0.482 
                 0.692 
               
               
                 ARHGAP15 
                 DTL 
                 0.001 
                 0.559 
                 0.340 
               
               
                 ARHGAP15 
                 IL7R 
                 0.059 
                 0.468 
                 0.835 
               
               
                 ARHGAP15 
                 UBA7 
                 0.048 
                 0.480 
                 0.566 
               
               
                 ARHGAP15 
                 NEK1 
                 0.004 
                 0.748 
                 0.327 
               
               
                 ARHGAP15 
                 CDKN2AIP 
                 0.002 
                 0.341 
                 0.244 
               
               
                 ARHGAP15 
                 APEX2 
                 0.000 
                 0.314 
                 0.305 
               
               
                 ARHGAP15 
                 KIF23 
                 0.475 
                 0.722 
                 0.988 
               
               
                 ARHGAP15 
                 SULF2 
                 0.006 
                 0.767 
                 0.898 
               
               
                 ARHGAP15 
                 PLK2 
                 0.006 
                 0.577 
                 0.069 
               
               
                 ARHGAP15 
                 EME1 
                 0.001 
                 0.329 
                 0.180 
               
               
                 ARHGAP15 
                 BIN2 
                 0.142 
                 0.793 
                 0.232 
               
               
                 IL1B 
                 ANLN 
                 0.004 
                 0.847 
                 0.813 
               
               
                 II1B 
                 RPS27A 
                 0.003 
                 0.508 
                 0.637 
               
               
                 IL1B 
                 MUM1 
                 0.004 
                 0.605 
                 0.531 
               
               
                 IL1B 
                 TOP2A 
                 0.940 
                 0.064 
                 0.347 
               
               
                 IL1B 
                 GNG11 
                 0.002 
                 0.912 
                 0.992 
               
               
                 IL1B 
                 CDKN3 
                 0.004 
                 0.732 
                 0.727 
               
               
                 IL1B 
                 HCLS1 
                 0.013 
                 0.613 
                 0.782 
               
               
                 IL1B 
                 DTL 
                 0.001 
                 0.475 
                 0.807 
               
               
                 IL1B 
                 IL7R 
                 0.032 
                 0.666 
                 0.932 
               
               
                 IL1B 
                 UBA7 
                 0.031 
                 0.730 
                 0.737 
               
               
                 IL1B 
                 NEK1 
                 0.005 
                 0.751 
                 0.403 
               
               
                 IL1B 
                 CDKN2AIP 
                 0.003 
                 0.537 
                 0.329 
               
               
                 IL1B 
                 APEX2 
                 0.001 
                 0.398 
                 0.392 
               
               
                 IL1B 
                 KIF23 
                 0.103 
                 0.764 
                 0.936 
               
               
                 IL1B 
                 SULF2 
                 0.007 
                 0.743 
                 0.870 
               
               
                 IL1B 
                 PLK2 
                 0.004 
                 0.422 
                 0.200 
               
               
                 IL1B 
                 EME1 
                 0.001 
                 0.385 
                 0.444 
               
               
                 IL1B 
                 BIN2 
                 0.028 
                 0.815 
                 0.487 
               
               
                 ANLN 
                 RPS27A 
                 0.003 
                 0.530 
                 0.142 
               
               
                 ANLN 
                 MUM1 
                 0.004 
                 0.585 
                 0.080 
               
               
                 ANLN 
                 TOP2A 
                 0.346 
                 0.061 
                 0.587 
               
               
                 ANLN 
                 GNG11 
                 0.001 
                 0.941 
                 0.307 
               
               
                 ANLN 
                 CDKN3 
                 0.006 
                 0.794 
                 0.098 
               
               
                 ANLN 
                 HCLS1 
                 0.018 
                 0.485 
                 0.128 
               
               
                 ANLN 
                 DTL 
                 0.000 
                 0.864 
                 0.693 
               
               
                 ANLN 
                 IL7R 
                 0.103 
                 0.868 
                 0.663 
               
               
                 ANLN 
                 UBA7 
                 0.097 
                 0.741 
                 0.138 
               
               
                 ANLN 
                 NEK1 
                 0.012 
                 0.785 
                 0.234 
               
               
                 ANLN 
                 CDKN2AIP 
                 0.006 
                 0.860 
                 0.132 
               
               
                 ANLN 
                 APEX2 
                 0.000 
                 0.677 
                 0.069 
               
               
                 ANLN 
                 KIF23 
                 0.431 
                 0.860 
                 0.060 
               
               
                 ANLN 
                 SULF2 
                 0.007 
                 0.433 
                 0.104 
               
               
                 ANLN 
                 PLK2 
                 0.009 
                 0.733 
                 0.018 
               
               
                 ANLN 
                 EME1 
                 0.001 
                 0.108 
                 0.334 
               
               
                 ANLN 
                 BIN2 
                 0.215 
                 0.375 
                 0.836 
               
               
                 RPS27A 
                 MUM1 
                 0.004 
                 0.737 
                 0.233 
               
               
                 RPS27A 
                 TOP2A 
                 0.114 
                 0.126 
                 0.918 
               
               
                 RPS27A 
                 GNG11 
                 0.004 
                 0.466 
                 0.684 
               
               
                 RPS27A 
                 CDKN3 
                 0.004 
                 0.918 
                 0.118 
               
               
                 RPS27A 
                 HCLS1 
                 0.018 
                 0.389 
                 0.696 
               
               
                 RPS27A 
                 DTL 
                 0.007 
                 0.698 
                 0.044 
               
               
                 RPS27A 
                 IL7R 
                 0.430 
                 0.879 
                 0.498 
               
               
                 RPS27A 
                 UBA7 
                 0.527 
                 0.541 
                 0.577 
               
               
                 RPS27A 
                 NEK1 
                 0.016 
                 0.659 
                 0.394 
               
               
                 RPS27A 
                 CDKN2AIP 
                 0.007 
                 0.523 
                 0.208 
               
               
                 RPS27A 
                 APEX2 
                 0.009 
                 0.432 
                 0.210 
               
               
                 RPS27A 
                 KIF23 
                 0.501 
                 0.652 
                 0.702 
               
               
                 RPS27A 
                 SULF2 
                 0.003 
                 0.763 
                 0.684 
               
               
                 RPS27A 
                 PLK2 
                 0.017 
                 0.257 
                 0.029 
               
               
                 RPS27A 
                 EME1 
                 0.013 
                 0.063 
                 0.028 
               
               
                 RPS27A 
                 BIN2 
                 0.976 
                 0.024 
                 0.007 
               
               
                 MUM1 
                 TOP2A 
                 0.036 
                 0.063 
                 0.751 
               
               
                 MUM1 
                 GNG11 
                 0.005 
                 0.221 
                 0.828 
               
               
                 MUM1 
                 CDKN3 
                 0.004 
                 0.881 
                 0.077 
               
               
                 MUM1 
                 HCLS1 
                 0.025 
                 0.829 
                 0.284 
               
               
                 MUM1 
                 DTL 
                 0.010 
                 0.808 
                 0.137 
               
               
                 MUM1 
                 IL7R 
                 0.330 
                 0.584 
                 0.673 
               
               
                 MUM1 
                 UBA7 
                 0.469 
                 0.817 
                 0.391 
               
               
                 MUM1 
                 NEK1 
                 0.025 
                 0.607 
                 0.249 
               
               
                 MUM1 
                 CDKN2AIP 
                 0.007 
                 0.621 
                 0.096 
               
               
                 MUM1 
                 APEX2 
                 0.011 
                 0.796 
                 0.152 
               
               
                 MUM1 
                 KIF23 
                 0.449 
                 0.474 
                 0.997 
               
               
                 MUM1 
                 SULF2 
                 0.001 
                 0.248 
                 0.792 
               
               
                 MUM1 
                 PLK2 
                 0.015 
                 0.257 
                 0.023 
               
               
                 MUM1 
                 EME1 
                 0.016 
                 0.034 
                 0.045 
               
               
                 MUM1 
                 BIN2 
                 0.931 
                 0.007 
                 0.020 
               
               
                 TOP2A 
                 GNG11 
                 0.107 
                 0.115 
                 0.978 
               
               
                 TOP2A 
                 CDKN3 
                 0.419 
                 0.089 
                 0.681 
               
               
                 TOP2A 
                 HCLS1 
                 0.032 
                 0.083 
                 0.949 
               
               
                 TOP2A 
                 DTL 
                 0.220 
                 0.155 
                 0.556 
               
               
                 TOP2A 
                 IL7R 
                 0.026 
                 0.189 
                 0.737 
               
               
                 TOP2A 
                 UBA7 
                 0.021 
                 0.085 
                 0.966 
               
               
                 TOP2A 
                 NEK1 
                 0.546 
                 0.112 
                 0.752 
               
               
                 TOP2A 
                 CDKN2AIP 
                 0.305 
                 0.282 
                 0.813 
               
               
                 TOP2A 
                 APEX2 
                 0.138 
                 0.131 
                 0.954 
               
               
                 TOP2A 
                 KIF23 
                 0.004 
                 0.100 
                 0.972 
               
               
                 TOP2A 
                 SULF2 
                 0.064 
                 0.068 
                 0.883 
               
               
                 TOP2A 
                 PLK2 
                 0.402 
                 0.357 
                 0.237 
               
               
                 TOP2A 
                 EME1 
                 0.413 
                 0.278 
                 0.632 
               
               
                 TOP2A 
                 BIN2 
                 0.013 
                 0.390 
                 0.542 
               
               
                 GNG11 
                 CDKN3 
                 0.002 
                 0.277 
                 0.485 
               
               
                 GNG11 
                 HCLS1 
                 0.032 
                 0.166 
                 0.375 
               
               
                 GNG11 
                 DTL 
                 0.009 
                 0.544 
                 0.035 
               
               
                 GNG11 
                 IL7R 
                 0.268 
                 0.269 
                 0.185 
               
               
                 GNG11 
                 UBA7 
                 0.366 
                 0.231 
                 0.592 
               
               
                 GNG11 
                 NEK1 
                 0.010 
                 0.307 
                 0.920 
               
               
                 GNG11 
                 CDKN2AIP 
                 0.002 
                 0.755 
                 0.670 
               
               
                 GNG11 
                 APEX2 
                 0.011 
                 0.528 
                 0.878 
               
               
                 GNG11 
                 KIF23 
                 0.772 
                 0.197 
                 0.369 
               
               
                 GNG11 
                 SULF2 
                 0.007 
                 0.038 
                 0.179 
               
               
                 GNG11 
                 PLK2 
                 0.007 
                 0.120 
                 0.063 
               
               
                 GNG11 
                 EME1 
                 0.025 
                 0.008 
                 0.010 
               
               
                 GNG11 
                 BIN2 
                 0.691 
                 0.017 
                 0.009 
               
               
                 CDKN3 
                 HCLS1 
                 0.033 
                 0.694 
                 0.157 
               
               
                 CDKN3 
                 DTL 
                 0.004 
                 0.509 
                 0.428 
               
               
                 CDKN3 
                 IL7R 
                 0.159 
                 0.312 
                 0.664 
               
               
                 CDKN3 
                 UBA7 
                 0.111 
                 0.654 
                 0.211 
               
               
                 CDKN3 
                 NEK1 
                 0.020 
                 0.561 
                 0.237 
               
               
                 CDKN3 
                 CDKN2AIP 
                 0.016 
                 0.787 
                 0.087 
               
               
                 CDKN3 
                 APEX2 
                 0.000 
                 0.724 
                 0.081 
               
               
                 CDKN3 
                 KIF23 
                 0.469 
                 0.340 
                 0.446 
               
               
                 CDKN3 
                 SULF2 
                 0.015 
                 0.571 
                 0.221 
               
               
                 CDKN3 
                 PLK2 
                 0.012 
                 0.321 
                 0.024 
               
               
                 CDKN3 
                 EME1 
                 0.002 
                 0.018 
                 0.251 
               
               
                 CDKN3 
                 BIN2 
                 0.203 
                 0.062 
                 0.782 
               
               
                 HCLS1 
                 DTL 
                 0.044 
                 0.605 
                 0.028 
               
               
                 HCLS1 
                 IL7R 
                 0.054 
                 0.828 
                 0.175 
               
               
                 HCLS1 
                 UBA7 
                 0.059 
                 0.894 
                 0.798 
               
               
                 HCLS1 
                 NEK1 
                 0.050 
                 0.500 
                 0.467 
               
               
                 HCLS1 
                 CDKN2AIP 
                 0.051 
                 0.596 
                 0.207 
               
               
                 HCLS1 
                 APEX2 
                 0.056 
                 0.648 
                 0.265 
               
               
                 HCLS1 
                 KIF23 
                 0.065 
                 0.437 
                 0.537 
               
               
                 HCLS1 
                 SULF2 
                 0.052 
                 0.173 
                 0.283 
               
               
                 HCLS1 
                 PLK2 
                 0.063 
                 0.230 
                 0.038 
               
               
                 HCLS1 
                 EME1 
                 0.065 
                 0.032 
                 0.016 
               
               
                 HCLS1 
                 BIN2 
                 0.080 
                 0.008 
                 0.001 
               
               
                 DTL 
                 IL7R 
                 0.210 
                 0.407 
                 0.005 
               
               
                 DTL 
                 UBA7 
                 0.211 
                 0.596 
                 0.026 
               
               
                 DTL 
                 NEK1 
                 0.015 
                 0.102 
                 0.151 
               
               
                 DTL 
                 CDKN2AIP 
                 0.006 
                 0.544 
                 0.152 
               
               
                 DTL 
                 APEX2 
                 0.008 
                 0.526 
                 0.199 
               
               
                 DTL 
                 KIF23 
                 0.997 
                 0.595 
                 0.109 
               
               
                 DTL 
                 SULF2 
                 0.009 
                 0.533 
                 0.033 
               
               
                 DTL 
                 PLK2 
                 0.005 
                 0.169 
                 0.492 
               
               
                 DTL 
                 EME1 
                 0.012 
                 0.063 
                 0.004 
               
               
                 DTL 
                 BIN2 
                 0.413 
                 0.299 
                 0.001 
               
               
                 IL7R 
                 UBA7 
                 0.017 
                 0.682 
                 0.424 
               
               
                 IL7R 
                 NEK1 
                 0.127 
                 0.486 
                 0.839 
               
               
                 IL7R 
                 CDKN2AIP 
                 0.302 
                 0.661 
                 0.648 
               
               
                 IL7R 
                 APEX2 
                 0.246 
                 0.995 
                 0.977 
               
               
                 IL7R 
                 KIF23 
                 0.011 
                 0.347 
                 0.187 
               
               
                 IL7R 
                 SULF2 
                 0.893 
                 0.210 
                 0.027 
               
               
                 IL7R 
                 PLK2 
                 0.158 
                 0.170 
                 0.091 
               
               
                 IL7R 
                 EME1 
                 0.150 
                 0.020 
                 0.003 
               
               
                 IL7R 
                 BIN2 
                 0.016 
                 0.049 
                 0.002 
               
               
                 UBA7 
                 NEK1 
                 0.114 
                 0.548 
                 0.517 
               
               
                 UBA7 
                 CDKN2AIP 
                 0.283 
                 0.701 
                 0.248 
               
               
                 UBA7 
                 APEX2 
                 0.318 
                 0.704 
                 0.267 
               
               
                 UBA7 
                 KIF23 
                 0.030 
                 0.342 
                 0.650 
               
               
                 UBA7 
                 SULF2 
                 0.934 
                 0.139 
                 0.552 
               
               
                 UBA7 
                 PLK2 
                 0.141 
                 0.263 
                 0.032 
               
               
                 UBA7 
                 EME1 
                 0.200 
                 0.021 
                 0.014 
               
               
                 UBA7 
                 BIN2 
                 0.020 
                 0.029 
                 0.016 
               
               
                 NEK1 
                 CDKN2AIP 
                 0.025 
                 0.868 
                 0.255 
               
               
                 NEK1 
                 APEX2 
                 0.003 
                 0.690 
                 0.303 
               
               
                 NEK1 
                 KIF23 
                 0.638 
                 0.471 
                 0.637 
               
               
                 NEK1 
                 SULF2 
                 0.018 
                 0.271 
                 0.619 
               
               
                 NEK1 
                 PLK2 
                 0.004 
                 0.122 
                 0.017 
               
               
                 NEK1 
                 EME1 
                 0.005 
                 0.031 
                 0.172 
               
               
                 NEK1 
                 BIN2 
                 0.147 
                 0.065 
                 0.445 
               
               
                 CDKN2AIP 
                 APEX2 
                 0.002 
                 0.553 
                 0.110 
               
               
                 CDKN2AIP 
                 KIF23 
                 0.777 
                 0.957 
                 0.686 
               
               
                 CDKN2AIP 
                 SULF2 
                 0.016 
                 0.947 
                 0.417 
               
               
                 CDKN2AIP 
                 PLK2 
                 0.013 
                 0.305 
                 0.008 
               
               
                 CDKN2AIP 
                 EME1 
                 0.004 
                 0.109 
                 0.155 
               
               
                 CDKN2AIP 
                 BIN2 
                 0.465 
                 0.381 
                 0.377 
               
               
                 APEX2 
                 KIF23 
                 0.992 
                 0.656 
                 0.809 
               
               
                 APEX2 
                 SULF2 
                 0.010 
                 0.911 
                 0.510 
               
               
                 APEX2 
                 PLK2 
                 0.010 
                 0.246 
                 0.013 
               
               
                 APEX2 
                 EME1 
                 0.024 
                 0.088 
                 0.116 
               
               
                 APEX2 
                 BIN2 
                 0.593 
                 0.175 
                 0.221 
               
               
                 KIF23 
                 SULF2 
                 0.198 
                 0.371 
                 0.405 
               
               
                 KIF23 
                 PLK2 
                 0.455 
                 0.160 
                 0.092 
               
               
                 KIF23 
                 EME1 
                 0.587 
                 0.059 
                 0.031 
               
               
                 KIF23 
                 BIN2 
                 0.032 
                 0.041 
                 0.023 
               
               
                 SULF2 
                 PLK2 
                 0.036 
                 0.163 
                 0.070 
               
               
                 SULF2 
                 EME1 
                 0.021 
                 0.022 
                 0.015 
               
               
                 SULF2 
                 BIN2 
                 0.464 
                 0.002 
                 0.000 
               
               
                 PLK2 
                 EME1 
                 0.006 
                 0.018 
                 0.642 
               
               
                 PLK2 
                 BIN2 
                 0.249 
                 0.072 
                 0.291 
               
               
                 EME1 
                 BIN2 
                 0.353 
                 0.005 
                 0.001 
               
            
           
         
       
     
     While the preferred embodiments of the invention have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.